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Protein phosphorylation plays an important role in transmitting cellular signals. 
Phosphorylation has been mostly characterized by hypothesis-driven and low-throughput 
approaches in the past. However, novel phosphorylation sites on not yet identified signaling 
effectors involved in cellular responses can only be investigated in an unbiased and large-scale 
manner. The global investigation of phosphorylation processes in a cellular system can help 
to understand signaling that drives malignant transformation of cells. Moreover, 
phosphorylation patterns might hint towards potential therapeutic targets e.g. activated 
kinases. The generation and analysis of large-scale PTM datasets was made feasible by 
improved enrichment protocols in combination with the fast evolution of high resolution, 
quantitative mass spectrometry, computational approaches, and functional databases. The 
data presented in this thesis comprises three large-scale phosphoproteomics projects.  
The main project represents the investigation of antigen-dependent and tonic BCR signaling 
in Burkitt’s lymphoma (BL). As antigen-dependent BCR signaling in BL has not yet been 
described, phosphorylation changes were investigated in a time-resolved manner in DG75 
cells and additionally in two other BL models including one primary BL cell culture. Overall, 
the MS-based antigen-dependent signaling analyses lead to the identification of thousands of 
altered phosphorylation sites upon BCR engagement in DG75. Based on this data, a higher 
order organization structure was extracted, complemented with database information and 
mapped to datasets derived from RNAseq, kinobead and kinase inhibition analyses. Signaling 
in BL cells was found to be highly individual in different cell lines. Tonic BCR signaling was 
investigated upon knockdown of the BCR signaling molecule CD79A and by inhibition of the 
receptor-proximal tyrosine kinase SYK. Comparison of the antigen-independent and -
dependent BCR signaling phosphoproteomes revealed substantial differences as well as 
certain similarities of both processes. The second project focused on the analysis of global 
phosphorylation dynamics in acute myeloid leukemia (AML) after BTK inhibition. As BTK was 
identified as an activated kinase in AML, the mechanism of its activation and the influence of 
BTK ablation were investigated in two AML cell lines with different genetic backgrounds. 
Phosphoproteomic changes observed upon BTK inhibition highlighted individual differences 
and similarities of BTK action and identified relevant upstream activators of BTK as well as 
downstream effector proteins in AML cells. The third project was aimed at profiling the 
phosphorylation site dynamics of the TCR adapter proteins LCP2 (SLP76) and GADS (GRAP2) 
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in time-resolved TCR stimulation. The dynamics of several phosphorylation sites could be 
captured over a time course, and provide a basis for further functional characterization by e.g. 
mutation of p-sites. In summary, this work globally characterized phosphorylation changes 
upon different cellular conditions by quantitative mass spectrometry-based 
phosphoproteomics and provides a basis for the identification of druggable proteins or yet 





 B cell and T cell signaling 
The human immune system is a highly complex defense system composed of different cells, 
tissues and organs that protect the human body from pathogens. Two of its major cell types, 
B and T cells are important cellular effectors of the adaptive immune system (Murphy, 2011). 
B-cell development and maturation are tightly regulated by various differentiation processes 
to produce a naïve B cell with a functional, monospecific B-cell antigen receptor (BCR) (Nossal 
and Lederberg, 1958; White, 1958). Terminally differentiated B cells execute unique functions 
in the immune system as either plasma cells (PC) or long-lived memory B cells. PCs secrete 
antibodies whereas memory B cells enable fast, high-affinity secondary immune responses i.e. 
after re-exposition to their cognate antigen or during vaccination (Gray and Skarvall, 1988) 
(reviewed in Klein and Dalla-Favera, 2007). As all hematopoietic cells, B cells arise from 
common pluripotent hematopoietic stem cells that reside in the bone marrow and can 
differentiate into either common myeloid or common lymphoid progenitor cells. Common 
lymphoid progenitor cells give rise to all cells of the lymphatic lineage: B cells, T cells and 
natural killer (NK) cells. Human B cells develop and mature in the bone marrow. Naïve B cells 
egress from the bone marrow niche to circulate through secondary lymphoid organs (such as 
lymph nodes, spleen, tonsils and Peyer’s patches in the small intestine) until activation via 
their B-cell receptor (BCR) by a cognate antigen (Harwood and Batista, 2011). Both B and T 
cells belong to the lymphoid lineage of hematopoietic cells. In contrast to B cells, T cells 
mature in the thymus, before circulating as naïve T cells in the secondary lymphoid organs. 
 
1.1.1. B-cell receptor signaling  
The BCR exerts two functions in B cells: first, it ensures B-cell development, survival and 
homeostasis independently of antigens, also referred to as tonic BCR signaling. Second, the 
BCR recognizes foreign antigens and subsequently induce characteristic B cell processes 
(reviewed in Kurosaki et al., 2009; Niiro and Clark, 2002; Rickert, 2013). The BCR is composed 
of two membrane-anchored parts: a ligand-binding, transmembrane immunoglobulin part (Ig) 
and the non-covalently associated, intracellular signaling chains CD79A and CD79B (Igα and 
Igβ) (Reth, 1989). The Ig molecule consists of two Ig heavy (IgH) and two Ig light (IgL) chains 
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which are linked to each other by disulfide bonds (Figure 1.1). Both, the IgH and the IgL part 
can be separated into a variable, antigen-binding domain and a constant region. The constant 
region of the IgH chain determines the antibody class such as IgM or IgG (Borst et al., 1996). 
The antigen-binding domain consists of a variable (V), diversity (D; only in the heavy chain) 
and joining (J) gene segment. For each segment, various variants are encoded at the respective 
gene locus that can be combined in a random fashion. Therefore the BCR can bind to a large 
variety of antigens (Brack et al., 1978).  
Almost all signals derived from the BCR are transmitted via the intracellular signaling chains 
CD79A and CD79B harboring a so-called immunoreceptor tyrosine-based activation motif 
(ITAM; Figure 1.1) (Engels et al., 2009; Reth and Wienands, 1997). The ITAM motif consists of 
two tyrosine residues in a conserved amino acids stretch (Reth, 1989). Antigen-independent 
tonic BCR signals dependent critically on the ITAM motif as its ablation leads to cell death of 
mature B cells (Kraus et al., 2004; Lam et al., 1997a). Compared to antigen-dependent 
signaling, tonic signaling is less well understood, and believed to transmits baseline signals 
mainly via PI3K signaling (Figure 1.1, right panel) (Srinivasan et al., 2009; Young and Staudt, 
2013). The initial step in antigen-dependent signaling is mediated by receptor engagement by 
antigen binding that leads to the formation of BCR-CD79A/CD79B clusters in the membrane 
(reviewed in Monroe, 2006). Phosphorylation of the two tyrosine residues in the ITAM motif 
is mediated by Src family kinases (SFKs) such as LYN after receptor engagement. The 
phosphorylated tyrosine residues provide a binding site for the tandem Src homology 2 (SH2) 




Figure 1.1: Antigen-dependent and -independent B-cell receptor signaling 
The left panel shows the signaling cascade after cognate antigen encounter of the BCR complex. Src family kinases (SFK) such 
as LYN phosphorylate the ITAM motifs of the CD79A/B signaling chains thereby providing a binding platform for SYK that 
leads to its activation. After activation, several downstream effectors (CIN85, BLNK, BTK, PLCɣ, PI3K, PKCβ and the CARD11-
BCL-10-MALT1-complex) that drive distinct signaling pathways (MAPK, PI3K, NFAT and NFκB) eventually become activated. 
The right panel shows tonic BCR signaling involving mainly PI3K signaling. The figure is adapted from Young and Staudt, 2013. 
SYK phosphorylates in the following various effector proteins (adapter proteins, 
phospholipases, kinases and other enzymes) such as BLNK, BTK, and PLCɣ2 (Figure 1.1, left 
panel). BCR signaling also involves the generation of second messengers like Ca2+, IP3 and DAG. 
Together these processes lead to the formation of BCR-dependent signalosomes that trigger 
the initiation of various signaling cascades i.e. NFκB-, PI3K-, NFAT- and MAP-kinase-signaling 
(Figure 1.1, left panel; reviewed in Kurosaki et al., 2009; Young and Staudt, 2013). In response 
to the membrane-associated antigen encounter, the BCR-antigen complex is internalized, the 
antigen becomes processed in the late endosome and coupled to major histocompatibility 
complex (MHC) class II molecules. The MHC-II complex is subsequently exported to the B cell 
surface for co-stimulatory interaction with cognate T cells, which is a pre-requisite for the 
formation of a germinal center (GC) (reviewed in Kurosaki et al., 2009; Rickert, 2013). Germinal 
centers are histological structures that are formed in secondary lymphoid organs and can be 
functionally divided into two parts: a light zone with mainly centrocytes, follicular dendritic 
cells and T follicular helper cells, and a dark zone with centroblasts. The dark zone is 
characterized by high proliferation and somatic hypermutation whereas the light zone 
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centrocytes are selected for high affinity Igs. During somatic hypermutation, base-pairs are 
exchanged in the V(D)J region of the IgV genes (reviewed in Küppers, 2005). Centrocytes with 
a high antigen-binding affinity undergo Ig class-switch recombination of the immunoglobulin 
heavy chain. During class-switch recombination the isotype of the BCR is switched from 
IgM/IgD to IgG, IgA or IgE thereby mediating different effector functions. Somatic 
hypermutation as well as class-switch recombination require the activity of the activation-
induced deaminase (AID) (reviewed in Rickert, 2013). GC B cells can switch between light and 
dark zone thereby changing their gene expression pattern. Eventually, centrocytes 
differentiate into long-lived plasma cells (PC) or memory B cells (reviewed in Küppers, 2005).  
 
1.1.2. T cells and TCR signaling  
Same as B cells, T cells possess a membrane-bound antigen receptor, the T-cell receptor (TCR) 
which is composed of two hetereodimeric variable TCR receptor chains (TCRα and β) 
associated with three different dimeric CD3 signaling modules, CD3 δ/ε, CD3 γ/ε and CD3 ζ/ζ. 
The accessory CD3 chains contains as CD79A and B ITAM motifs in their intracellular domains. 
In contrast to the BCR, the TCR does not exist in a soluble form, has only one antigen-binding 
site, and does solely bind to antigen-MHC complexes and not to soluble antigens (Garcia and 
Adams, 2005; Hwang et al., 2015). Dependent on the MHC class (I or II) the antigen is 
presented on, T cells with either CD4 or CD8 co-receptors become activated and differentiate 
in specialized T cell effector classes. CD8+ cells differentiate into cytotoxic T cells (CTL) that 
directly eliminate virus-infected cells whereas CD4+ T cells differentiate in various T helper 
classes like TH1, TH2, TH17 or T follicular helper (TFH) cells. Especially CD4+ TH1, TH2 and TFH 
provide a co-stimulatory signal to antigen-activated B cell for further differentiation (reviewed 
in Samelson, 2011).  
The signaling cascades initiated upon MHC/antigen recognition on the cell surface leading to 
T cell responses are in principle similar to the ones in B cells, as in both cases they are mainly 
mediated by phosphorylation. The processes and the involved adapter proteins and kinases 
are also very similar. The earliest events after cognate antigen encounter is the activation of 
the Src family kinase LCK, phosphorylating the ITAM motifs in the CD3 chains (Chakraborty 
and Weiss, 2014; Guy et al., 2013). ZAP70, a SYK family kinase primarily expressed in T cells, 
binds with its tandem SH2 domain to the doubly tyrosine phosphorylated ITAM-motif and 
thereby becomes activated (reviewed in Samelson, 2011). Downstream phosphorylation of 
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ZAP70 targets the adapter proteins SLP76 (LCP2) and membrane-attached LAT which provides 
a binding platform and therefore leads to the recruitment of other adapter proteins 
(Balagopalan et al., 2010; Myung et al., 2001). The SLP76/LAT-nucleated complex activates 
other adapter proteins (amongst others GADS and GRB2) and leads to the generation of 
second messenger molecules (reviewed in Huang and Sauer, 2010). Downstream events of 
TCR signaling are transcriptional activation and cytoskeletal changes leading to the 
aforementioned, defined T cell responses. 
 
 Hematologic malignancies - leukemia and lymphoma 
Hematological malignancies comprise a huge class of neoplasms derived from cells of the 
hematopoietic lineage that affect the blood, bone marrow, and the lymphatic system. There 
are two major classes of hematological malignancies: liquid tumors - leukemias and solid 
tumors - lymphomas. Leukemias are characterized by massive proliferation of immature cells 
(blasts) in the bone marrow that outcompete normal hematopoiesis and eventually spread 
out to the blood. Dependent on the malignant transformed cell type, they can be classified as 
of myeloid or lymphatic origin. Leukemias can be classified into chronic or acute clinical forms: 
Chronic leukemias spread more slowly and can stay undiagnosed for several years while acute 
leukemias manifest within a short time (weeks or months) (reviewed in Estey and Döhner, 
2006; Koeffler and Golde, 1978). Lymphomas comprise a heterogeneous entity of tumors 
derived from lymphatic cells that arise in lymphatic tissues (Campo et al., 2011). They can be 
divided into Hodgkin lymphomas with their characteristic Hodgkin-Reed-Sternberg-Stern 
(HRS) cells, and the heterogeneous group of non-Hodgkin-lymphomas (NHL). Hodgkin 
lymphomas are exclusively derived from B cells whereas NHL neoplasia can be either derived 
from B or T cells, although the B-cell derived disease is more common (reviewed in Shaffer et 
al., 2012; Young and Staudt, 2013a). NHLs can be divided into slow-growing indolent, or rapid-
proliferating, aggressive lymphomas. Different types of NHL exhibit features (gene expression 
profile, surface markers, the occurrence of somatic hypermutation or class-switch 
recombination) that can be attributed to a defined developmental stage of healthy precursor 
B cells (reviewed in Shaffer and Staudt, 2012). Two hematological malignancies were 
intensively analyzed in this work and will be described in further detail: Burkitt’s lymphoma 




1.2.1. Burkitt’s lymphoma 
Burkitt’s lymphoma (BL) is an aggressive NHL derived from B cells. The disease was first 
described in 1958 in Uganda, Africa by the physician Dennis Burkitt in children with jaw 
‘sarcomas’ (Burkitt, 1958). Two years later, BL was identified to be of lymphatic origin and in 
1964 its association with Epstein-Barr virus (EBV) was detected (Epstein and Barr, 1964; 
O'Conor and Davies, 1960). The connection between the disease and the causative viral agent 
turned out to be one of three clinical variants of BL: EBV-associated endemic variant (eBL), the 
immunodeficiency-associated (hivBL) and the sporadic form (sBL). The endemic form is also 
associated with malaria infection and is geographically correlated to EBV- and malaria-
endemic regions (Burkitt, 1961; 1962). The immunodeficiency-associated form occurs 
exclusively in combination with human immunodeficiency-associated virus (HIV) infection 
(Kalter et al., 1985). The sporadic form is evenly distributed all over the world and the most 
dominant BL type in non-malaria regions. BL tumors grow fast and their localization varies 
between the clinical variants: in the sporadic form they are primarily intraabdominal, in the 
endemic form mainly in the jaw, face or neck (reviewed in Molyneux et al., 2012). The three 
forms are hardly distinguishable by morphology and immunophenotyping. The histological 
appearance of BL specimen is the characteristic ‘starry sky’ present in the bone marrow and 
lymph nodes. The ‘starry sky’ is caused by macrophages containing dead apoptotic tumor cells 
(reviewed in Ferry, 2006). Tumor B cells are of intermediate size with round nuclei, multiple 
nucleoli and a high proliferation index (reviewed in Fujita et al., 2004a; 2004b; Nakamura et 
al., 2002). The standard treatment for BL is classical chemotherapy. Although BL is very 
chemosensitive and modern multiagent treatment regimens show a good cure rate, the 
treatment has severe toxic side effects that may not be well tolerated by older patients or 
require intensive supportive care (Hoelzer et al., 2014; Rizzieri et al., 2004). Rituximab, a 
monoclonal antibody directed against the B cell-specific surface marker CD20 was added as a 
therapeutic option to classical chemotherapeutic agents that act by introducing DNA strand 
breaks, DNA intercalation, microtubule inhibition and immunosuppression (Rizzieri et al., 
2014).  
The karyotype of Burkitt’s lymphoma cells is of low complexity and the BL gene expression 
pattern resembles that of healthy germinal center B cells (Dave et al., 2006; Seitz et al., 2011). 
Of special importance in this gene expression program is the activation-induced deaminase 
(AID). The AID mediates somatic hypermutation in the variable antigen-binding domain 
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occurring in the dark zone and class-switch recombination of the immunoglobulin constant 
region in the light zone of the GC (reviewed in Rickert, 2013). The hallmark of BL is an Ig-MYC 
translocation caused by the action of the AID (Bergsagel et al., 1996; Neri et al., 1988; Schmitz 
et al., 2014). MYC is a transcription factor and oncogene involved in many cellular processes 
such as metabolism, cell growth, proliferation and apoptosis (reviewed in Cai et al., 2015; 
Dang, 2012). MYC presumably increases the expression of all active genes at a given time 
rather than imposing a particular gene expression program on a cell (Lin et al., 2012; Nie et 
al., 2012). In non-oncogenic cells, MYC expression is tightly controlled and aberrant expression 
leads to apoptosis (Evan et al., 1992; Felsher and Bishop, 1999; Gibson et al., 1995; Kanazawa 
et al., 2003; Lowe et al., 2004; Nilsson and Cleveland, 2003). The BL associated translocation 
brings Ig genes with their enhancer regions in close proximity to the transcription factor MYC 
leading to its constitutive overexpression (Dalla-Favera et al., 1982; Taub et al., 1982). BL cells 
circumvent MYC-induced apoptosis by additional mutations in genes that cooperate with 
MYC-mediated proliferation (Cai et al., 2015; Srinivasan et al., 2009). The most common Ig-
MYC translocation variant is (8;14) (q24;q32) where MYC is brought under the transcriptional 
control of the IgH locus on chromosome 14. The other two less frequent variants include MYC 
fusions with Ig light chains (reviewed in Ferry, 2006). In BL patients there is an overall MYC 
mutation rate of 70% (Bahram et al., 2000; Schmitz et al., 2012). Other common mutational 
events affect the transcription factor TCF3 and its negative regulator ID3. TCF3 encodes the 
transcription factor E2A which is expressed in GC centroblasts and regulates the expression of 
immunoglobulin genes and other B cell-specific genes (Schmitz et al., 2012; 2014). Both 
mutations in the TCF3/ID3-module circumvent the inactivation of TCF3. Moreover, the cell 
cycle regulator cyclin D3 (encoded by CCND3) and the tumor suppressor TP53 are affected 
(Küppers, 2005; Schmitz et al., 2012; 2014). Although BL cells depend on a functional BCR, the 
disease is thought to be driven by tonic, antigen-independent BCR activation indicated by 
activation of the PI3K signaling pathway rather than the antigen-dependent NFκB involvement 
(Figure 1.1, right panel) (Dave et al., 2006; Schmitz et al., 2012; Young and Staudt, 2013b). 
1.2.2. Acute myeloid leukemia 
Acute myeloid leukemia (AML) is derived from transformed hematopoietic progenitor cells 
(blasts) and is characterized by a huge variety of genetic mutations. AML blasts are derived 
from a clonal hierarchy and proliferate fast and uncontrollably in the bone marrow. The 
symptoms of AML are caused by the replacement of normal hematopoiesis in the bone 
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marrow. This leads to a decrease in erythrocyte, thrombocyte and leukocyte cell numbers and 
results in anemia, an increased risk of bleeding and vulnerability to infections due to a 
compromised immune system (reviewed in Chen et al., 2013; Czibere et al., 2006; Estey and 
Döhner, 2006). A common risk factor for AML is age, but there are also predisposing factors 
such as trisomy 21, exposition to ionizing radiation, chemicals such as benzene or previous 
chemotherapeutic treatment with cytostatic drugs (reviewed in Chen et al., 2013; Czibere et 
al., 2006; Estey and Döhner, 2006). Treatment options for AML consist of different 
chemotherapy regimens possibly followed by allogeneic hematopoietic stem cell 
transplantation. In general, chemotherapeutic treatment is highly toxic and therefore not well 
tolerated. The success of the treatment strategy also correlates with patient age and the 
mutational profile of the disease (reviewed in Czibere et al., 2006). In recent years, a huge 
effort was made to gain insights into AML biology, to characterize the impact of different 
disease genotypes on prognosis and to identify efficient targeted treatment strategies. 
Different recurrent mutations and gene fusions were identified in nine functional protein 
classes involving genetic aberrations in transcription factors, NPM1, tumor suppressor genes, 
epigenetic modifier genes, signaling genes, myeloid transcription factor genes, cohesin- and 
spliceosome-complex genes (Figure 1.2) (Chen et al., 2013).  
 
 
Figure 1.2: Mutations in functional protein categories and their cooperation in AML 
The Circos plot shows co-occurring mutations in AML. Proteins are grouped into nine different functional groups (represented 
by different colored boxes). Co-occurring mutations between these groups are illustrated by ribbons connecting those groups. 
The figure is published by Chen et al., 2013. 
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 Mass spectrometry-based proteome and PTM analysis 
The underlying cause of lymphoma and leukemia, or in general cancer can be often traced 
back to genetic alterations that manifest themselves at the protein or post-translational 
modification (PTM) level, such as elevated protein expression or altered phosphorylation. The 
proteome is defined as the complete set of proteins expressed from a genome in a specimen 
i.e. on the cellular or subcellular level at any given time point (Wilkins et al., 1996). In contrast 
to the genome, the proteome is more diverse as genes can exist on the protein level in various 
isoforms and additionally can be post-translationally modified (Wilkins et al., 1996). Mass 
spectrometry became a powerful tool for the high-throughput characterization of proteins 
and PTMs within the last years. It offers the possibility to investigate proteins and PTMs in a 
hypothesis-free, global and unbiased manner which makes it a valuable tool for the analysis 
of cancer proteomes and signaling (reviewed in Mann and Jensen, 2003).  
 
1.3.1. Tandem mass spectrometry  
For unambiguous protein identification it is necessary to identify a unique peptide derived 
from that particular protein. Solely the mass of the intact peptide is not enough information 
for its unambiguous identification, especially in highly complex samples. For unambiguous 
peptide identification it is therefore necessary to deduce its primary amino acid sequence. The 
addition of a PTM is accompanied by a mass increase of the peptide and, in most cases its 
fragment ions. From these sequence specific fragment ions, the position of the PTM on the 
primary amino acid sequence can be determined (reviewed in Mann and Jensen, 2003b). 
Tandem mass spectrometry is a suitable tool for the identification of proteins and the 
localization of PTMs. In general, a mass spectrometer is an analytical instrument that 
measures the mass-to-charge (m/z) ratio and the intensity of ions in the gas-phase. Tandem 
mass spectrometry or (commonly referred to as MS/MS) combines the measurement of an 
intact peptide mass followed by its fragmentation for the determination of the peptide amino 
acid sequence (Steen and Mann, 2004). After fragmentation of the precursor, the localization 
of the PTM along the amino acid chain can be determined at the MS/MS level by the mass 
increase of the fragment ion (reviewed in Mann and Jensen, 2003b). 
Tandem mass spectrometry can be performed either in instruments containing distinct mass 
analyzers for separation, fragmentation and fragment analysis, commonly referred to as 
tandem-in-space such as performed by triple quadrupoles, quadrupole-time-of-flight or 
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orbitrap instruments. Instruments where all the before mentioned steps are performed in one 
device are referred to as tandem-in-time instruments for instance Fourier transform ion 
cyclotron resonance (FT-ICR) or ion trap instruments (Gross, 2011). In tandem mass 
spectrometry, as a first step, the peptide mass-over-charge (m/z) ratio or Thomson of all 
peptides eluting from chromatographic separation at a given time point is determined in a 
survey or MS1 scan. Precursor peptides are selected in a first mass filter and fragmented into 
smaller parts, ideally along the peptide backbone. A product ion scan (alternatively MS/MS or 
MS2) experiment is then performed on the peptide precursor, giving information about the 
amino acid composition. In modern tandem mass spectrometers, the precursor selection for 
the MS2 scan is data driven and occurs in an automated fashion, the so-called data-dependent 
acquisition (DDA). In DDA, the top N most abundant precursor peptides from a survey scan 
are consecutively extracted from all other precursors for fragmentation for the whole duration 
of the chromatographic separation. Moreover, precursor ions are selected for fragmentation 
at their elution apex to decrease ion accumulation time and to improve MS2 spectra quality. 
The software can also automatically recognize if a precursor ion is likely to be derived from a 
peptide according to its isotopic pattern (averagine model of an amino acid; Senko et al., 
1995). Although these features were designed to increase peptide identification rates, the 
precursor selection is of stochastic nature. This leads to some variability between replicate 
samples and a bias towards high abundant peptides at the expenses of low abundant species 
which are less likely to become analyzed (Liu et al., 2004; Michalski et al., 2012). A recent trend 
to overcome these drawbacks is the development and establishment of data-independent 
acquisition (DIA). In DIA methods, peptides over the whole m/z range are subjected 
consecutively with a defined m/z window range to fragmentation independently of the 
precursor intensity (Egertson et al., 2013). The method of choice for data generation in this 
work was DDA and thus will be explained in more detail in section 1.3.5. 
1.3.2. Sample ionization 
The foundation for the success of mass spectrometry was laid by the inventions of matrix-
assisted laser desorption ionization (MALDI) and electrospray ionization (ESI). MALDI and ESI 
are both soft ionization techniques, leaving biomolecules like peptides and proteins intact 
during the ionization process. The gain for the scientific field was so fundamental and 
significant that the inventors John B. Fenn (ESI) and Koichi Tanaka (MALDI) were jointly 
awarded the Nobel Prize in 2002 (Fenn et al., 1989; 1990; Tanaka et al., 1988). In MALDI, the 
Introduction 
13 
analyte molecules are desorbed from a surface into the gas phase by laser irradiation. The 
basic principle of ESI is a high electrostatic voltage between the tip of the capillary needle and 
the entrance of the mass spectrometer. The analyte-containing solution becomes dispersed 
from a cone that is formed on the capillary tip to form multiple charged droplets. Those 
droplets are attracted towards the orifice into the vacuum of the mass spectrometer. The 
solvent removal mechanism and the analyte ionization can be explained by two models: the 
charge-residue model and the ion evaporation model, respectively (reviewed in Mallick and 
Kuster, 2010). In the charge-residue model, the surface charge concentration of the droplet 
increases by continuous solvent evaporation. When the internal Coulombic repulsion 
becomes greater than the surface tension (Rayleigh limit), the droplet dissociates into smaller 
droplets with a lower charge. Eventually, this leads to an iterative series of solvent evaporation 
and explosions until single ions are formed (Dole et al., 1968). The ion evaporation model 
postulates that single ionized peptides emit from the surface of the charged droplet by field 
desorption (Thomson and Iribarne, 1979). The exact mechanism is still under debate and 
might be dependent on the analyte properties (Konermann et al., 2012). However, both 
models result in multiple positively charged ions in the gas phase which makes the peptides 
susceptible for manipulation as required for MS measurement (reviewed in Mallick and 
Kuster, 2010). 
Over the years, ESI became the dominant ionization method due to the advantage of ESI over 
MALDI that samples get ionized out of a liquid phase which makes it directly compatible to 
reversed-phase high-performance liquid chromatography (RP-HPLC; in combination with 
MS/MS abbreviated as LC-MS/MS) (Fenn et al., 1990). A further advancement of ESI is nano-
ESI which utilizes lower flow rates of a few hundred nL/min. This leads to lower sample and 
mobile phase consumption, higher ionization efficiency due a slightly different ionization 
mechanism and therefore increased sensitivity (Karas et al., 2000; Schmidt et al., 2003).  
1.3.3. Peptide sequencing 
In tandem mass spectrometry the mass measurement of the peptide precursor is followed by 
its dissociation for the determination of the primary amino acid sequence (reviewed in Mann 
and Jensen, 2003b). The most commonly applied fragmentation techniques is collision 
induced dissociation (CID). In order to deduce the peptide amino acid sequence the analyte 
peptide ions are collided with inert gas such as helium (He), nitrogen (N2) or argon (Ar). CID 
fragmentation technique typically generates b- and y-ion species, where b-ions contain the 
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peptide N-terminus and y-ions contain the peptide C-terminus, respectively (Figure 1.3) 
(Roepstorff and Fohlman, 1984). Two types of CID fragmentation can be distinguished: ion 
trap CID and beam-type CID which is also commonly referred to as higher energy collisional 
dissociation (HCD). The former, as the name suggests, is often performed in ion trap mass 
analyzers where the ions are activated in a radio frequency field. The peptide ions collide 
multiple times with He molecules thereby breaking along the peptide backbone at the peptide 
bonds generating typically b- and y-ions (Figure 1.3). CID ion trap fragmentation follows the 
lowest energy pathway fragmentation (Jedrychowski et al., 2011; Michalski et al., 2012). In 
case the peptide carries a labile PTM like phosphorylation or glycosylation, this bond is likely 
to break leading to loss of small, neutral molecules such as H2O or H3PO4 which is commonly 
referred to as neutral loss (reviewed in Mallick and Kuster, 2010; Mann et al., 2002). Overall, 
this leads to insufficient fragmentation and therefore incomplete peptide sequence 
information (reviewed in Mallick and Kuster, 2010). Moreover, ion traps suffer from a low 
mass cut-off which means that ions with an m/z of less than 30% of the precursor cannot be 
detected (Zhang et al., 2005). 
An alternative to ion trap CID is beam-type CID that does not take place in the analyzer but in 
a separate collision cells e.g. collision multipole in Q Exactive instruments or in the ion-routing 
multipole in the Orbitrap Fusion. Compared to ion trap CID, peptide ions collide fewer times 
with collision gas molecules but also preferably generate peptide backbone cleavages leading 
to b- and y-ions (Figure 1.3). The collisions happen on a higher kinetic energy regime compared 
to ion trap CID which reduces neutral losses of PTMs. After beam-type fragmentation, ions are 
accumulated and trapped before they are sent for analysis to a high resolution analyzer e.g. 





Figure 1.3: Nomenclature of fragment ion species from peptide backbone breakage  
A- and x-ions (blue) are generated after the breakage of the alkyl-carbonyl bond, the breakage of the amide (or peptide) bond 
results in b- and y-ions (green) and breakage of the amino-alkyl bond leads to c- and z-ions (orange). A-, b-, and c-ions contain 
the N-terminal part of the peptide while x-, y-, and z- ions the corresponding C-terminal part (Roepstorff and Fohlman, 1984). 
 
Another common fragmentation technique is electron transfer dissociation (ETD) where the 
peptide ions collide with an electron donor. This reduces the peptide charge by one and 
generates an unpaired electron on the peptide. The peptide ions become instable and break 
between the N-C bond, thereby generating c- and z-fragment ions (Figure 1.3). ETD 
fragmentation is advantageous for very large peptides or peptides modified with a labile PTM 
as serine and threonine phosphorylation or O-linked GlcNac (Coon et al., 2005; Jedrychowski 
et al., 2011). 
 
1.3.4. Mass spectrometry instrumentation 
Modern tandem mass spectrometry is performed on instruments that possess two different 
mass analyzer devices, so called hybrid instruments. There are many types of mass analyzers 
available in hybrid instruments, most commonly: quadrupole, ion traps (cubic or linear ion 
trap), time-of-flight (TOF) and orbitraps. Every analyzer type offers different performance 
characteristics, such as mass accuracy, m/z range, dynamic range, scan speed and resolving 
power. Moreover, different mass analyzers show different levels of suitability for 
functionalities such as ion separation, ion trapping and fragmentation or detection. Mass 
analyzers can be divided into high resolution and low resolution analyzers: orbitrap and TOF 
analyzers belong to the high resolution class whereas quadrupoles and linear ion traps belong 
to the low resolution analyzers. The advantages of different m/z separating devices and 
analyzers are exploited by their combination in hybrid instruments (Glish and Burinsky, 2007). 
Common combinations are e.g. linear ion trap-orbitrap, quadrupole-TOF or quadrupole-
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orbitrap. Due to the huge contribution of orbitrap-based mass spectrometry for this research 
project, this technique will be explained in more detail.  
The basic idea behind the orbitrap mass analyzer existed previously as the so-called ‘ideal 
Kingdon trap’ that was invented in its actual form by Alexander Makarov (Makarov, 2000). The 
working principle is similar to FT-ICR where the ion motion is controlled by an axial magnetic 
field (Gillig et al., 1996). The orbitrap mass analyzer does not require a magnetic but an 
electrostatic field. It consists of two parts, an axial central electrode and a two part outer 
electrode parallel to the axis of the central electrode. The electrostatic field traps ions rotating 
around and oscillating along its central electrode (Makarov, 2000). The frequencies of the 
oscillating axial movement are detected by an image current induced between the halves of 
the outer electrode and are converted by Fourier transformation into m/z values (Scigelova 
and Makarov, 2006). The orbitrap mass analyzer is a high resolution >70.000 and sub-ppm 
high mass accuracy mass analyzer (Olsen et al., 2005). Recently, an advancement of the 
orbitrap analyzer was introduced, the high-field (HF) orbitrap. Due to the reduced trap size, 
increased field strength can be applied and therefore a higher resolution can be achieved 
within the same transient time (Makarov et al., 2009; Scheltema et al., 2014).  
1.3.5. Shotgun proteomics workflows 
A typical MS-based proteomics experiment can be divided into several parts: protein 
extraction, fractionation and/or enrichment on the protein or peptide level, proteolytic 
digestion, RP-HPLC separation, ESI followed by mass spectrometric analysis of the precursor 




Figure 1.4: Outline of generic building blocks of a bottom-up/shotgun proteomics workflow 
The starting material (cells or tissues) can be metabolically or chemically labeled. Samples can be subjected to fractionation 
or enrichment on the protein level or after digestion with the respective endoproteinase (represented by scissors) to 
peptides. Peptides are subjected to RP-HPLC, ionized by ESI and the charged ions are then transferred into the gas phase to 
the mass spectrometer. During the whole RP-HPLC gradient ions are transmitted to the mass spectrometer for DDA. A survey 
scan (MS1) is followed by a user defined number of consecutive fragment scans (MS2) of the highest abundant precursor 
ions. Peptides are identified by matching theoretical peptide fragmentation spectra derived from a sequence database after 
in silico digest to the experimentally acquired spectra. RP-HPLC: reversed-phase high performance liquid chromatography; 
DDA: data-dependent acquisition; SCX: strong cation exchange; TiO2: Titanium dioxide; I: Intensity; m/z: mass-to-charge ratio. 
 
The proteome can be extracted from different sources such as cell culture or paraffin-
embedded tissue samples. It can be fractionated or specifically enriched for PTMs, specific 
proteins or classes by affinity- or immunopurification (Figure 1.4). A common fractionation 
step is SDS-PAGE where proteins are separated according to apparent molecular weight and 
interfering detergent or salt ions from cell culture or lysis buffers are removed. For protein 
interactome analysis affinity purification or antibody-based purification of the target protein 
is performed (Figure 1.4).  
In bottom-up proteomics the intact proteins are hydrolyzed into smaller peptides with a 
sequence specific endoproteinase (Figure 1.4). This can be done either in-gel, after SDS-PAGE, 
or in solution (Shevchenko et al., 2007). Most commonly trypsin is the proteinase of choice 
Introduction 
18 
because it cleaves with high specificity C-terminally of arginine (R) and lysine (K). The 
frequency of occurrence of arginine and lysine in the proteome is advantageous to generate 
peptides of an optimal MS/MS length (between 7 and 20 amino acids) (Olsen et al., 2004). 
Moreover, arginine and lysine have basic side chains and therefore can carry, besides the N-
terminal NH2-groups, a second proton after ionization. Other frequently used proteinases are 
Lys-C which cleaves C-terminal to lysine, or chymotrypsin which cleaves C-terminal of leucine 
and the aromatic amino acids phenylalanine, tryptophan and tyrosine, respectively (reviewed 
in Zhang et al., 2013b). 
Fractionation or enrichment steps do not necessarily have to occur prior to digestion. 
Especially PTM enrichment steps are preferentially performed after in-solution digest on the 
peptide level to increase the binding selectivity and thereby increase the sensitivity of LC-
MS/MS detection (reviewed in Zhao and Jensen, 2009). Peptide fractionation is mostly based 
on ion exchange chromatography providing an orthogonal separation method compared to 
reversed phase chromatography. Enrichment procedures for PTMs involve affinity purification 
e.g. by metal affinity complexation for phosphorylated peptides, lectins for glycosylated 
peptides or immunoprecipitation with PTM-specific antibodies (Figure 1.4) (reviewed in 
Macek et al., 2008; Nilsson, 2011; Zhang et al., 2013a).  
The resulting sample peptides are submitted to reversed-phase high performance liquid 
chromatography (Figure 1.4). The stationary phase is non-polar, therefore peptides are 
separated according to their hydrophobicity. The elution is achieved by an increase of the non-
polar solvent like acetonitrile or methanol together with an ion pairing reagent e.g. 
trifluoroacetic acid (TFA) or an organic acid such as formic acid (FA) in the mobile phase 
(reviewed in Mallick and Kuster, 2010). Throughout the whole RP-HPLC gradient, MS1 and 
MS2 spectra are consecutively recorded with a user-defined acquisition method. The 
acquisition method is most commonly DDA (Figure 1.4; previously described in section 1.3.1) 
and defines several parameters, i.e. selection of the top N most abundant precursor ions for 
fragmentation, use of a defined isolation window for selected precursor ions, fragmentation 
energy, MS1 and MS2 resolution, number of ions and the time required for measurement, 
exclusion of already sequenced ions. The resulting raw data is submitted to a search engine 
e.g. Andromeda or Mascot. Spectra interpretation occurs in an automated fashion by 
matching experimentally acquired spectra to theoretical spectra derived from a database such 





Besides the m/z ratios of the precursor and the fragment ions, a third piece of information is 
acquired during mass spectrometric measurement, the peptide ion intensity. While the m/z 
values identify a peptide/protein, its intensity (on the MS1 or the MS2 level, respectively) 
provides quantitative information. Overall, quantitation strategies can be divided into relative 
and absolute quantitation (Table 1). In relative quantitation, one or more experimental states 
are compared to a reference state, whereas in absolute quantitation the protein 
concentrations are determined (reviewed in Zhang et al., 2013b). Absolute quantitation can 
be achieve either in a label-free manner or by using a defined amount of a labeled standard 
(Bantscheff et al., 2007b; Schwanhäusser et al., 2011). For this work, only relative quantitation 
strategies were applied and therefore will be explained in more detail. Relative quantitation 
strategies can be achieved by labeling or label-free approaches. Labeling strategies can be 
divided in metabolic and chemical/enzymatic approaches. A common chemical labeling 
strategy is isobaric tags for relative and absolute quantitation (iTRAQ). The iTRAQ reagent 
reacts with the primary amine group of the N-terminus or lysine side chains. Quantitation is 
performed after fragmentation of the peptide on the MS2 level (Ross et al., 2004). The most 
popular and successful labeling strategies due to its robustness and accuracy is the stable 
incorporation of labeled amino acids in cell culture (SILAC) (Ong and Mann, 2007; Ong et al., 
2002). Label-free quantitation is based on ion intensities or spectral counting approaches 
(reviewed in Nikolov et al., 2012). For this work, SILAC labeling and label-free quantitation 
were used and thus will be explained in more detail.  
Table 1: Overview of commonly applied label-based and label-free relative and absolute quantitation strategies (Nikolov 
et al., 2012). 
Relative quantitation Absolute quantitation 
Label-based Label-free Label-free Label-based 
Metabolic Chemical/Enzymatic        
SILAC iTRAQ XIC-based AQUA peptides iBAQ 
 TMT Spectral counting    
 DML      
SILAC: stable isotope labeling by amino acids in cell culture; iTRAQ: isobaric tags for relative and absolute quantitation; TMT: 
tandem mass tag; DML: dimethyl labeling; XIC: extracted ion chromatogram; AQUA: absolute quantitation; iBAQ: intensity 




1.3.6.1. Stable isotope labeled amino acids in cell culture (SILAC) 
The SILAC amino acids are introduced metabolically i.e. during the growth of the cells. 
Therefore, cells are cultivated in medium that is depleted of arginine (R) and lysine (K) and 
instead is supplemented with the respective labeled lysine and arginine amino acids (Ong et 
al., 2002). Cells have to undergo several rounds of cell divisions, to achieve full incorporation 
of the labeled amino acids (Ong and Mann, 2007). ‘Heavy’ or labeled amino acids contain 
different numbers of the stable isotopes 2H (deuterium), 13C, 15N or 18O which introduces a 
mass shift in the MS1 spectrum. Generally, arginine and lysine are labeled because after 
tryptic digest peptides contain ideally one heavy C-terminal amino acid. SILAC experiments 
can be conducted as triplex experiments, comparing up to three different cell conditions 
states: light (K+0, R+0), medium or intermediate (K+4, R+6) and heavy (K+8, R+10). The 
intensity differences of the fragments in the MS1 spectrum reflect the relative quantities of 
the different states. Due to early mixing of the samples, ideally after cell lysis, parallel sample 
handling makes the method robust and less prone to sample preparation bias  (Figure 1.5) 
(Ong and Mann, 2006). However, not all biological systems are amenable to SILAC labeling e.g. 
in vivo probes or non-auxotrophic cell lines. For those, alternative quantitation strategies such 
as label-free quantitation can be applied.  
1.3.6.2. Label-free quantitation 
Label-free quantitation has evolved as a serious addition to the quantitation toolbox as with 
improved MS instrumentation, computational power and algorithms, quantitation value 
determination became more robust. Two label-free quantitation approaches can be 
distinguished: spectral counting or quantitation of peak area intensities (Table 1). Spectral 
counts are a measure of the number of MS/MS sequencing events that lead to peptide 
identification originating from the same protein during an LC-MS/MS run. The assumption is 
that the abundance of the proteins correlate with MS/MS spectrum matches (Liu et al., 2004; 
Washburn et al., 2001). Another approach is the quantitation of integrated peptide peak areas 
observed in extracted ion chromatograms (XICs), derived from the same protein (Cox et al., 
2014b). The protein abundance ratio is measured by comparing the XIC intensities of same 
peptides of proteins from different experiments (Bondarenko et al., 2002).  
Advances in label-free quantitation were made through improvements in instrumentation and 
quantitation algorithms. With fast acquisition, high mass resolution and accuracy MS 
instruments, more data points can be collected. Consequently, more sophisticated 
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quantitation algorithms can be applied e.g. for normalization of data. Recently an 
advancement of XIC-based label-free quantitation was published, the MaxLFQ algorithm 
which is implemented in the MaxQuant computational proteomics platform which was used 
in this work (Cox et al., 2014; Cox and Mann, 2008). Label-free methods can be applied to 
samples that cannot be metabolically labeled and the number of samples that can be 
compared to each other is unlimited. However, label-free quantitation leads to an increase in 
measuring time due to parallelized measurements, the requirement for simple, robust sample 
handling and is more prone to potential inaccuracy (Figure 1.5) (Cox et al., 2014; Dephoure 
and Gygi, 2012). 
 
 
Figure 1.5: SILAC labeling and label-free quantitation 
The upper panel shows a schematic double SILAC labeling workflow. The light (K+0, R+0) and heavy (K+8, R+10) amino acids 
are introduced during cell growth. The isotope positions in the amino acids are indicated (13C: red, 15N: green). Cell lysates 
are mixed, digested and measured by mass spectrometry. Quantitation is achieved by comparing MS1 intensities of the 
different SILAC states. The lower panel shows a label-free quantitation approach comparing two different states. Sample 
preparation and measurement are performed in parallel. Quantitation is achieved by comparing the XICs of the two different 
states. SILAC: stable isotope labeling by amino acids in cell culture; K: lysine; R: arginine; m/z: mass-to-charge ratio; DDA: 
data-dependent acquisition. 
 
1.3.7. Peptide and protein identification 
With the advent of high-throughput proteomics experiments, manual spectra interpretation 
became outdated and unfeasible. Hence, data produced from large-scale proteomic analyses 
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require computational power, sophisticated search engines and highly complex data analysis 
algorithms to perform peptide and protein identification, PTM localization and quantitation 
with high confidence and in an automated fashion (reviewed in Bantscheff et al., 2012; Mallick 
and Kuster, 2010; Mann et al., 2002). Some search engines are stand-alone software such as 
Mascot or SEQUEST, whereas the search engine Andromeda is integrated in the proteomic 
software platform MaxQuant which offers a higher degree of data compiling and organization 
(Cox and Mann, 2008; Cox et al., 2011). Results derived from Mascot can be further integrated 
into platforms such as Proteome Discoverer, Skyline, Scaffold, Progenesis or OpenMS 
(Brownridge et al., 2012; Sturm et al., 2008) (reviewed in Zhang et al., 2013a). Every software 
platform offers unique advantages over the others and therefore different applications might 
require the use of several different platforms. The basic functionality of search engine 
identification is similar: theoretical MS2 fragment spectra are compared to experimentally 
acquired MS2 spectra. The pool of theoretical MS2 spectra relies on a database containing a 
defined set of protein sequence entries. Theoretical MS2 spectra are generated in silico 
according to endoproteinase specificity and, if applicable, quantitation labels and PTMs. 
Candidate MS2 spectra within the predefined MS1 precursor and MS2 fragment mass 
tolerances are matched to the experimentally obtained MS2 spectra. For every experimental 
spectrum several theoretical candidate peptides can be obtained. The identification is based 
on a score value which reflects the quality of a peptide-spectrum-match (PSM) between a 
theoretical and an experimental spectrum (reviewed in Zhang et al., 2013). To increase 
confidence on a global level, identifications are filtered according to their false discovery rate 
(FDR). The FDR is a statistical approach to estimate and control the number of false positive 
identified proteins. The FDR is estimated by matching the experimental data against a target-
decoy database, containing the forward and the reversed or scrambled protein sequences 
derived from the forward database. All entries in this ‘nonsense’ database are false hits by 
definition (Elias and Gygi, 2007). The target-decoy approach is used to estimate and control 
the FDR. Generally, a FDR of 1% is an accepted value for large data-sets. 
For this work, the freely available computational platform MaxQuant with its search engine 
Andromeda was used due to its superior performance in large-scale, quantitative (SILAC and 
label-free) PTM analysis (Cox and Mann, 2008; Cox et al., 2011). MaxQuant performs SILAC-
based peptide, protein and PTM site quantitation by 3D peak extraction (retention time, m/z 
value, intensity) on the MS1 level while label-free quantitation is based on XIC extraction as 
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mentioned previously in section 1.3.6.2 (Cox et al., 2014). Quantitation values are calculated 
according to the user-specified experimental design can be accessed by plain, tab-separated 
text files with dedicated software tools to perform statistical and partly functional analyses. 
1.3.8. Identification of post-translational modification by mass spectrometry 
Previously, a large effort was made for high-throughput transcriptome and proteome 
analyses. However, transcriptome and proteome levels of enzymes might not correlate with 
the biological activity of a protein. Moreover, gene expression and protein copy number 
changes are far downstream processes that are initiated by an extracellular stimulus and 
therefore represent a final outcome rather than an active signal (reviewed in Larsen et al., 
2006; Mann and Jensen, 2003). Post-translational modifications introduce an additional level 
of protein regulation by occurring immediately after and proximal to the initiating stimulus. 
They control many cellular processes as proliferation, metabolism, differentiation and 
apoptosis by changing the conformational state of a protein, tagging them for processing or 
subcellular relocalization or providing a binding platform and thereby regulating protein 
activity or degradation (reviewed in Mann and Jensen, 2003; Olsen and Mann, 2013; Witze et 
al., 2007). PTMs are covalent, chemical modifications of proteins after translation. Hundreds 
of different PTMs have been described, however only a handful of them are being investigated 
extensively: phosphorylation of serine, threonine and tyrosine, acetylation, ubiquitination, 
methylation, SUMOylation and N- and O-linked glycosylation (Jensen et al., 2006; Uy and 





Figure 1.6: Post-translational modifications investigated in this work 
The upper panel shows phosphorylated (highlighted in blue) serine, threonine and tyrosine side chains. The lower panel 
shows acetylated (red) and ubiquitinated (a generic ubiquitin molecule is depicted as yellow rectangle; the GG remnant motif 
is highlighted in orange) lysine side chains, respectively. The zigzag line indicates the peptide bond.  
 
PTM-mediated signaling networks consist of a dynamic interplay between writer (e.g. tyrosine 
kinases), eraser (e.g. tyrosine phosphatases) and reader (e.g. SH2-domain containing proteins) 
enzymes that process information in a spatiotemporal manner such as the afore mentioned 
BCR and TCR signaling cascades after antigen encounter (reviewed in Jin and Pawson, 2012). 
A specific function is rarely mediated by just a single type or site of modification, but especially 
cross talk of different modifications leads to a precise cellular outcome (Hunter, 2007; Swaney 
et al., 2013). Cross talk entails combinatorial effects of PTMs and can be either negative or 
positive. Negative cross talk occurs in a competitive manner i.e. one PTM occupies the same 
position on the same amino acid side chain, e.g. acetylation and ubiquitination on lysine 
residues, or indirectly competitive by masking secondary PTM sites (Hunter, 2007; Wagner et 
al., 2011). Positive, non-competitive cross talk between PTMs is characterized by one PTM 
priming the addition or removal of a second or more PTMs leading to combinatorial regulation 
effects. Cross talk was first described in histones where a multitude of PTMs (‘histone marks’) 
on the N-terminal tail form the so-called histone code (Strahl and Allis, 2000). Another 
important example are phosphodegrons where an initial phosphorylation of a dedicated site 
on a protein is followed by subsequent ubiquitination leading to its proteasomal degradation 
(Ang and Harper, 2005). In general, PTMs can influence each other in many ways: (i) a first 
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PTM regulates the catalytic activity of a second PTM writer or eraser enzyme by allosteric 
changes, (ii) a PTM provides a binding platform for a writer or eraser enzyme which then can 
mediate its catalytic activity on a site in close proximity or (iii) a PTM on a substrate hinders 
the interaction with the catalytic active enzyme by steric hindrance (Hunter, 2007). 
As mentioned previously, the presence of a PTM on a peptide is accompanied by a mass 
increase of the precursor and, in most cases the sequence-specific fragment ions. From these, 
the position of the PTM on the peptide sequence can be determined (reviewed in Mann and 
Jensen, 2003). However, PTM identification is not a trivial task as some challenges have to be 
overcome. Recent developments in MS technology, sample preparation methods and 
computation made the generation of large-scale, high-throughput PTM datasets feasible 
(reviewed in Mann and Jensen, 2003; Olsen and Mann, 2013). One challenge that has to be 
dealt with is that all PTMs occur at substochiometric levels, meaning that only a small 
proportion of proteins are modified at any given time point. This leads to masking of the post-
translationally modified peptides by their unmodified, high abundant counterparts. Some 
PTMs can be enriched by making use of the physical and chemical properties of the PTM by 
affinity-based enrichment procedures or by their immunogenicity using target-specific 
antibodies (reviewed in Mann and Jensen, 2003; Witze et al., 2007). Not only specific 
enrichment steps are required, also the PTM eraser enzymes e.g. PSP/PTP, KDACs, DUBs need 
to be inhibited. Another challenge is that PTM identification requires high sequence coverage 
because every single PTM site stands for its own and can have an individual biological 
meaning. Also, efficient fragmentation is required in order to unambiguously localize the site 
of modification in case there are several theoretical possibilities (reviewed in Olsen and Mann, 
2013). However, complete fragment ion series and unambiguous site localization cannot 
always be achieved for peptides with multiple potential sites of modification e.g. a 
phosphorylated peptides containing several serine, threonine or tyrosine residues, especially 
when potential acceptor residues are in close proximity to each other. The confidence of these 
positional PTM isomers is reflected by site localization scores such as the A score 
(implemented in SEQUEST), localization probability (implemented in Andromeda), Mascot 
Delta (MD) score and phosphoRS (embedded in Proteome Discoverer) (Beausoleil et al., 2006; 
Olsen et al., 2006; Savitski et al., 2010; Sharma et al., 2014; Taus et al., 2011). Of note, all of 
the above scoring schemes were originally developed for large-scale phosphorylation site 
analyses but can also be applied to other post-translational modifications. In the following the 
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PTMs investigated in this work will be described in more detail in terms of biological function, 
enrichment strategies and mass spectrometric analysis. 
1.3.8.1. Phosphorylation 
Reversible serine, threonine and tyrosine phosphorylation is by far the most studied PTM 
(Figure 1.6). This can be partly explained by its early detection: Serine and threonine kinase 
activity was detected in the middle of the 50s, and tyrosine phosphorylation in the beginning 
of the 80s of the last century (Burnett and Kennedy, 1954; Eckhart et al., 1979; Sefton et al., 
1980). Also its major regulatory importance e.g. in immune receptor signaling and the 
availability of convenient enrichment procedure strategies have been important factors 
(reviewed in Hunter, 2007). Phosphorylation of a target protein leads commonly to changes 
in protein activity, protein-protein interactions or re-localization of proteins within a cell as 
described previously (reviewed in Hunter, 2007; Lim and Pawson, 2010). The proportions of 
modified amino acid residues reported in large-scale studies vary in the literature, dependent 
on the methodology used. However, serine is by far the most frequently phosphorylated 
amino acid (59%) followed by threonine (24.7%) and tyrosine (16.3%; according to PSP 
phosphorylation modification site statistics in September 2015, www.phosphosite.org). The 
addition of a phosphate group to a target amino acid increases the peptide or fragment mass 
by 80 Da (reviewed in Larsen et al., 2006). 
Additionally, the phosphorylation of the basic amino acids, lysine, arginine and histidine and 
cysteine residues has been described (Bertran-Vicente et al., 2014; Elsholz et al., 2012; Hess 
et al., 1988; Meins et al., 1993). The phosphorylation on these unconventional amino acids 
was for a long time believed to be merely found in prokaryotes. However, there is growing 
evidence that they could also play a role in eukaryotes (reviewed in Cieśla et al., 2011; 
Cozzone, 1988). The phosphorylation is rare compared to serine, threonine and tyrosine 
phosphorylation and is furthermore acid labile which makes common enrichment procedures 
unfeasible, therefore it will not be mentioned further in this thesis (Cieśla et al., 2011; 
Matthews, 1995). 
Phosphorylation of serine, threonine and tyrosine is regulated by the dynamic interplay of 
kinases which add the ɣ-phosphoryl group from the donor ATP to the amino acid residue, and 
phosphatases that remove the phosphate group (Hunter, 1995). 478 human eukaryotic 
protein kinases were identified that can be divided into seven major branches (CMGC, CAMK, 
AGC, CK1, STE, TKL and TK) and 40 atypical kinases (Manning et al., 2002). Atypical kinases do 
Introduction 
27 
not have sequence homology to other kinases but execute kinase activity. Six branches of the 
eukaryotic protein kinases account for serine/threonine kinases while the tyrosine kinase (TK) 
family consists of 90 members of whom 58 are receptor tyrosine kinases (Lemmon and 
Schlessinger, 2010; Manning et al., 2002). Receptor tyrosine kinases mediate ligand-induced 
tyrosine phosphorylation for transmission of signals across a plasma membrane e.g. the EGFR 
or the insulin receptor family. Moreover, there are two-component receptors like the BCR and 
TCR antigen receptors that are composed of an extracellular ligand-binding subunit that forms 
a complex with a cytoplasmic tyrosine kinase (Samelson, 2011). Phosphorylated tyrosine 
residues are especially low abundant but are of major significance especially in the context of 
(immune)-receptor signaling. Tyrosine phosphorylation has slightly distinct chemical 
properties compared to its phosphorylated serine and threonine counterparts which provide 
binding specificity (reviewed in Hunter, 2014; Lim and Pawson, 2010). The phosphorylation is 
linked to the phenolic ring which makes hydrophobic or π-bond-ring interactions possible, and 
the phosphorylation is farther away from the peptide backbone which requires deeper binding 
pockets (reviewed in Hunter, 2014). These steric differences makes the generation of highly-
specific, motif-independent anti-phosphotyrosine antibodies possible which are a valuable 
tool for the investigation of tyrosine phosphorylation (Larsen et al., 2005; Rush et al., 2004). 
Phosphorylation is counteracted by the removal of the phosphate group by protein 
phosphatases which as kinases can be divided in two classes: protein serine/threonine 
phosphatases and protein tyrosine phosphatases (Hunter, 1995). Originally, phosphorylated 
serine and threonine residues were thought to merely introduce allosteric changes in proteins 
rather than providing protein-protein interaction platforms (reviewed in Hunter, 2014). 
However, five domain families that bind phosphoserine and threonine were identified that 
regulate various mechanisms like ubiquitination, cell cycle control and DNA damage signaling 
(Yaffe and Elia, 2001). Specific phosphotyrosine-binding domains comprise of the Src 
homology 2 (SH2) and the phosphotyrosine-binding (PTB) domain and can be primarily found 
in adapter proteins proximal of immune-receptor such as SYK or ZAP-70, BTK, GRB2, NCK and 
many others (reviewed in Schlessinger and Lemmon, 2003; Yaffe, 2002).  
Standard enrichment strategies for phosphorylated peptides include the complexing of the 
phosphate group with immobilized metals e.g. IMAC or titanium/zirconium metal oxides (TiO2 
or ZrO2). This affinity complexation exploits the chemical behavior of the phosphate group 
regardless of the site of modification (reviewed in Witze et al., 2007). Additionally, 
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phosphotyrosine can be specifically enriched with the respective antibodies whereas 
phosphoserine and -threonine specific antibodies are not available (reviewed in Grimsrud et 
al., 2010).  
Under CID fragmentation, phosphorylated serine and threonine residues are prone to neutral 
loss of phosphoric acid (H3PO3, 98 kDa) (Boersema et al., 2009; Schroeder et al., 2004). 
Tyrosine residues tend to lose metaphosphoric acid (HPO3, 80 kDa) (reviewed in Mann et al., 
2002; Mann and Jensen, 2003). This leads to inefficient fragmentation of the peptide 
backbone and requires an additional fragmentation step (MSn or MS3). Furthermore, tyrosine 
residues tend to N- and C-terminal fragmentation that lead to a characteristic diagnostic 
immonium ion of m/z 216.0426 (Steen et al., 2001). As mentioned before, the low mass cut-
off of ion traps prevents the low mass tyrosine immonium ion from detection in many cases. 
In beam-type CID (HCD) and ETD fragmentation the phosphorylation detaches to a lesser 
extend from the peptide due to different fragmentation principles and mechanisms. 
Phosphorylated amino acids stay intact and the peptide backbone gets fragmented which 
leads to more meaningful spectra (Nagaraj et al., 2010). The advent of different fragmentation 
options posed a challenge to the community to find the optimal conditions for phosphorylated 
peptides. In several studies it was shown that beam-type CID (HCD) outperforms CID for the 
fragmentation of phosphopeptides (Frese et al., 2011; Marx et al., 2013; Nagaraj et al., 2010; 
Savitski et al., 2010). Furthermore it was shown that HCD in general gives a better outcome 
for the identification of phosphopeptides compared to ETD, although the latter is more 
suitable for higher charge states and leads to more unambiguous site identification (Marx et 
al., 2013). Current efforts aim at the development of alternative fragmentation techniques for 
particularly fragile modifications. Recently a hybrid fragmentation mode that combines ETD 
and HCD fragmentation, namely EThcD, that is especially suitable for phosphorylation site 
localization was described (Frese et al., 2012; 2013).  
1.3.8.2. Deregulated phosphorylation 
Phosphorylation is undoubtedly of major importance in cell signaling, and its deregulation 
caused by dysfunctional kinases has been already associated with several types of diseases 
e.g. Alzheimer’s disease, immunological diseases, metabolic diseases and especially cancer 
(Bramblett et al., 1993; Goedert, 2015) (reviewed in Cohen, 2002). Kinases with an oncogenic 
potential regulate important signaling pathways at central positions. These kinases can be 
either directly affected by mutation or they act as downstream recipients of oncogenic 
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upstream signals (reviewed in Zhang et al., 2008). Direct deregulation which render the 
kinases constitutively active can be caused by various mechanisms, amongst others by an 
internal tandem duplication e.g. of the FLT3 receptor in AML (FLT3-ITD), amino acid 
substitution e.g. BRAF V600E which affects the kinase activation loop or gene fusions e.g. BCR-
ABL1 (also called Philadelphia chromosome) (Davies et al., 2002; Quentmeier et al., 2003) 
(reviewed in Zhang et al., 2008a). A kinase affected by a mutational hit withdraws itself from 
regulation and therefore cell survival becomes dependent on this kinase, a process referred 
to as oncogene addiction. This dependency also makes the malignant cell vulnerable to kinase 
ablation (Weinstein et al., 1999; Weinstein and Joe, 2006). Given the importance of kinases 
for cell signaling, they are an important target for pharmacological manipulation. Kinases have 
a bi-lobed structure, with an active-site cleft between the N- and C-terminal lobe and a highly 
conserved activation loop that lies outside the cleft. The ATP interaction occurs in the catalytic 
cleft within the hinge that connects both lobes. Kinase activity itself is regulated by 
phosphorylation of amino acid residues in the activation loop leading to conformational 
changes, for example MAP-kinases possesses a TXY motif in their activation loop that is 
required to be phosphorylated at both positions to become fully active (Burack and Sturgill, 
1997; Canagarajah et al., 1997). At the N-terminal side of the activation loop protein kinases 
possess an aspartate-phenylalanine-glycine (DFG) motif that mediates catalytic activity. In the 
active, phosphorylated conformation (DFG in), the loop can interact with the substrate 
whereas in the inactive kinase conformation (DFG out), the activation loop blocks the 
substrate binding site (Nagar et al., 2002). The common ATP dependency of phosphorylation 
makes the ATP interaction sites a popular target for inhibitor design. The ATP binding sites of 
kinases are highly conserved, yet sufficiently distinct to achieve a certain degree of specificity 
to fit in chemical compounds. These are small molecules that function as ATP analogues and 
therefore as selective kinase inhibitors (Capdeville et al., 2002) (reviewed in Zhang et al., 
2008). The majority of small-molecule kinase inhibitors are ATP competitors that target the 
kinase active site. Staurosporine, a microbial alkaloid produced by the bacterium 
Streptomyces staurosporeus was detected early as a kinase inhibitor but exhibited low 
specificity (Sako et al., 1988). In 1986, Novartis started with the development of a specific 
Abelson tyrosine kinase (ABL1) inhibitor which was 15 years later approved for clinical use in 
chronic myelogenous leukemia, named Imatinib or Gleevec® (Capdeville et al., 2002). Since 
then, several small-molecule kinase inhibitors have been approved for clinical administration 
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for diverse indications and many more are currently in clinical studies (Cohen and Alessi, 
2012). Two types of ATP-competitive kinase inhibitors can be classified: Type I inhibitors bind 
to the kinase in a conformation-independent manner (e.g. Dasatinib), while type II inhibitors 
only bind in the inactive conformation (e.g. Imatinib) (Hari et al., 2013; Schindler et al., 2000). 
Most small-molecule inhibitors bind reversibly, however, there are also irreversible inhibitors 
that form a covalent bond with a cysteine or nucleophilic residue in the kinase active site e.g. 
the BTK inhibitor Ibrutinib (Cohen et al., 2005). Another class are allosteric inhibitors that bind 
outside the ATP-binding site thereby inducing activity altering allosteric changes e.g. the MEK1 
and MEK2 inhibitor CI-1040 (Ohren et al., 2004). Targeted therapies lead to improvements in 
cancer treatment but are hampered by resistance mechanisms against kinase inhibitors due 
to the selective pressure for cells. These resistance mechanisms can be acquired by mutations 
in the kinase, target amplification, upregulation of alternative pathways that drive cancer 
(reviewed in Zhang et al., 2008). The class of selective ATP competitive kinase inhibitors has 
grown and the search for new inhibitors and potential new targets is still going on. 
1.3.8.3. Acetylation 
Another important PTM is the acetylation of proteins on lysine residues. For a long time 
acetylation was mostly known in the context of epigenetic marks at the N-terminal histone 
tail, thereby regulating gene transcriptional activity (Allfrey et al., 1964). Transcriptionally 
active euchromatin is associated with acetylation while inactive heterochromatin is modified 
to a lesser extent. Later, acetylation was also recognized to modify non-histone proteins such 
as tubulin and p53 (Gu and Roeder, 1997; L'Hernault and Rosenbaum, 1985). Acetylation is 
nowadays recognized as the predominant PTM in mitochondria and is associated with the 
regulation of metabolic processes (Kim et al., 2006; Wang et al., 2010; Weinert et al., 2011; 
Zhao et al., 2010). The acetyl group is transferred from acetyl-coenyzme A (acetyl-CoA) to the 
ɛ-amino group of lysine residues by the class of acetyltransferases (KATs), and can be removed 
by lysine deacetylases (KDACs) (Figure 1.6). In contrast, the N-terminal protein acetylation is 
a common co-translational modification in eukaryotes that differs from PTM acetylation and 
will not be further discussed here (Hwang et al., 2010; Polevoda and Sherman, 2000). 
Bromodomains are the acetyl-lysine reader domains and can be mainly found in lysine 
acetyltransferases and nuclear proteins (reviewed in Zeng and Zhou, 2002). Recently, 
bromodomain inhibitors evolved as new class of small-molecule inhibitors that can be applied 
for the targeted inhibition of oncogene transcription (Delmore et al., 2011). The generation of 
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acetyl-lysine-specific antibodies made the efficient enrichment in a large-scale, MS-based 
manner possible (Choudhary et al., 2009; Kim et al., 2006). Acetylation induces as mass shift 
of 42 Da and can be confused with trimethylation which has the same nominal mass. As for 
ubiquitination, trypsin does not cleave after acetylated lysine, formally leading to a missed 
cleavage (reviewed in Zhang et al., 2013). 
1.3.8.4. Ubiquitination  
Ubiquitin (Ub) is a 76 amino acid long protein which is attached with its C-terminal glycine to 
the lysine ɛ-amino group of a substrate protein (Figure 1.6 shows the di-glycine remnant motif 
after trypsin digestion). Ubiquitination is a three step process starting with ATP-dependent 
ubiquitin activation by an ubiquitin-activating enzyme (E1), followed by the transfer to an 
ubiquitin-conjugation enzyme (E2) and finally the transfer to the target protein by an 
ubiquitin-protein ligase (E3) (Ye and Rape, 2009). The modification can be reversed by 
deubiquitinating enzymes (DUBs). A single Ub-molecule or poly-Ub chains can be added to a 
target protein. For the assembly of poly-Ub chains the seven lysine residues in ubiquitin, and 
additionally the N-terminal methionine (Met1) can become ubiquitinated and lead to different 
branched structures (Fiil and Gyrd-Hansen, 2014). Poly-Ub chains iteratively linked to lysine 
residue 48 (K48) mark proteins for proteasomal degradation (Fiil and Gyrd-Hansen, 2014; 
Kulathu and Komander, 2012; Thrower et al., 2000). In contrast, K63 linked poly-Ub does not 
drive degradation but is involved in various cellular regulation and signaling processes 
(Kulathu and Komander, 2012; Sun and Chen, 2004). Linear methionine ubiquitination (Met1-
Ub) is linked to NF-κB signaling regulation whereas the other possible poly-Ub chain variants 
and mono-Ub regulate degradation or different cellular signaling mechanisms, respectively 
(Iwai and Tokunaga, 2009; Kulathu and Komander, 2012). Eleven families of Ub-binding 
domains (UBDs) are known that either bind to single ubiquitination or to different linked 
variants of the poly-Ub chains (Hicke et al., 2005) (reviewed in Kirkpatrick et al., 2005).  
Ubiquitin enrichment for mass spectrometric measurement can be achieved by the expression 
of His-tagged ubiquitin in combination with anti-His purification protocols or by using 
ubiquitin binding domains for affinity purification (Hicke et al., 2005; Kirkpatrick et al., 2005; 
Peng et al., 2003). Furthermore, the intact ubiquitin molecule can be enriched with an anti-
ubiquitin antibody (Vasilescu et al., 2005). Recently, a K-GG remnant motif antibody that 
proved to be a valuable tool for the large-scale enrichment of ubiquitinated peptides was 
developed (Figure 1.6) (Xu et al., 2010). As mentioned before, ubiquitin is attached with its C-
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terminal glycine at position 76 to the lysine side chain of the target protein (Figure 1.6). During 
digestion with trypsin, ubiquitin is cleaved between the arginine at position 74 and glycine at 
position 75. The motif is immunogenic and therefore can be targeted by specific antibodies. 
The C-terminal end of the ubiquitinated lysine cannot be cleaved by trypsin leading to a missed 
cleavage. However, after digestion neither mono- or poly-ubiquitination nor the linkage 
structure of poly-ubiquitination can be deduced anymore (reviewed in Kirkpatrick et al., 
2005b; 2005a). The missed cleavage and the remnant motif are characteristic for MS-based 
identification of ubiquitin as the latter introduces a mass shift of 114.0429 Da on the 
respective lysine residue. The identification of ubiquitin remnants has to be considered 
carefully as the use of iodoacetamide for cysteine alkylation during sample preparation can 
introduce artifacts that mimic the GG remnant (Nielsen et al., 2008). Recently it was shown 
that ETD is the fragmentation method of choice for the identification of ubiquitinated peptides 
as those peptides are higher charged on average due to the missed cleavage (trypsin does not 
cleave after modified lysine) and the additional N-terminus of the di-glycine adduct (Porras-





Post-translational protein modifications such as serine, threonine and tyrosine 
phosphorylation play a crucial role in translating extracellular signals into highly specific 
cellular responses by a complex interplay of intracellular signaling cascades. Previously such 
signaling cascades have been investigated by low-throughput and targeted approaches. As 
dysregulated signaling is often involved in diseases such as cancer, global knowledge about 
phosphorylation dynamics is required to understand transformed signaling processes of 
malignant cell and to identify potential pharmacological targets such as kinases. Tandem 
mass-spectrometry is a suitable tool for the global and unbiased detection, quantitation, and 
localization of phosphorylation sites on proteins in a given cellular context. Like most PTMs 
phosphorylation occurs at substoichiometric levels, and therefore phosphopeptides need to 
be enriched by selective enrichment strategies prior to MS analysis. In combination with SILAC 
labeling, different cellular states can be compared simultaneously in one experiment. This 
work comprises three distinct large-scale, quantitative phosphoproteomic projects. The main 
project of this work is the investigation of B-cell receptor (BCR) signaling in Burkitt’s lymphoma 
(BL), an aggressive B-cell derived lymphoma. Currently, BL is treated with aggressive 
chemotherapy as targeted therapeutic options are not available. BL cells critically depend on 
BCR expression and BL cell survival is thought to be driven by antigen-independent, so-called 
tonic BCR signaling. Until now tonic BCR signaling has not been analyzed and it is not known if 
tonic and antigen-dependent BCR signaling activate similar effector proteins. To characterize 
these two modes of receptor signaling, antigen-dependent signaling was analyzed by time-
dependent receptor stimulation, whereas tonic BCR signaling was investigated upon CD79A 
knockdown and pharmacological SYK inhibition, respectively. Antigen-dependent 
phosphoproteomic analyses were complemented with transcriptional analysis and the 
determination of activated kinases to further characterize signaling mechanisms, and to 
identify other potentially pharmacologically targetable effectors.  
Quantitative phosphoproteomics was applied to analyze another hematological disease, 
namely acute myeloid leukemia (AML). AML is an aggressive, hematologic cancer whose 
outcomes depend on the genetic background of malignant transformed cells. BTK, a tyrosine 
kinase known to be involved in BCR signaling was found to be activated in AML and its 
inhibition was shown to induce apoptosis in AML cells in preclinical models. Two genetically 
different AML cell lines were investigated on their phosphoproteomic level to investigate the 
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activation mechanism of BTK and signaling alterations upon BTK inhibition to generate a 
molecular rationale for BTK inhibitors in AML treatment. T cell signaling is similar to that of B 
cells although the immunological effector functions of B and T cells differ. Phosphorylation 
site dynamics of two essential TCR signaling adapters, LCP2 (SLP76) and GADS (GRAP2), were 
analyzed in a defined TCR stimulation time course in Jurkat cells to better understand their 
modes of action and regulation. Taken together, the aim of the presented work is to globally 
characterize phosphorylation site changes in different cellular conditions by quantitative mass 
spectrometry-based phosphoproteomics, with a particular focus on identifying regulatory p-
sites on effector proteins that can be further investigated functionally and that might point 
towards druggable protein targets. 
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2. Materials and Methods 
 Materials 
2.1.1. Technical devices 
Table 2: Technical devices 
 Technical device Company 
Centrifuges Biofuge pico Heraeus, Thermo Scientific, DE 
 Centrifuge 5415R Eppendorf, Hamburg, DE 
 Fresco 17 Heraeus, Thermo Scientific, DE 
 Multifuge X3R Thermo Scientific, DE 
 Pico 17 Heraeus, Thermo Scientific, DE 
 Sorvall Lync 6000 Thermo Scientific, DE 
Computation (MaxQuant 
server) 
PowerEdge R815 Dell, DE 
LC systems Agilent 1100 Agilent, DE 
 EASY n-LC 1000  Thermo Fisher Scientific, DE 
 SMART Pharmacia, GE Healthcare, DE 
 Ultimate 3000 RSLC UHPLC Dionex, DE 
Mass spectrometers Hybrid linear ion trap-orbitrap (LTQ 
Orbitrap Velos) 
Thermo Fisher Scientific, DE 
 Hybrid quadrupole-orbitrap 
(Q Exactive HF) 
Thermo Fisher Scientific, DE 
 Hybrid quadrupole-orbitrap 
(Q Exactive) 
Thermo Fisher Scientific, DE 
 Tribrid mass spectrometer (Orbitrap 
Fusion) 
Thermo Fisher Scientific, DE 
Other Laminar flow HeraSafe Thermo Fisher Scientific, DE 
 Electrophoresis system for SDS-PAGE 
Xcell SureLock 
Invitrogen, DE 
 Lyophilization apparatus alpha 2-4 Christ, DE 
 Microtip sonication Sonifier W-250D Branson Digital Sonifier, DE 
 Sonication device Sonorex Super Bandelin, DE 
 Spectrophotometer NanoDrop 
ND-1000 
PeqLab, DE 
 SpeedVac Thermo Fisher Scientific, DE 
 Thermomixer Comfort Eppendorf, DE 
 
2.1.2. Chemicals and reagents 
Table 3: Chemicals and reagents 
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Acetone Merck, DE 
Acetonitrile (ACN), LiChroSolv Merck, DE 
Ammonium bicarbonate (ABC) Sigma-Aldrich, DE 
Ammonium formate Sigma-Aldrich, DE 
Ammonium hydroxide (NH4H2O) 28-30% (w/v) Acros Organics, USA 
C18 column material: ReproSil-Pur 120 C18-AQ, 120 Å (1.9 µm, 3 µm, 5 µm) Dr. Maisch, DE 
C18 Empore Octadecyl 47 mm Extraction Disks  3M, USA 
Chloroacetamide (CAA) Sigma-Aldrich, DE 
Coomasie Brilliant Blue G-250   Sigma-Aldrich, DE 
Dihydroxybenzoic acid (DHB) Sigma-Aldrich, DE 
Dithiothreitol (DTT) Roth, DE 
Ethanol, LiChroSolv Merck, DE 
Formic acid (FA) Fluka and Sigma-Aldrich, DE 
Glycerol, >99%, p.a. Roth, DE 
HEPES Merck, DE 
IAP buffer (10x) Cell Signaling Technology, DE 
Iodoacetamide (IAA)  Sigma-Aldrich, DE 
Methanol, LiChroSolv Merck, DE 
Methylated ethanol Merck, DE 
NuPAGE Antioxidant Invitrogen, DE 
NuPAGE LDS sample buffer (4X) Invitrogen, DE 
NuPAGE MOPS SDS running buffer (10X) Invitrogen, DE 
NuPAGE Sample reducing agent (10X) Invitrogen, DE 
Potassium phosphate dibasic (K2HPO4) Merck, DE 
Potassium phosphate monobasic (KH2PO4) Merck, DE 
RapiGest Waters, UK 
Sodium dodecyl sulphate (SDS) Biorad, DE 
Titanium dioxide (TiO2) GL Sciences, JP 
Trifluoroacetic acid (TFA) Roth, DE 
Tris(2-carboxyethyl)phosphin (TCEP) Sigma-Aldrich, DE 
Tris(hydroxymethyl)aminomethane (Tris) VWR, DE 
Urea Sigma-Aldrich, DE 
Water, LiChroSolv Merck, DE 
 
2.1.3. Buffer and solutions 
All buffers and solutions were sterilized with bottle top or syringe 0.2 µM sterile filters. 
Table 4: Buffers and solutions 
Experimental purpose Buffer/solution Composition 
General MS sample preparation 1.25 M DTT stock in water (stored at -20°C) 
 100 mM CAA in 25 mM ABC 
 100 mM IAA  in 25 mM ABC (freshly prepared, 
kept in dark) 
 25 mM ABC in water 
 50 mM DTT  in 25 mM ABC (freshly prepared) 
 5 mM TCEP, 10 mM IAA in 25 mM ABC 
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 LC-MS/MS sample loading 
solution 
5% (v/v) acetonitrile, 0.1% (v/v) 
formic acid and 2% (v/v) 
acetonitrile, 0.05 (v/v) TFA 
Other Coomassie staining solution 0.08% (w/v) Coomassie Brilliant 
Blue G-250, 20% (v/v) methanol, 
1.6% (v/v) orthophosphoric acid, 
8% (w/v) ammonium sulfate 
PTM immunopurification 
(PTMScan Kits) 
0.1 M PBS pH 8 0.2 M KH2PO4, 0.2 M K2HPO4 in 
water 
 200 mM HEPES stock pH 8 in water, pH adjusted with NaOH 
 Bead elution buffer 0.15% (v/v) TFA 
 StageTip purification solution C  50% (v/v) ACN, 0.1% (v/v) TFA 
 StageTip purification solution D 0.1% (v/v) TFA 
 StageTip purification solution E 40% (v/v) ACN, 0.1% (v/v) TFA 
 Sep-Pak purification solvent A  0.1% (v/v) TFA 
 Sep-Pak purification solvent B 40% (v/v) ACN, 0.1% (v/v) TFA 
 Sep-Pak washing solution  5% (v/v) ACN, 0.1% (v/v) TFA 
Phosphoproteome enrichment 
(SCX + TiO2) 
SCX buffer A  10 mM ammonium formate, 30% 
(v/v) ACN, pH 2.65 (adjusted with 
FA) 
 SCX buffer B 500 mM ammonium formate, 
30% (v/v) ACN, pH 2.65 (adjusted 
with FA) 
 TiO2 loading solution 200 mg DHB in 80% (v/v) ACN, 5% 
(v/v) TFA 
 TiO2 wash solution 80% (v/v) ACN, 5% (v/v) TFA 
 TiO2 elution solution 0.6 N NH4OH (4.2 mL NH4OH + 
95.8 mL H2O) 
 TiO2 column packing solution 80% (v/v) ACN, 0.1% (v/v) TFA 
Liquid chromatography Buffer A (Velos, Fusion, Q 
Exactive, Q Exactive HF) 
0.1% FA 
 Buffer B (Velos, Q Exactive) 95% ACN, 0.1% FA 
 Buffer B (Fusion, Q Exactive HF) 80% ACN, 0.08% FA 
 
2.1.4. Consumables 
Table 5: Consumables 
Product Company 
65MMLTIFLEX-Tips 1-200 ML, round Carl Roth, DE 
Combitips (different sizes) Eppendorf, DE 
Diamond Tower Pack pipet tips (10 µL, 20-200 µL, 1,000 µL) Gilson, F 
Falcon reaction tube (15 mL, 50 mL) Greiner, DE 
GELoader tip Eppendorf, DE 
Micro SpinColumns, C18, 5 µm frit Harvard Apparatus, USA (Serva, DE) 
Empty Micro SpinColumns, 5 µm frit Hoefer Inc., USA (Serva, DE) 
NuPAGE Novex 4-12% Bis-Tris Mini Gels Invitrogen, DE 
Parafilm Bemis, B 
Safe-Lock Tubes (0.5 mL, 1.5 mL, 2 mL, 5 mL) Eppendorf, DE 
Sep-Pak Vac tC18 Columns (1 cc, 3 cc, 6 cc) Waters, DE 
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Bottle-top and syringe sterile filters (pore size 0.2 µM) Sarstedt, DE 
Syringe (1 mL, 5 mL, 10 mL, 50 mL) B.Braun, DE 
Syringe canules (different sizes) B.Braun, DE 
 
2.1.5. Kits, enzymes and HPLC columns 
Table 6: Kits 
Kit  Company 
Pierce BCA Protein Assay Kit Thermo Scientific Fisher, DE 
PTMScan Phospho-Tyrosine Rabbit mAb (P-Tyr-1000)  Cell Signaling Technology, DE 
PTMScan Ubiquitin Remnant Motif (K-ɛ-GG) Cell Signaling Technology, DE 
PTMScan Acetyl-Lysine Motif [Ac-K] Cell Signaling Technology, DE 
 
Table 7: Enzymes 
Enzyme Company 
AspN (sequencing grade) Roche, DE 
Benzonase Novagen, USA 
Chymotrypsin (sequencing grade) Roche, DE 
Rnase A Ambion, Applied Biosystems, DE 
Rnase T1 Ambion, Applied Biosystems, DE 
Trypsin (sequencing grade) Serva Electrophoresis,  DE 
Trypsin, modified (sequencing grade) Promega, USA 
 
Table 8: HPLC columns 
Column Company 
BioBasic SCX 2.1 x 50 mm Thermo Fisher, DE 
Xbridge C18 1.0 x 150 mm, 3.5 µm Waters, IE 
 
2.1.6. Cell lines 
Table 9: Cell lines 
Cell line Comments Reference Provided by (also refer 
to Table 12) 
BL2 Sporadic BL cell line (Denépoux et al., 1997) University Medical 
Center, FFM 
Daudi EBV-positive endemic BL; 
Myc translocation; 
inactivating ID3 mutation 
(Haluska et al., 1987; 
Klein et al., 1968) 
University Medical 
Center, FFM 
DG75 Sporadic BL cell line; Myc 
translocation 
(Ben-Bassat et al., 1977; 
Gabay et al., 1999; Penas 
et al., 2014) 
University Medical 
Center, FFM 
FFM_BL1 (or BL1) Patient derived BL cells: 
Point mutations in ELP2, 
FOXO1, MYC and TOP2A 
 University Medical 
Center, FFM 
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J14 Jurkat derivative SLP76 
deficient cell line 
(Yablonski et al., 1998) Technion, Haifa, Israel 




MV4-11 AML FLT3-ITD-positive 
cell line 
(Santoli et al., 1987) University Medical 
Center, FFM 
 
2.1.7. Software and databases 
Table 10: Software 
Name Company/ Institution 
Cytoscape Cytoscape Consortium 
MaxQuant Max Planck Institute for Biochemistry, DE  
Perseus Max Planck Institute for Biochemistry, DE 
PhosphoPath app (for Cytoscape) Bijvoet Center for Biomolecular Research and Utrecht Institute 
for Pharmaceutical Sciences, Utrecht University, NLD 
R R Project 
R Studio R studio, USA 
Venn Diagram Plotter Pacific Northwest National Laboratory, USA 
Xcalibur Thermo Fisher Scientific, DE 
 
Table 11: Databases 










National Institute of 
Allergy and Infectious 






pathway and motif 
annotation 
Johns Hopkins 













Harvard Medical School http://motif-
x.med.harvard.edu 
PhosphOrtholog Mapping of 
orthologous sites 
between species 
University of Sydney 
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Victor Chang Cardiac 
Research Institute, 
Australia 
PhosphoSitePlus (PSP) (Functional) annotation 






Swiss Institute of 
Bioinformatics, NNF 










UniProtKB Comprehensive protein 
database 
UniProt Consortium www.uniprot.org 







Table 12: Collaborations 
Project Collaborator 
Cell-based assays and functional experiments for the 
analysis of phosphorylation-based signaling in 
Burkitt’s lymphoma and BTK inhibition in acute 
myeloid leukemia; Western blotting and Ca2+ flux 
analysis 
 
Thomas Oellerich - Department of Internal Medicine, 
Hematology/Oncology at the University Hospital 
Frankfurt/Main, DE 
Cell-based assays and functional experiments for 
studying phosphorylation site analysis in TCR 
signaling adapters 
 
Debbie Yablonski - ‘Immune Cell Signaling Lab’ at the 
Rappaport Faculty of Medicine, Technion, Israel 
Institute of Technology in Haifa, Israel 
Sample preparation, MS/MS measurement, data 
analysis for kinobead analysis in DG75 (Burkitt’s 
lymphoma) 
 
Bernhard Küster - Chair of Proteomics and 
Bioanalytics at the Technical University München, 
Freising, DE 
RNA seq measurements for DG75 Ekkehard Schütz - Chronix Biomedical, San Jose, USA 
Data analysis for DG75 RNA seq analysis Tim Beißbarth - Institute of Medical Statistics, 
University Medical Center Göttingen, DE 
 
 Methods 
Cell-based sample preparation methods used to culture, label, treat and lyse cells from 
different experimental model systems performed by different collaborators are described in 
Table 12. In general, obtained protein lysates were further processed by different sample 
preparation techniques. Sample probes were measured by LC-MS/MS on different MS 
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instruments and raw data was processed and analyzed by various data analysis tools. The 
mentioned steps towards (phospho)-proteomic analysis will be described in detail in the 
following. 
2.2.1. Cell-based sample preparation 
2.2.1.1. Cell culture 
 Burkitt’s lymphoma and acute myeloid leukemia 
All Burkitt’s lymphoma (BL) and acute myeloid leukemia (AML) cell lines were cultured in RPMI 
1640 (Invitrogen) supplemented with 10% fetal calf serum (FBS; PAA), 2 mM L-glutamine 
(Lonza), 100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies) at 37°C and 5% 
CO2. 
FFM_BL1 cells were isolated from a patient with BL showing bone marrow infiltration. The 
cells were cultured in RPMI 1640 supplemented with 20% heat-inactivated FBS, 100 U/ml 
penicillin and 100 µg/ml streptomycin and L-glutamine (all mentioned cell culture reagents for 
FFM_BL1 cells were purchased from Invitrogen). 
 TCR signaling adapters 
Jurkat derivative J14 cells (SLP76-deficient) were stably infected with Migr-strep-SLP-76 WT 
(Twin-Strep-Tag) and were cultured in RPMI lacking lysine, arginine and tyrosine with L-
glutamine (Bet HaEmek bioindustry) supplemented with PSG, 10% dialyzed FBS (Bet HaEmek). 
2.2.1.2. SILAC labeling 
 Burkitt’s lymphoma and acute myeloid leukemia 
SILAC labeling of DG75, Daudi, MV4-11 and KG1 was achieved by culturing the cells in SILAC-
RPMI 1640 medium lacking arginine and lysine (Pierce) supplemented with 10% heat-
inactivated dialyzed FBS (PAA), 100 U/ml penicillin and 100 µg/ml streptomycin as well as the 
respective SILAC amino acids (all Cambridge Isotopes): ‘Light’ (L): 12C614N4 L-arginine (R+0 or 
Arg+0), 12C614N2 L-lysine (K+0 or Lys+0), ‘Medium’ (M): 13C614N4 L-arginine (+6 Da; R+6 or 
Arg+6), L-lysine-4,4,5,5-D4 (+4 Da; K+4 or Lys+4) and ‘Heavy’ (H): 13C615N4 L-arginine (+10 Da; 
R+10 or Arg+10), 13C615N2 L-lysine (+8 Da; K+8 or Lys+8). L-arginine and L-lysine were 
supplemented to a final concentration of 0.132 mM and 0.316 mM or the doubled or tripled 
concentration depending on the cultivated cell type. To avoid arginine-to-proline conversion, 
affected cells were cultured as above with additional 200 mM unlabeled L-proline. 
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 TCR signaling adaptors 
The SILAC-RPMI medium lacking lysine, arginine and tyrosine was supplemented with the 
respective ‘light’ or ‘heavy’ amino acids: ‘Light’ (L): 12C914N L-tyrosine (Y+0 or Tyr+0), 12C614N4 
L-arginine (R+0 or Arg+0), 12C614N2 L-lysine (K+0 or Lys+0) and ‘Heavy’ (H): 13C915N L-tyrosine 
(+10 Da; Y+10 or Tyr+10), 13C615N4 L-arginine (+10 Da; R+10 or Arg+10), 13C615N2 L-lysine (+8 
Da; K+8 or Lys+8). The following concentrations were used, L-tyrosine 0.11 mM, L-lysine 0.22 
mM and L-arginine 0.115 mM (light amino acids: Bet Haemek, heavy amino acids: Cambridge 
Isotopes). Cells were adapted to the above medium for about 2 weeks, using light amino acids, 
and then grown in heavy or light medium for at least seven doublings and expanded to 120 to 
160 million light- and heavy-labeled cells, respectively. 
2.2.1.3. Functional analyses 
 BCR stimulation 
For BCR stimulation DG75, Daudi and FFM_BL1 cells were starved in RPMI without 
supplements for 15 minutes. Subsequently, BCRs were stimulated with 10 µg/ml F(ab)2 anti-
human IgM antibodies (Dianova) at 37°C for the durations indicated below. Light-labeled 
batches of DG75 cells were left in the unstimulated ground state (0 min) while the BCRs of the 
medium-labeled batches were stimulated for 2 min and the heavy-labeled batches were 
stimulated for 5 min. For the second SILAC triplet, the medium and heavy batches were 
stimulated for 10 and 20 min, respectively. Light-labeled Daudi batches were left non-
stimulated (0 min), while the BCRs of medium- and heavy-labeled cells were stimulated for 2 
or 10 min, respectively. The non-SILAC labeled FFM_BL1 cells were stimulated for the same 
BCR stimulation durations as Daudi cells.  
For kinobead affinity purification the BCRs of non-labeled DG75 cells were left non-stimulated 
and were stimulated for 2, 5, 10 or 20 min, respectively. For the RNAseq analysis, the BCRs of 
non-labeled DG75 cells were stimulated for 10 min, 20 min, 1 h or 2 h, respectively. As a 
control, one batch of DG75 cells was not stimulated (0 min). 
 BCR knockdown and Syk inhibition 
The tetracycline-inducible CD79A knockdown in DG75 cell lines was performed in light-labeled 
cells. Heavy-labeled DG75 cells were treated with the Syk inhibitor PRT062607 (also P505-15 
or BIIB057) for one hour. 
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 BRAF inhibition in BL 
Heavy SILAC labeled DG75 cells were pre-treated with 2 µM of the BRAF inhibitor Raf265 
(Selleckchem) for 45 min in SILAC RPMI without any supplements before addition of 10 µg/ml 
F(ab)2 anti-human IgM antibody (Dianova) to stimulate BCR signaling.  
 BRAF interactome analysis in BL 
1 x 108 SILAC labeled (light, medium and heavy) DG75 and BL2 cells were washed once with 
PBS, resuspended in SILAC RPMI without any supplements and incubated at 37°C for 20 min. 
Heavy SILAC labeled cultures were BCR stimulated for 5 min by addition of 10 µg/ml F(ab)2 
anti-human IgM antibody (Dianova) while light and medium SILAC labeled cultures were left 
unstimulated. Cells were harvested by centrifugation (1200 rpm, 5 min, 4°C) and washed once 
with ice-cold PBS. Cells were lysed in 1 ml NP-40 lysis buffer for 10 min on ice. Cellular debris 
were removed by centrifugation (15000 rpm, 10 min, 4°C). An anti-BRAF antibody (5 µg of 
rabbit anti-BRAF, Bethyl or 6 µg of mouse anti-Raf-B (F-7), Santa Cruz Biotechnology) was 
added to the lysates of medium and heavy SILAC labeled cells while the lysates of light SILAC 
labeled cells were left untreated. Lysates were incubated overnight at 4°C on a turning wheel. 
50 µl of protein A/G agarose beads (Santa Cruz Biotechnology) were added to all lysates and 
incubated for 1.5 hours at 4°C on a turning wheel. Beads were washed three times with lysis 
buffer and were boiled with NuPAGE LDS Sample at 95°C for 5 min.  
 Kinobead sample preparation 
DG75 cell pellets were lysed in lysis buffer containing 50 mM Tris/HCl pH 7.5, 5% glycerol, 1.5 
mM MgCl2, 150 mM NaCl, 1mM Na3VO4, 0.8% NP-40, 0.375 mM NaF, 1 mM DTT including 
protease inhibitors (Sigma-Aldrich). Cells were lysed by subsequent cycles of thawing and 
freezing. The lysate was ultracentrifuged for 1 h at 4°C and 145.000 xg. The supernatant was 
saved while the majority of the lipid layer was discarded. Kinobead pulldowns were performed 
as described previously by Bantscheff et al., 2007. Cell lysates were diluted with equal volumes 
of 1x compound pulldown (CP) buffer (50 mM Tris/HCl pH 7.5, 5% glycerol, 1.5 mM MgCl2, 150 
mM NaCl, 20 mM NaF, 1 mM sodium ortho-vanadate, 1 mM DTT, 5 mM calyculin A and 
protease inhibitors). Lysates were further diluted to a final protein concentration of 5 mg/ml 
using 1x CP buffer supplemented with 0.4% NP-40. Kinobeads (100 µl suspension) were 
incubated with lysates (total of 5 mg protein per state) at 4°C for 4 h. Subsequently, beads 
were washed with 1x CP buffer and collected by centrifugation. Bound proteins were eluted 
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with 2x NuPAGE® LDS Sample Buffer (Invitrogen) and reduced and alkylated by 10 mM DTT 
and 55 mM iodoacetamide, respectively. All samples were run 1 cm into a 4–12% NuPAGE gel 
(Invitrogen) in order to concentrate the sample prior to in-gel trypsin digestion.  
 BTK interactome and inhibition in AML 
Details about BTK immunoprecipitation in KG1 and FLT3 in MV4-11 cells and interactome 
analysis are described in Oellerich et al., 2013; 2015. Heavy-labeled KG1 and MV4-11 cells 
were treated with 500 nM Ibrutinib and their light-labeled counterparts with DMSO as a 
control for one hour. Further details are described in Oellerich et al., 2015. 
 TCR stimulation and SLP76 affinity purification 
Light-labeled cells were incubated in PBS (unstimulated) and heavy-labeled cells were 
incubated with an anti-TCR antibody C305 at a final concentration of 1:500 in PBS for the 
respective time durations (1 min, 2 min, 5 min and 10 min). Cells were lysed for 15 min on ice 
with 1.3 mL lysis buffer containing 20 mM HEPES pH 7.3, 1% Triton, 150 mM NaCl, 1 mM EGTA, 
10 mM NaF, 1 mM Na3VO4, 50 mM β-glycerol phosphate, 20 mM sodium pyrophosphate, 10 
μg/ml aprotinin, 10 μg/ml leupeptin, 2 mM PMSF, 10% glycerol and 1 mM DTT. Lysates were 
cleared by 10 min centrifugation at max. speed at 4°C and the supernatant was removed. 600 
μl of the respective lysates, corresponding to 120 million cells were mixed with 120 μl 
prewashed streptactin beads and were incubated for 1 h at 4°C. Bound proteins were eluted 
with 1.5x NuPAGE sample buffer containing 10% (v/v) NuPAGE reducing agent by heating for 
6 min at 85°C. The yield was validated by SDS-PAGE and confirmed by immunoblotting with 
antibodies directed against SLP76 (LCP2) and GADS (GRAP2). 
2.2.1.4. Cell lysis 
Depending on the sample preparation method, different cell lysis approaches, if not already 
done during functional analysis, were required. For proteomics and global 
phosphoproteomics analysis, SILAC labeled cells (5x107-108) were lysed in a NP-40-based lysis 
buffer (50 mM Tris-HCl pH 7.5-7.8, 150 mM NaCl, 0.5% NP-40, 5 mM NaF, 1 mM Na3VO4, 
Complete Protease Inhibitor Cocktail (Roche)) for 10 min on ice. Cellular debris was removed 
by centrifugation (15000 rpm, 10 min, 4°C). Protein concentrations were determined with the 
BCA Protein Assay Kit (Pierce) according to the manufacturer´s protocol and stored at -80°C 
until use. 
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Cell lysis for antibody-based PTM enrichment was performed according to the manufacturer’s 
instruction (PTMScan Kit, Cell Signaling Technology) using an urea-based lysis buffer. Briefly, 
1 x 108 cells were washed once with PBS and lysed in 10 ml of urea lysis buffer (20 mM HEPES 
pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate). Samples were stored at -80°C until further processing. 
2.2.2. Sample preparation for LC-MS/MS analysis  
2.2.2.1. Proteomic analysis 
For protein expression analysis, the protein concentration was estimated with a BCA assay for 
SILAC labeled or label-free cell lysates (in NP-40 lysis buffer). For SILAC labeled cell lines, 
equimolar amounts of each labeling state were mixed. For label-free cells each experimental 
condition was treated independently. A total of 150 µg protein was mixed with SDS sample 
buffer and heated for 10 min at 70°C. Proteins were separated with SDS-PAGE for 50 min at 
200 V using precast Bis-Tris minigels and visualized by staining with Coomassie Brilliant Blue 
overnight. In-gel digestion was performed as described previously by Shevchenko et al. with 
minor modifications (Shevchenko et al., 2007). Briefly, after gel destaining, each lane was cut 
into 23 slices with an in-house made gel cutter, reduced with 10 mM DTT for 50 min at 56°C 
and alkylated with 55 mM IAA for 20 min at 37°C in the dark. Proteins were digested overnight 
in-gel with trypsin, peptides were extracted, dried in a SpeedVac apparatus and subjected to 
mass spectrometric analysis. 
2.2.2.2. PTM analysis 
For the enrichment of PTMs several workflows were used. Global phosphoproteomic analyses 
of Burkitt’s lymphoma and the acute myeloid leukemia cells were done by strong cation 
exchange (SCX) followed by titanium dioxide (TiO2) enrichment. To specifically enrich peptides 
harboring phosphorylated tyrosine residues in the Burkitt’s lymphoma and the acute myeloid 
leukemia project, specific antibodies directed against phosphotyrosine were used. 
Additionally, acetylation and ubiquitination enrichment for the Burkitt’s lymphoma project 
was performed with PTM-specific antibodies. For the investigation of phosphorylation sites 
on purified TCR signaling proteins, SDS-PAGE together with TiO2 enrichment was performed.  
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 Global phosphoproteomic analysis 
Protein concentration of each SILAC state was determined by BCA assay according to 
manufacturer’s recommendations. SILAC labeled protein lysates were mixed in equimolar 
amounts, diluted 1:4 with 25 mM ABC buffer and treated with 1 U Benzonase for hydrolysis 
of all nucleic acids for 1 h at 37°C. Proteins were precipitated by adding fivefold volume of ice 
cold acetone and sequent storage of samples for at least one hour at -20°C. The precipitate 
was pelleted by centrifugation for 30 min with max. rpm at 4°C. The acetone was removed 
and the pellet was washed with 80% ice cold EtOH (v/v) for 10 min with max. rpm at 4°C. The 
80% EtOH was removed and the pellet was subsequently dried. After drying, the pellet was 
dissolved by sonication in 1% RapiGest Surfactant (w/v) in 25 mM ammonium bicarbonate for 
at least one to six h. Dissolved proteins were reduced at a final concentration of 10 mM DTT 
for 1 h at 65°C and reduced with CAA at a final concentration of 20 mM for 1 h at 37°C. Proteins 
were digested with trypsin at a 1:20 to 1:100 trypsin-to-protein (w/w) ratio in the presence of 
0.1% RapiGest at 37°C overnight. For RapiGest degradation, the digest was acidified to 2% FA 
or 1% TFA and incubated for 30 min to 2 h at 37°C. RapiGest precipitations were cleared by 
centrifugation with max. rpm at RT. The peptide containing supernatant was taken to dryness 
in a SpeedVac concentrator. Peptides were fractionated by strong cation exchange (SCX) as 
described by Gruhler et al. with some modifications (Gruhler et al., 2005).  
Briefly, SCX chromatography was performed on a FPLC system (SMART, Pharmacia) using an 
ammonium formate based buffer system. Buffer A had a final concentration of 10 mM 
ammonium formate and buffer B had a final concentration of 500 mM ammonium formate 
both at pH 2.7 and containing 30% ACN (v/v). 20 Fractions were collected over a 50 min 
gradient with a flow rate of 100 µL/min. The first twelve fractions were dried in a SpeedVac 
concentrator and subsequently used for phosphopeptide enrichment or stored at -20°C until 
use. The following TiO2 spin column phosphopeptide enrichment was performed with minor 
modifications as described by Larsen et al. (Larsen et al., 2005b). Dried peptides were 
suspended by intensive vortexing and sonication in 60 µL of loading solution. All following 
centrifugation steps were performed with 3000 rpm at RT for 5 min. In-house made titanium 
dioxide spin columns were equilibrated with 60 µL of loading solution followed by sample 
loading. Phosphopeptides bound to TiO2 beads were washed three times with 60 µL loading 
solution and five times with 60 µL washing solution. Phosphopeptides were eluted with a 0.6 N 
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solution of NH4OH (pH ≥ 10.5), dried in a SpeedVac concentrator and stored at -20°C until 
mass spectrometric analysis. 
 Antibody-based PTM enrichment  
Antibody-based enrichment for tyrosine-phosphorylated peptides was performed using the 
PTMScan Phospho-Tyrosine rabbit mAB (P-Tyr-1000) Kit as described in the manufacturer’s 
instructions and according to Rush et al. (Cell Signaling Technology) (Rush et al., 2004a).  
Briefly, DNA was removed by microtip sonication on ice in three 15 s intervals with an 
amplitude of 50% and an one min break in between. Debris and precipitations were removed 
by centrifugation at 14k xg at 15°C for 30 min. Aliquots for SDS-PAGE-based digestion controls 
were taken and proteins were reduced with DTT at a final concentration of 4.5 mM at 55°C 
for 30 min. Reduced cysteine residues were alkylated with IAA at a final concentration of 10 
mM at RT for 10 min in the dark. The protein lysate was diluted 1:4 with 20 mM HEPES pH 8 
to reduce the urea concentration to 2 M. Trypsin was added in a 1:20 to 1:100 trypsin-to-
protein mass ratios and incubated overnight at 37°C. The digest was acidified to 1% TFA final 
concentration; precipitations were removed by centrifugation with 1,780 xg at RT for 15 min. 
Peptides were purified with Sep-Pak tC18 columns (1cc or 6cc, Waters). The 1cc columns were 
used for centrifugation based desalting, whereas the 6cc columns were used for gravity flow 
purification. Sep-Pak columns were equilibrated in a first step with 100% ACN, followed by 
0.1% TFA. The acidified sample was loaded on the columns; bound peptides were washed with 
0.1% TFA and 5% ACN, 0.1% TFA. Purified peptides were eluted with 40% ACN, 0.1% TFA, 
subsequently frozen in a bulb, stored at -20°C at least for 2 h, lyophilized until dryness and 
stored at -20°C until use. Lyophilized peptides were re-suspended in 1.4 mL 1x IAP buffer 
(supplied by Cell Signaling Technology), the pH was controlled and precipitates were removed 
by centrifugation at 10k xg at 4°C for 5 min. All following centrifugation-based washing steps 
were performed with a maximum of 2k xg at 4°C for 30 s. The antibody-bead slurry was 
washed four times with 1 mL PBS followed by incubation with the purified peptides for at least 
2 h at 4°C on an head-over-tail rotator. After incubation, the supernatant was removed; beads 
were washed two times with 1x IAP buffer and three times with LiChroSolv water. Antibody-
peptides were eluted by incubation of the antibody-bead-peptide slurry with 0.15% TFA for 
10 min. The eluate was removed and a second elution step was performed. In order to remove 
the antibody from phosphorylated peptides, StageTip purification was applied as follows: 5 
layers of C18 Empore Octadecyl material were placed in a GELoader tip. C18 material was 
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equilibrated with solution C, followed by sample loading. The bound sample was washed two 
times with solution D (0.1% TFA) and purified phosphotyrosine enriched peptides were eluted 
with solution E (40% ACN, 0.1% TFA). The eluate was dried in a SpeedVac apparatus and stored 
at -20°C until mass spectrometric measurement. Ubiquitinated and/or acetylated peptides 
were enriched using the manufacturer’s instructions and the procedure described above with 
the difference that the PTMScan Acetyl-Lysine Motif [Ac-K] and the Ubiquitin Remnant Motif 
(K-ɛ-GG) antibody kits were used. 
Experiments were conducted by Kai-Hsin Chan and Zivojin Jevtic (MSc Molecular Biology 
Program of the International Max Planck International Research School) under the supervision 
of Jasmin Corso within a lab rotation internship from the 5th of January 2015 until the 27th of 
Febuary 2015.  
 Phosphoproteomic analysis of TCR signaling adapters 
For the analysis of phosphorylation sites of the TCR signaling adapters SLP76 and GADS, 
equimolar mixed light- and heavy-labeled cell lysates after SLP76 affinity purification were 
separated with SDS-PAGE for 50 min at 200 V using precast Bis-Tris minigels (NuPAGE Novex 
4-12%, Life Technologies). For each TCR stimulation time point (1 min, 2 min, 5 and 10 min), 
three lanes were run on the gel. Proteins were visualized by staining with Coomassie Brilliant 
Blue (Serva) overnight. After gel destaining, gel bands corresponding to GRAP2 (GADS) at 37.9 
kDa and LCP2 (SLP76) at 60.1 kDa were excised over a wide range and cut into small quadratic 
pieces, respectively. Proteins were reduced with 10 mM DTT for 50 min at 56°C, alkylated with 
55 mM IAA (both Sigma-Aldrich) for 20 min at 37°C in the dark. Samples were digested with 
0.75 µg of the endoproteinases trypsin (Promega), AspN or chymotrypsin (both Roche) per gel 
slice overnight at 25°C (Chymotrypsin) or 37°C (Trypsin and AspN). After extraction from the 
gel, peptides were dried in a SpeedVac apparatus and stored until enrichment by TiO2 
microcolumns. Dried peptides were suspended in 60 µL of 200 mg/mL dihydrobenzoic acid 
(DHB, Sigma-Aldrich) in 80% ACN, 5% TFA. All following centrifugation steps were performed 
with 3000 rpm at RT for 5 min. In-house made titanium dioxide (GL Science, Japan) spin 
columns were equilibrated one time with 80% ACN, 5% TFA followed by sample loading. The 
TiO2 bound peptides were washed three times with solution B containing 200 mg/mL DHB in 
80% ACN, 5% TFA followed by five washes with 80% ACN, 5% TFA. Phosphopeptides were 
eluted with a 0.6 N solution of NH4OH (pH ≥ 10.5), dried in a SpeedVac concentrator and 
stored at -20°C until mass spectrometric measurement. 
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2.2.3. LC-MS/MS analysis 
In the following paragraphs, MS instruments that were used to perform LC-MS/MS analysis of 
the before mentioned samples are described. All MS instruments used for this work were 
obtained from the instrument manufacturer Thermo Scientific. The LTQ Orbitrap Velos, the Q 
Exactive, the Q Exactive HF and the Orbitrap Fusion were operated by the Bioanalytical Mass 
Spectrometry Group at the Max Planck Institute for Biophysical Chemistry (Table 2). The 
Orbitrap Elite was operated within the collaboration with Bernhard Küster as mentioned 
previously (Table 12). In each paragraph, the generalized, most important instrument 
operating parameters are described. Detailed LC-MS/MS instrumental settings for each 
sample can be found in the Appendix. 
2.2.3.1.  LTQ Orbitrap Velos 
Peptide fractions were analyzed on a nanoflow liquid chromatography system (Agilent 1100 
series, Agilent) coupled to a hybrid linear ion trap-Orbitrap mass spectrometer (LTQ Orbitrap 
Velos, Thermo Scientific). Samples were pre-concentrated and desalted on a trap column (100 
µm x 20 mm, ReproSil-Pur 120 C18-AQ, 5 µm, Dr. Maisch GmbH, packed in-house) at 5 μl/min 
in loading buffer (2% ACN, 0.1% FA). Peptides were separated on an analytical column (75 µm 
x 200 mm, ReproSil-Pur 120 C18-AQ, 3 µm, Dr. Maisch GmbH, packed in-house) using different 
linear gradients (see Appendix) from 5% to 34% buffer B (95% ACN, 0.1% FA) at a flow rate of 
300 nl/min. The mass spectrometer was operated in data-dependent acquisition (DDA) mode. 
Full scan spectra from m/z 350-1600 were acquired in the Orbitrap with a resolution of 30,000 
FWHM at m/z 400. Product ion spectra of the ten most abundant precursors per cycle were 
acquired. Collision induced dissociation (CID) of selected precursors with charge states 2+ to 
4+ was performed in the linear ion trap with normalized collision energy (NCE) of 35% and an 
isolation window of 2 m/z. The dynamic exclusion time was set to 60 s, the automatic gain 
control (AGC) target value and maximum injection time (max. IT) for MS and MS/MS were 
1 x106 in 500 ms and between 5 x104 and 1 x105 in 100 ms, respectively.  
2.2.3.2. Q Exactive 
Samples were measured on an EASY n-LC 1000 (Thermo Scientific) coupled to a hybrid 
quadrupole-Orbitrap mass spectrometer (Q Exactive, Thermo Scientific). The samples were 
pre-concentrated and desalted on a trap column (100 µm x 20 mm, ReproSil-Pur 120 C18-AQ, 
5 µm, Dr. Maisch GmbH, packed in-house) at 5 μl/min in loading buffer (2% ACN, 0.1% FA). 
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Peptides were separated on an analytical column (75 µm x 200 mm, ReproSil-Pur 120 C18-AQ, 
3 µm, Dr. Maisch GmbH, packed in-house) using linear gradients (see Appendix) with an 
increasing %age of buffer B (95% ACN, 0.1%FA) and a decreasing %age buffer A (0.1% FA) at a 
flow rate of 300 nl/min. The Q Exactive was operated in DDA selecting the top most abundant 
precursors (see Appendix) for higher-energy collisional dissociation (HCD) in the collision cell 
with an isolation window of 2 m/z and a NCE of 28%. Full scan spectra from m/z 350-1600 
were acquired with a MS resolution setting of 70,000 at m/z 200 and fragment spectra with a 
MS/MS resolution of 17,000 or 35,000 in the Orbitrap (see Appendix). The AGC target value 
and max. IT for MS and MS/MS were set to 1 x106 in 60 ms and 1 x104 or 2 x105 in 50, 60 or 
120 ms, respectively.  
2.2.3.3. Q Exactive HF  
Peptides were dissolved in 2% ACN, 0.05% TFA and were analyzed with an Ultimate 3000 RSLC 
UHPLC (Dionex, USA) coupled to a Q Exactive HF (Thermo Fisher). Peptides were concentrated 
on a precolumn (100 µm x 30 mm, ReproSil-Pur 120 C18-AQ, 3 µm, Dr. Maisch GmbH, packed 
in-house) and separated on an analytical column (75 µm x 280 mm, ReproSil-Pur 120 C18-AQ, 
1.9 µm, Dr. Maisch GmbH, packed in-house) with a linear gradient of increasing buffer B (80% 
ACN, 0.08 % FA) and decreasing buffer A (0.1% FA in water) at constant flow rate of 300 nl/min. 
The Q Exactive HF mass spectrometer was operated in DDA top 15, 20 or top 30 methods with 
a MS survey scan resolution of 120,000 and a MS/MS resolution of 15,000 or 30,000. HCD was 
performed with NCE of 28% and isolation window of 1.4 to 2 m/z. Charge states rejected for 
fragmentation and the dynamic exclusion time settings can be found in the Appendix. AGC 
target value and max. IT for MS and MS/MS were 1 x106 in 50 ms or 80 ms and 1 x105 in 50 to 
80 ms, respectively. 
2.2.3.4. Orbitrap Fusion 
Peptides were analyzed with an Ultimate 3000 RSLC UHPLC (Dionex, USA) coupled to an 
Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific). Peptides were concentrated on 
a precolumn (100 µm x 30 mm, ReproSil-Pur 120 C18-AQ, 3 µm, Dr. Maisch GmbH, packed in-
house) and separated on an analytical column (75 µm x 280 mm, ReproSil-Pur 120 C18-AQ, 
1.9 µm, Dr. Maisch GmbH, packed in-house) with a 74 min linear gradient of increasing buffer 
B (80% ACN, 0.08 % FA) from 2% to 44% and decreasing buffer A (0.1% FA in water) at constant 
flow rate of 300 nl/min. The Orbitrap Fusion mass spectrometer was operated with the ‘top 
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speed’ option with a cycle time of 3 s and MS survey scan resolution of 120,000 and a MS/MS 
resolution 30,000. HCD was performed in the multipole with NCE of 30% and isolation window 
of 1.4 m/z. Charge states 2 to 5 were included for fragmentation and the dynamic exclusion 
time was set to 20 s. AGC target value and max. IT for MS and MS/MS were 5 x105 in 50 ms 
and 1 x104 in 128 ms, respectively. 
2.2.3.5. Orbitrap Elite 
The kinobead analysis was performed on an Eksigent nanoLC-Ultra 1D+ (Eksigent, Dublin, CA) 
coupled to an Elite-Oribtrap (Thermo Scientific, Bremen, Germany). Peptides were delivered 
to a trap column (100 μm × 20 mm, Reprosil PUR C18-AQ, 5 µm, Dr. Maisch GmbH, packed in-
house) at a flow rate of 5 µL/min in 100% buffer A (0.1% FA in HPLC grade water). After 10 min 
of loading and washing, peptides were transferred to an analytical column (75 µm x 400 mm, 
Reprosil PUR C18-AQ, 3 µm, Dr. Maisch GmbH, packed in-house) and separated using a 210 
minute gradient from 2% to 35% of buffer B (0.1% FA in ACN) at 300 nL/min flow rate. The 
Orbitrap Elite was operated in DDA mode, automatically switching between MS1 and MS2 
scans. Full scan MS spectra were acquired in the Orbitrap at 30,000 resolution. Internal 
calibration was performed using the ion signal (Si(CH3)2O)6H+ at m/z 445.120025 present in 
ambient laboratory air. Tandem mass spectra were generated for up to 15 peptide precursors 
in the linear ion trap for fragment by using HCD.  
2.2.4. MS raw file processing 
The output from one LC-MS/MS run from the above mentioned instruments is a raw file 
containing amongst others information about retention time, m/z values, intensities and the 
charge state of intact peptide precursors and product ions of selected precursors. In order to 
identify and quantify peptides, proteins, and PTM sites, the raw files were submitted to the 
software MaxQuant. MS/MS spectra were searched against a human proteome database with 
the search engine Andromeda which is implemented in MaxQuant (Cox and Mann, 2008; Cox 
et al., 2011). In the following paragraph, raw file processing for the different projects are 
described. 
2.2.4.1. BL experiments 
All raw files were processed using MaxQuant (Versions between 1.5.0.25 and 1.5.2.8) against 
a UniProtKB/Swiss-Prot human database containing 88,993 and 89,706 entries (downloaded 
July 2014 or January 2015), respectively (Cox and Mann, 2008). Raw files of the protein 
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expression, global phosphoproteome and pYome experiments and different cell lines were 
processed either independently from each other or categorically grouped e.g. all pYomes or 
all files of one cell line together. Cysteine carbamidomethylation was set as fixed modification, 
methionine oxidation and serine, threonine and tyrosine phosphorylation for both the pYome 
and the global phosphoproteome dataset as variable modification. The ‘Minimum Andromeda 
Score’ and ‘Delta score’ for modified peptides was set to 40 and 6, respectively. The following 
parameters were applied: the MS1 first search peptide tolerance was set to 20 ppm and the 
main search peptide tolerance to 4.5 ppm. The FTMS MS/MS tolerance was set to 20 ppm, a 
false discovery rate (FDR) of 1% for peptide spectrum matches (PSM), protein and site decoy 
was applied, 7 amino acids as minimum peptide length and 2 maximum missed cleavages were 
allowed. Multiplicity was set to two in a double or to three in a triple SILAC-based quantitation 
experiments (duplex label: Lys+0 Arg+0, Lys+8 Arg+10; additionally for triplex labeling Lys+4 
Arg+6). The ‘Re-quantify’ option of MaxQuant was enabled. Unique, razor, unmodified, N-
terminally acetylated and methionine oxidized peptides were used for protein quantitation 
and the minimum ratio count required was two. For label-free quantitation, the MaxLFQ 
algorithm was enabled with a LFQ min. ratio count two (Cox et al., 2014). Additionally, the 
‘Match between runs’ function was enabled at default settings of a match time window of 0.7 
min and an alignment time window of 20 min.  
2.2.4.2. Kinobead analysis 
Progenesis software (Version 3.1; Nonlinear Dynamics, Newcastle, UK) was used for intensity-
based label-free quantitation. Briefly, after selecting one sample as a reference, the retention 
times of all eluting precursor m/z values in all other samples within the experiment were 
aligned creating a large list of ‘features’ representing the same peptide in each sample. 
Features with two to five charges were included; features with two or less isotopes were 
excluded for further analysis. After alignment and feature filtering, raw abundances of all 
features were normalized to determine a global scaling factor for correcting experimental 
variation such as differences in the quantity of protein loaded into the instrument. Given that 
multiple MS/MS spectra are frequently collected for the same feature (precursor ion) across 
all the samples, the precursor intensities were ranked, and the MS/MS spectra of the five most 
intense precursors for each feature were transformed into peak lists and exported to generate 
Mascot generic files. The Mascot generic files were searched against the Uniprot human 
protein sequence database (Version 22.07.13, containing 88,354 entries) using Mascot 
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(Version 2.2, Matrix Science, London, UK). Search parameters were set as follows: 
carbamidomethylation of cysteine residues as fixed modification, serine, threonine, and 
tyrosine phosphorylation and methionine oxidation as variable modification, trypsin as 
proteolytic enzyme with up to two miss cleavages, precursor ion mass tolerance of 10 ppm, 
fragment ion mass tolerance of 0.05 Da, decoy search enabled. Search results for spectrum to 
peptide matches were exported in xml format and then imported into Progenesis software to 
enable the combination of peptide quantitation and identification. Peptides with Mascot ion 
scores <25 were filtered out, and only unique peptides for corresponding proteins were used 
for identification and quantitation. For protein quantitation, the feature intensities of all 
unique peptides of a protein were summed up. 
2.2.4.3. AML experiments 
The protein expression and pYome raw files were analyzed with MaxQuant v1.3.0.5 and the 
GP was analyzed with MaxQuant v1.5.0.25 against a UniProtKB/Swiss-Prot human database 
containing 88,993 or 89,706 entries (downloaded July 2014 or January 2015). Raw files of KG1 
and MV4-11 cells were processed together whereas protein expression, global 
phosphoproteome and pYome experiments were processed independently from each other. 
Cysteine carbamidomethylation was set as fixed modification, methionine oxidation and 
serine, threonine and tyrosine phosphorylation for both the pYome and the global 
phosphoproteome datasets as variable modification. The ‘Minimum Andromeda Score’ and 
‘Delta score’ for modified peptides was set to 40 and 6, respectively for the global 
phosphoproteome (analyzed with MaxQuant v1.5.0.25). The following parameters were 
applied: the MS1 first search peptide tolerance was set to 20 ppm and the main search peptide 
tolerance to 4.5 ppm for the global phosphoproteome (Protein expression and pYome were 
analyzed with MaxQuant v1.3.0.5: 6 ppm), respectively. The FTMS MS/MS tolerance was set 
to 20 ppm, a FDR of 1% for PSM/peptide, protein and site levels was applied. Seven amino 
acids as minimum peptide length and maximum two missed cleavages were allowed. 
Multiplicity was set to two (duplex label: Lys+0 Arg+0, Lys+8 Arg+10). The ‘Re-quantify’ option 
of MaxQuant was enabled and the minimum ratio count required was set to two. 
2.2.4.4. TCR signaling adapters 
Raw files from four independent biological replicates were processed together as 
distinguishable experimental groups using MaxQuant (Version 1.5.2.8) against a 
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UniProtKB/Swiss-Prot human database containing 89,706 entries (downloaded January, 
2015). Raw files of different biological replicates were defined in experimental groups and 
different proteinase specificities were defined in parameter groups. Cysteine 
carbamidomethylation was set as fixed modification, methionine oxidation and serine, 
threonine and tyrosine phosphorylation as variable modification. The ‘Minimum Andromeda 
Score’ and ‘Delta score’ for modified peptides was set to 40 and 6, respectively. The following 
parameters were applied: the MS1 first search peptide tolerance was set to 20 ppm and the 
main search peptide tolerance to 4.5 ppm, respectively. The FTMS MS/MS tolerance was set 
to 20 ppm, the decoy mode was set to revert, a FDR of 1% for PSM, protein and 
phosphorylation site was applied, seven amino acids as minimum peptide length and 
maximum two missed cleavages were allowed. Multiplicity was set to two: Lys+0 Arg+0 Tyr+0 
and Lys+8 Arg+10 Tyr+10. Unique, razor, unmodified, N-terminally acetylated and methionine 
oxidized peptides were used for protein quantitation and the minimum ratio count required 
was two. The ‘Re-quantify’ option of MaxQuant was enabled. 
2.2.5. Data analysis 
In the following the data analysis pipelines for each project are described. In general, class I 
phosphorylation sites (true for all PTM sites) are defined as p-sites with a localization 
probability greater than 0.75 (Olsen et al., 2006). These p-sites are considered as localized 
with high confidence to a particular amino acid residue. Furthermore, a multiplicity (not to be 
confused with the SILAC multiplexing MaxQuant search parameters) of greater than 1 
indicates the presences of an additional phosphorylation on a peptide. Therefore, in some 
cases same p-sites can be listed as mono- or multiply-phosphorylated peptide (multiplicity 
column in the supplementary tables). This information is of biological importance in case of 
combinatorial phosphorylation for example the TXY motif phosphorylation of MAP-kinases 
(Burack and Sturgill, 1997). Unique or non-redundant p-sites refer to a list of p-sites where 
same positions with different multiplicity were removed. 
2.2.5.1. DG75 BCR stimulation time course 
Downstream data analysis of the resulting proteinGroups.txt and Phospho(STY)Sites.txt tables 
from the DG75 BCR stimulation time course experiment was performed with Perseus 
(Versions 1.5.0.15 to 1.5.2.6). ‘Reverse’ and ‘contaminant’ (in the proteinGroups.txt also 
‘identified only by site’ entries) were removed as well as phosphorylation sites with a global 
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localization probability lower than 0.75. P-sites were considered as quantified if at least 50% 
of biological replicates had a quantitation ratio reported. The binary logarithm of normalized 
p-site and protein SILAC ratios and the logarithm to the base 10 of intensity values were 
derived. For quality control, multi-scatter plots displaying Pearson’s correlation coefficients 
were generated for technical and biological replicates (data not shown). P-site ratios for time 
point 0 min (no stimulation) were set to 0. For each time point, median ratios were extracted 
and used for further analysis. For the global phosphoproteome and the pYome data the 
following p-site annotation was mapped: kinase motifs (phospho motifs; HPRD database) 
according to sequence window, known sites (PSP and UniProt database) and known kinase-
substrate relations (PSP database) according to sequence window and UniProt protein IDs. 
Each protein group entry was annotated according to UniProt ID by Pfam, KEGG, GO BF and 
UniProt Keywords. P-sites with a SILAC ratio ≤ -0.75 or ≥ 0.75 for the global phosphoproteome 
and ≤ -1 or ≥ 1 for the pYome at least one time point were considered as regulated. For the 
protein expression analysis protein SILAC ratios ≤ -0.75 or ≥ 0.75 were accounted as regulated. 
For the phosphoproteomic cluster analysis, z-scoring (rows, no grouping) and the hierarchical 
clustering algorithm (row clustering with Euclidean distance, average linkage, preprocess with 
k-means, number of clusters 300) implemented in Perseus were applied. Four row clusters 
were defined for the global phosphoproteome data, and two row clusters were defined for 
the pYome data. 
2.2.5.2. Functional annotation of BCR signaling effectors 
Gene names of proteins with at least one regulated phosphorylation site in the DG75 BCR time 
course experiments were searched manually in the UniProt and the PSP database for 
functional information. Furthermore, the respective gene name was searched in combination 
with the terms ‘B lymphocytes’ and/or ‘B cell lymphoma’ in the PubMed database for relevant 
association which is not yet implemented in common databases. 
2.2.5.3. BCR stimulation time course in three distinct BL cell lines 
The DG75/Daudi and the label-free FFM_BL1 primary cell line dataset were loaded from the 
respective Phospho(STY)Sites.txt table. ‘Reverse’ and ‘contaminant’ entries were filtered, sites 
with a localization probability < 0.75 and were removed and the SILAC ratios (DG75 and Daudi) 
were logarithmized. The log2 of the LFQ intensities of label-free BL1 cells was calculated and 
sites with less than two quantitation value in the time course were removed. Missing data was 
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imputed from a normal distribution with a width of 0.5 and a down shift 1.6 for each column 
separately. The log2 LFQ intensity values after 2 and 10 minutes of stimulation were 
normalized to the non-stimulated time point (0 min). P-site annotation was mapped as 
described above. For each protein group entry Reactome, Pfam, KEGG, GO BF, MF and CC and 
UniProt Keywords annotation was added according to UniProt identifier. The 31 amino acids 
long sequence motif was shortened, starting at amino acid position six and a total length of 
eleven amino acids. For the analysis of common sites, the FFM_BL1 dataset was matched to 
the DG75/Daudi dataset by the short sequence windows. Sites with less than two quantitation 
ratios in either cell line were removed. Z-scoring (rows, no grouping) and the hierarchical 
clustering algorithm (row clustering with Euclidean distance, average linkage, preprocess with 
k-means, number of clusters 300) implemented in Perseus were applied. Three clusters were 
defined and the most differential sites were manually extracted for further analysis. 
2.2.5.4. Antigen-dependent and -independent signaling in DG75 
‘Reverse’ and ‘contaminant’ entries were removed from the Phospho(STY)Sites.txt, as well as 
sites with a global localization probability lower than 0.75. The normalized H/L ratios of the 
CD79A knockdown were reversed, all ratios were logarithmized (log2) and p-site annotation 
was mapped as described above. Each protein group entry was annotated according to 
UniProt ID by Reactome, Pfam, KEGG, GO BF, MF and CC and UniProt Keywords. Two separate 
BCR signaling groups were defined: tonic (BCR knockdown (BCR kd) and Syk inhibition (Syk-)) 
and antigen-dependent (BCR antigen stimulation time course)). For each group, sites with less 
than two quantitation ratios were removed. Z-scoring (rows, no grouping) and the hierarchical 
clustering algorithm (row clustering with Euclidean distance, average linkage, preprocess with 
k-means, number of clusters 300) implemented in Perseus were applied for heat map analysis. 
Three clusters were defined and the most differential sites were manually extracted for 
further analysis.  
2.2.5.5. BRAF interactome and inhibition 
For the BRAF interactome and BRAF inhibition analysis in DG75, proteinGroups.txt tables and 
Phospho(STY)Sites.txt (BRAF inhibition only) were filtered and processed as mentioned in 
2.2.5.1. Proteins with normalized SILAC ratios ≤ -1.5 and ≥ 1.5 in the BRAF interactome analysis 
and proteins with SILAC ratios ≤ -1 and ≥ 1 after BRAF inhibition were considered to be 
Materials and Methods 
57 
specifically depleted or enriched, respectively. Regulation thresholds for the global 
phosphoproteome after BRAF inhibition were a normalized SILAC ratio ≤ -2 or ≥ 2.  
2.2.5.6. BTK inhibition in AML 
Downstream data analysis of MaxQuant results was done with Perseus v1.5.0.15 (GP) and 
v1.4.1.3 (pYome) (Cox and Mann, 2008). ‘Reverse’ and ‘contaminant’ (in the protein 
expression analyses also ‘identified only by site’ entries) were removed as well as 
phosphorylation sites with a global localization probability lower than 0.75. Normalized SILAC 
ratios and the intensity values were logarithmized (log2 and log10, respectively). For the global 
phosphoproteome and the pYome data, information about kinase motifs (phospho motifs; 
HPRD database) according to sequence window, known sites (PSP and UniProt database) and 
known kinase-substrate relations (PSP database) according to sequence window and UniProt 
protein IDs were added with Perseus. Each protein group entry was annotated according to 
UniProt ID by Pfam, KEGG, GO BF and UniProt Keywords. For the global phosphoproteome 
two out of three technical replicates were required to have a SILAC ratio. The median of at 
least two SILAC ratios was calculated. For the global phosphoproteome, phosphorylation sites 
with a SILAC ratio ˂ -0.5 or ˃ 0.5 and for the pYome SILAC ratios ˂ -1 or ˃ 0.5 were considered 
to be regulated and used for further analysis.  
2.2.5.7. Protein network analyses 
 Phosphorylation interaction network analysis in BL 
Interaction network analysis of phosphorylated tyrosine (pY) site containing proteins derived 
from the pYome dataset and phosphorylated serine and threonine (pS/pT) site containing 
proteins from the global phosphoproteome dataset were submitted to the STRING database 
(Version 9.1) for the retrieval of protein-protein interactions (Szklarczyk et al., 2014). High 
confidence (score 0.7), ‘experiments’ and ‘databases’ as active prediction parameters were 
required. Networks were visualized with Cytoscape (Version 3.2.0.), further adaptations and 
modifications were done with Illustrator 5.1 (Shannon et al., 2003). 
 PhosphoPath analysis 
Additional network visualization of quantitative phosphoproteomic datasets were performed 
with the Cytoscape (Version 3.2.1) App PhosphoPath (Version 1.1). Protein-protein interaction 
information was retrieved from BioGRID and STRING databases, pathway information from 
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WikiPathways and kinase-substrate information from PSP. The quantitative networks were 
prepared as described by Raaijmakers et al., 2015. The networks were expanded with kinases 
from PSP and proteins from BioGRID (Raaijmakers et al., 2015). 
 BTK inhibition networks in AML 
All proteins with one or several phosphorylation sites considered to be regulated in the pYome 
experiment (normalized p-sites SILAC ratios on a log2 scale ≤ -1 or ≥ 0.5) were used to generate 
a protein-protein interaction network based on the STRING database (Version 9.1). High 
confidence (score 0.7), ‘experiments’ and ‘databases’ were used as active prediction 
parameters. Visualization was performed with Cytoscape (Version 3.0.2) (Shannon et al., 
2003). 
2.2.5.8. TCR signaling adapters 
Downstream data analysis of MaxQuant results was done with Perseus v1.5.0.15. SLP76 (LCP2) 
and GADS (GRAP2) p-sites were extracted from the Phospho(STY)Sites.txt. Normalized SILAC 
ratios and the intensity values were logarithmized (log2 and log10, respectively). P-sites with 
less than three quantitation values for every TCR stimulation time point (1, 2, 5 and 10 min) in 
four biological replicates and those sites with a global localization probability lower than 0.75 
were removed. Information about kinase motifs (phospho motifs; HPRD database) according 
to sequence window, known sites (PSP and UniProt database) and known kinase-substrate 
relations (PSP database) according to sequence window and UniProt protein IDs were added. 
The median of at least three SILAC ratios was calculated with Perseus. Sites were manually 
grouped according to their phosphorylation behaviour and visualized with Excel. 
2.2.5.9. Manual spectra annotation 
MS or MS/MS spectra were extracted from the raw data with Xcalibur or the MaxQuant viewer 
(implemented in MaxQuant) and modified with Illustrator (v5.1) for better legibility.  
2.2.5.10. Arginine-to-proline conversion 
For the determination of potential arginine-to-proline conversion, the peptides.txt table was 
loaded in Perseus (any version). ‘Reverse’ and ‘contaminant’ entries were removed, non-
normalized SILAC ratios were logarithmized (log2) and the density of the SILAC ratios against 
the proline content (P count) was calculated. SILAC ratios were plotted against the proline 
content and color-coded according to the density.  
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2.2.5.11. Kinobead analysis 
The list of identified proteins was filtered for kinases. Intensity values for 2, 5, 10 and 20 min 
of BCR stimulation were divided by the intensity value measured at 0 min (non-stimulated). 
Resulting ratios were logarithmized and kinases with values ≤ -1 or ≥ +1 were considered to 
have an altered binding behavior to the kinobeads after BCR stimulation and were considered 
for further investigations.   
2.2.6. Complementary analyses 
In the following, analysis methods other than LC-MS/MS measurement that were performed 
by collaborators are listed in Table 12. 
2.2.6.1. RNA sequencing 
 Sample preparation and data analysis 
Pellets were thawed in RNAlater (Qiagen) for RNA stabilization and total RNA was extracted 
using the RNeasy Mini Kit (Qiagen) following the manufacturer’s instruction for total RNA 
extraction from human cells. The RNA Integrity Number (RIN) was determined for all samples 
on an Agilent 2100 Bioanalyzer using the ‘Eukaryote Total RNA Nano Chip’ (Agilent). All RNA 
samples had a RNA integrity number (RIN) greater than 8 in order to provide good quality 
sequences. Sequencing libraries were prepared from the poly-A RNA fraction of 1 µg total RNA 
using the TruSeq RNA Sample Preparation Kit according to manufacturer’s instructions 
(Illumina). Paired-end sequencing was conducted on an Illumina HiSeq2000 with 100 bp per 
read. A mean of 63 million reads with a standard deviation of 12 million was generated for the 
60 samples. Generated sequences were aligned to the RefSeq human transcriptome using the 
Burrows-Wheeler Alignment (bwa) and concordance between reads and the reference 
genome (raw 'hits') per transcript were merged gene-wise (Li and Durbin, 2009; Pruitt et al., 
2013). Counts per gene were analyzed using DeSEQ describing gene expression as a 
generalized linear model including treatment (BCR vs CONTROL), a factorial time effect and 
the combined effect as full model and a model lacking the combined effect as reduced model 
(Anders and Huber, 2010). The resulting p-values (indicating a change over time depending on 
the treatment) were adjusted according to Benjamini-Hochberg (Benjamini and Hochberg, 
1995). Heat maps were generated using the package 'gplots' for the statistical programming 
language R (R Core Team, 2014; Warnes et al., 2013). 
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 Transcription factor enrichment analysis 
The transcription factor analysis was performed with the statistical computing environment R 
(Version 3.0.2). The TRANSFAC database (Version 2014.1) was used to match human upstream 
transcription factors to differentially expressed target genes found in the transcriptomic 
analysis (Matys et al., 2005; R Core Team, 2014). Fisher's exact test was used for transcription 
factor enrichment analysis. The resulting p-values were corrected for multiple testing with the 
Benjamini-Hochberg method (Benjamini and Hochberg, 1995). The heatmap.2 function of the 
R package 'gplots' was used for visualization of the dynamic target gene counts of significantly 
enriched transcription factors (Warnes et al., 2013). For cluster analysis, distances were 
measured as 1 - Pearson’s correlation coefficient. The row dendrogram was computed and 
ordered based on row means. 'Rgraphviz' R package was used for visualization of transcription 
factor target gene assignments (Hansen et al., 2010). 
2.2.6.2. Western blot and Ca2+ flux analysis 
Western blotting was performed as described in Oellerich et al., 2013. For Ca2+ flux analysis 
after BCR engagement, DG75 cells were loaded with the ratiometric Ca2+-chelator INDO-1-AM 




Protein PTMs such as phosphorylation play an important role in cell signaling processes. As 
dysregulated signaling is often involved in diseases such as cancer, a large-scale analysis of 
phosphorylation sites (p-sites) by tandem mass spectrometry was used to globally quantify 
the dynamic phosphoproteome in Burkitt’s lymphoma (chapter 3.1), acute myeloid leukemia 
(chapter 3.2) and T cells (chapter 3.3) under various experimental conditions. The resulting 
large-scale datasets were analyzed in terms of global parameters. Furthermore, single 
interesting phosphorylation sites were additionally highlighted in a functional context based 
on literature search.  
 
 BCR signaling in Burkitt’s lymphoma 
BCR-dependent signaling mechanisms in malignant transformed BL cells are poorly 
understood. The experimental setup described in the following aimed to globally characterize 
the B-cell receptor dependent phosphorylation status in BL cells during a defined time course 
of BCR stimulation. BCR stimulation was achieved with antibodies directed against the 
receptor as described in 2.2.1.3.1 leading to BCR engagement on the cell surface similar to 
antigen binding (Cao et al., 2012; Kishimoto et al., 1977; Schwartz et al., 2010). The 
comprehensive characterization of BCR signaling in DG75 was done by additional 
complementary time-dependent approaches i.e. transcriptional analysis and kinobead affinity 
purification. The kinase BRAF that was assumed to be activated according to the 
phosphoproteomic results was further screened for its interaction partners and its influence 
on the global phosphoproteome level. Time-dependent phosphorylation changes after BCR 
receptor engagement was additionally investigated in two other genetically distinct BL cell 
lines (Daudi and a primary, patient derived cell line FFM_BL1, or BL1) and compared to DG75 
phosphorylation dynamics (Table 9). In this study, experimental emphasis is made on DG75 
because it carries the MYC-IGH translocation t(8:14)(q24;q32) variant that is most common 
among BL patients (Molyneux et al., 2012). Moreover, the cell line has functional BCR signaling 
and can be genetically manipulated by targeted knockout/-down approaches (Feederle et al., 
2004). The BL cell line DG75 was established in 1975 from a metastatic pleural effusion of a 
male 10 year old patient suffering from primary abdominal Burkitt’s lymphoma (Ben-Bassat 
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et al., 1977). DG75 is derived from a sporadic, Epstein Barr virus (EBV)-negative Burkitt’s 
lymphoma and expresses a surface BCR of the IgM isotype (Ben-Bassat et al., 1977).  
Daudi is derived from an endemic BL with a MYC translocation and FFM_BL1 a primary, 
sporadic BL cell line that carries various MYC point mutations (Table 9) (Haluska et al., 1987; 
Klein et al., 1968). As the main part of the Burkitt’s lymphoma project is based on DG75, details 
about Daudi and FFM_BL1 cells will be provided in the respective results section 3.1.13. As 
mentioned previously in 1.2.1, BL is mainly driven by tonic, antigen-independent BCR signaling 
(Refaeli et al., 2008; Schmitz et al., 2012). Tonic BCR signaling was also investigated on the 
phosphoproteome level by two experimental approaches that allowed analysing BCR antigen-
independent signaling in DG75 as described in 3.1.14.  
3.1.1. Strategy for the phosphoproteomic analysis of BCR signaling 
As a first step, the functional BCR signaling output was verified by BCR stimulation with anti-
IgM antibodies mimicking antigen binding followed by visualization of global tyrosine 
phosphorylation by western blot (Figure 3.1). BCR engagement lead to a sustained increase in 
total tyrosine phosphorylation after 2 min of stimulation (second to fifth lane, Figure 3.1 A) 
compared to the non-stimulated state (first lane, Figure 3.1 A). B-cell activation was 
additionally visualized by intracellular Ca2+ release. Ca2+ levels peak at around 60 s after BCR 
engagement and slowly approximate ground state after 10 min (Figure 3.1 B). In order to 
characterize global, time-resolved protein expression and phosphorylation events after BCR 
engagement, a double triplex SILAC experiment covering the BCR stimulation time points 2, 5, 
10 and 20 min after the stimulus was designed (Figure 3.1 C). Global protein expression 
profiling of the before mentioned time points was done via SDS-PAGE separation and in-gel 
digest followed by LC-MS/MS analysis as described in 2.2.2.1. Phosphoproteomic 
characterization was achieved using two different approaches: First, a combination of strong 
cation exchange (SCX) and titanium dioxide chromatography (TiO2), which will be referred in 
the following as global phosphoproteome (GP); Second, an antibody-based purification of 
phosphorylated tyrosine peptides, which will be referred to as pYome (both approaches are 




Figure 3.1: Phosphoproteomic BCR signaling analysis 
(A) DG75 BL cells were left untreated or were BCR-stimulated for 2, 5, 10 and 20 min with anti-IgM antibodies, mimicking 
antigen stimulus. The western blot membrane was stained with an anti-pY antibody (4G10; upper panel) for visualization of 
total phosphotyrosine in the cells and for actin (lower panel) as loading control. (B) The intracellular Ca2+ concentration was 
measured until 10 min after BCR stimulation by flow cytometry. (C) Schematic representation of the experimental design of 
the double triplex SILAC approach for profiling protein expression and phosphorylation dynamics in resting and BCR 
stimulated DG75 cells. Cell lysates were mixed in equimolar amounts and digested by trypsin. For protein expression analysis, 
proteins were separated by SDS-PAGE, digested by trypsin and analyzed by LC-MS/MS. Phosphopeptides were enriched by a 
combination of SCX and TiO2 chromatography (global phosphoproteome; GP) or phosphotyrosine immunoprecipitation 
(pYome) and analyzed by LC-MS/MS. The pan anti-phosphotyrosine western blot and the flow cytometry-based Ca2+ flux 
assay shown in (A) and (B) were performed at the Department of Internal Medicine, Hematology/Oncology at the University 
Hospital Frankfurt/Main as part of the collaboration mentioned in Table 12. 
 
3.1.2. Protein expression levels  
Protein expression profiling for the BCR stimulation time course in DG75 was performed in 
order to confirm whether alterations in protein abundances through fast transcription, 
translation or protein degradation processes could influence correct phosphorylation site 
quantitation. Although a few proteins showed altered expression levels (proteins highlighted 
in red and with the gene name indicated; Figure 3.2) no general expression changes could be 
detected. Normalized SILAC ratios of the protein populations per time point of stimulation 
were normally distributed with the median value around zero (supplementary table S1). No 
previously known BCR signaling protein showed altered protein expression levels upon BCR 
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stimulation. All proteins and quantitation ratios for all time points can be found in 




Figure 3.2: Protein expression after BCR stimulation in DG75 
Scatter plots show the distribution of normalized SILAC ratios (log2) of the protein groups versus their intensity (log10) for 2, 
5, 10 and 20 min after BCR stimulation. Proteins with normalized SILAC ratios ≤ -0.75 or ≥ 0.75 (on a log2 scale) were 
highlighted in red. For better legibility, only gene names of proteins with the highest SILAC ratios were indicated. The 
complete protein list with quantitation values can be found in supplementary table S1. 
 
3.1.3. Identification, quantitation and regulation of phosphorylation sites 
The global SCX/TiO2-based phosphopeptide enrichment lead to the identification of 
approximately 9000 individual phosphorylation sites (dashed outer circle, Figure 3.3 A). 4390 
phosphorylation sites met the quality criteria of a localization probability ≥ 75%, referred to 
as class I sites, and quantitation values in at least 50% biological replicates at single BCR 
stimulation time points as described in 2.2.5.1 (outer circle, Figure 3.3 A). 730 of these sites 
were considered in the following to be regulated. This was defined by the normalized SILAC 
ratio ≤ -0.75 or ≥ 0.75 (on a log2 scale; inner circle, Figure 3.3 A) for at least one time point. 
The distribution of the regulated p-sites derived from the GP was split between the three 
amino acid residues as follows: 85% pS, 13% pT and 2% pY. As mentioned earlier, tyrosine 
phosphorylation is on the one hand known to play a major role in signaling processes, but on 
the other hand is less abundant; therefore, antibody-based phosphotyrosine enrichment was 
additionally applied. Immunopurification with specific phosphotyrosine antibodies resulted in 
the identification of approximately 900 phosphorylation sites of which 336 fulfilled the quality 
criteria mentioned above (dashed outer circle and outer circle, Figure 3.3 B). 181 of p-sites 
were considered to be regulated with a normalized SILAC ratio (log2) ≤ -1 or ≥ 1 (inner circle, 
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Figure 3.3 B). 82% of the regulated sites were phosphorylated tyrosines (blue grey pie, Figure 
3.3 B). Different regulation thresholds were applied to the global phosphoproteome and the 
pYome respectively, to take the higher magnitude of phosphotyrosine site regulation for the 
pYome into account (Olsen et al., 2006; Satpathy et al., 2015) (reviewed in Hunter, 2014; Lim 
and Pawson, 2010). Normalized SILAC ratios of regulated p-sites of both experimental datasets 
were Z-scored and subjected to unsupervised hierarchical cluster analysis, respectively (Figure 
3.3 C and D). Z-scoring transforms the time-dependent SILAC ratios of a p-site into 
standardized values with mean 0 and standard deviation 1. P-sites from the global 
phosphoproteome analysis could be separated into four main clusters while those derived 
from the pYome analysis fell into two distinct clusters (Figure 3.3 C and D). The dominant 
cluster identified from the GP analysis represented immediate dephosphorylation of p-sites 
after BCR engagement (Cluster 1, Figure 3.3 C), while in the pYome dataset, early upregulation 
followed by sustained phosphorylation after BCR engagement was characteristic (Cluster 1, 
Figure 3.3 D). Cluster 2 from the GP dataset showed immediate upregulation of p-sites after 
receptor stimulation whereas p-sites in cluster 3 showed a delayed, more gradual 
upregulation peaking after 5 min of BCR engagement (Figure 3.3 C). Gradual 
dephosphorylation of a few p-sites could be observed in both the GP and the pYome (Cluster 
4, Figure 3.3 C; Cluster 2, Figure 3.3 D). Detailed information about all quantified p-sites and 
assigned cluster from the GP and the pYome analysis can be found in supplementary tables S2 





Figure 3.3: Phosphoproteome dynamics in DG75 after BCR stimulation 
(A) and (B) Numbers of identified (dashed circle), quantified (outer circle) and regulated p-sites (inner circle) in the global 
phosphoproteome (A) and the pYome (B). The outer dashed circle represents non-proportionally the number of all p-sites 
identified across all BCR stimulation time points and biological replicates. The outer solid circle represents the number of 
quantified class I p-sites (localization probability ≥ 0.75) at all stimulation durations in at least 50% biological replicates and 
the proportions of phosphoserine, -threonine and -tyrosine. The inner circle represents the relative abundance of quantified 
class I p-sites that were regulated in at least one time point during stimulation including the distribution of amino acids. The 
p-site distribution between the three amino acid residues is shown as pie chart within the outer and the inner circle. (C) and 
(D) shows the hierarchical cluster analysis of all regulated p-sites (inner solid circles in A and B) of the global phosphoproteome 
(C) and the pYome (D) upon BCR stimulation, respectively. Values for each p-site (row) at all BCR stimulation durations 
(columns) are colored based on the log2-transformed and Z-scored normalized SILAC ratios (color scale at the right lower 
bottom). Line graphs next to the heat maps illustrate the phosphorylation dynamics upon BCR stimulation for each identified 
cluster. All quantified p-sites and assigned cluster shown in (C) and (D) can be found in supplementary tables S2 and S3. 
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3.1.4. Validation of MS-based quantitation 
To validate the quantitative, time-resolved proteomic and phosphoproteomic mass 
spectrometric results, the dynamics of selected phosphorylation sites of commonly known 
BCR effectors (BTK, MAPK1, MAPK3, SYK, BLNK, and CD79A/B) were visualized with western 
blot by using p-site- and protein-specific antibodies. The semi-quantitative western blot 
analysis of a BCR stimulated Burkitt’s lymphoma cell line was compared to the MS-based 
quantitative results of DG75 (Figure 3.4 A and B). Selected sites are activation state-specific p-
sites such as BTK Y551, SYK Y525, CBL Y674 or the dual phosphorylation TXY motif in MAPK1 
and MAPK3 (ERK2 and ERK1) (Burack and Sturgill, 1997; Teckchandani et al., 2005; Tsang et 
al., 2008). For CD79A (Ig) Y210, no site-specific antibody is available, therefore a p-site in 
close proximity, CD79A Y182 was visualized by western blot instead. Y182 is a valid substitute 
of Y210 as it lies outside the ITAM motif as well but flanks it from the N-terminal site (Suthers 
and Young, 2014). BLNK and CD79A protein expression levels could not be monitored by MS-
based proteome analysis. As CD79A forms a heterodimer with CD79B in the B-cell receptor, 
CD79B was visualized instead (Figure 3.4 A, lower panel). BLNK Y119 phosphorylation levels 
could be observed by MS-based phosphoproteomics only after 2 and 5 min of BCR stimulation 
(Figure 3.4 A, right lower panel). Protein expression levels did not undergo changes in any of 
the investigated proteins as can be seen both in MS-based quantitation and western blot 
analysis (Figure 3.4: bar diagrams in A and lower panels in B). Phosphorylation levels for all 
chosen p-sites increased immediately after 2 min of BCR stimulation and remained high until 
at least 10 min post-stimulation. In general, MS-based phosphorylation site dynamics of 
selected, regulated BCR-proximal effectors (BTK Y551, MAPK1 T185/Y187, MAPK3 T202/Y204, 
SYK Y525, CBL Y674, and BLNK Y119) could be reproduced by western blot (Figure 3.4: line 
diagrams in A and upper panels in B), confirming that the quantitative MS-approach is a 





Figure 3.4: Validation of key phosphorylation sites in BCR signaling 
(A) Mass spectrometric, SILAC-based quantitation (log2) of known BCR-dependent proteins (bar graphs) and selected p-sites 
(line graphs) of BTK, MAPK1 and 3 (ERK2 and 1), SYK, CBL, CD79A and BLNK (SLP65) that are representative for monitoring 
the activation state of the proteins. BLNK and CD79A protein expression levels could not be quantified. CD79B is shown 
instead of CD79A. (B) Phosphorylation dynamics and expression levels of the respective proteins at the indicated time points 
of BCR stimulation analyzed in (A) were visualized by immunoblotting with site- and protein-specific antibodies, respectively. 
Western blot analysis shown in (B) was performed at the Department of Internal Medicine, Hematology/Oncology at the 
University Hospital Frankfurt/Main as part of the collaboration mentioned in Table 12. 
3.1.5. Manual annotation of BCR signaling effectors 
Unbiased, large-scale data analysis harbours a wealth of information that need to be 
evaluated carefully in order to yield meaningful biological information. The global 
phosphoproteome and the pYome approach led in total to the identification of 857 unique 
regulated p-sites derived from 498 non-redundant proteins in DG75 cells upon BCR 
stimulation. Common annotation databases (e.g. KEGG, GO) often lag with the 
implementation of the most recent published information or do not provide enough biological 
detail. Therefore, an extensive literature (PubMed) and database search (UniProt and 
PhosphoSitePlus) was performed for the identified effector proteins in order to assign more 
detailed protein functions as described in 2.2.5.2. The three most prominent groups of BCR 
effector functions are transcriptional regulation (13.3%), cytoskeleton (9.2%) and kinases 
(9.0%) (Figure 3.5). The most dominant functional group of transcription regulators was found 
to be modified mostly by serine and threonine phosphorylation (blue and red proportion of 
the bar), while tyrosine phosphorylation (green proportion of the bar) targets mainly 





Figure 3.5: Manual annotation of regulated BCR effector proteins in DG75 cells 
Distribution of protein effector functions responding to BCR stimulation according to manual protein function annotation. 
The proportions of phosphoserine, -threonine and –tyrosine for each category are color-coded within the bars. The manual 
protein annotation categories shown can be found in supplementary tables S2 and S3. 
 
3.1.6. Network analysis of BCR-dependent phosphorylation sites 
Tyrosine phosphorylation plays a major role in BCR receptor proximal signaling events 
(reviewed in Kurosaki et al., 2009). To examine how changes in tyrosine phosphorylation 
events are integrated into BCR downstream signaling, the identified effectors were visualized 
as a pY-signaling network based on the pYome data. Protein-protein interaction (PPI) 
information derived from the STRING database was retrieved for proteins identified with a 
regulated tyrosine-phosphorylation site in at least one BCR stimulation time point from the 
pYome analysis. Additionally, protein functions that were assigned by the manual annotation 
approach mentioned above (section 3.1.5) were added. Figure 3.6 A shows the generated 
pYome network, in which well-established BCR-proximal signaling effectors (highlighted in 
red), including Src kinases, SYK, BTK, PI3K, BLNK, the BCR co-receptor CD19 and MAP-kinases 
cluster highly connected in the center of the network. Other proteins responding to BCR 
stimulation are not yet linked to the central BCR signaling hub or are not yet described in the 
context of B-cell signaling and thus can be found connected in the periphery, respectively. 
Compared to the pYome network, the pS/pT interaction network derived from cluster 2 p-
sites (described in section 3.1.3, Figure 3.3 C) of the global phosphoproteomic dataset is far 
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less interconnected and does not have a central BCR signaling hub (Figure 3.6 B). Overall, also 
far fewer BCR effectors (highlighted in red) are known. In line with the manual protein function 
annotation shown in Figure 3.5 B, the first and second most abundant categories 
‘Cytoskeleton’ and ‘Transcription regulation’ contain the most, however yet non-






Figure 3.6: BCR effector protein-protein interaction networks 
(A) Signaling network with all BCR effectors identified in the pYome dataset that have at least one regulated phosphotyrosine 
site during the time course. Sites quantified for 2 and 5 min upon BCR stimulation were also considered for this analysis. 
Proteins were grouped according to their enlisted protein-protein interaction (PPI) status in the STRING database. Red ellipses 
mark previously known BCR effectors, black rectangles depict those BCR effectors that have not been described in the B cell 
context before according to manual annotation. Proteins not engaged in the signaling network are categorized and grouped 
according to their manual annotated function. (B) Signaling network containing all pS and pT BCR effectors identified in Cluster 
2 of the global phosphoproteome experiment (Figure 3.3 C). Grouping of proteins and color coding of the nodes is described 
in (A). 
 
3.1.7. Transcriptional changes after BCR signaling 
Binding of an extracellular antigen to the membrane-bound BCR leads, after PTM-mediated 
signaling through the cytosol, finally to changes in transcriptional regulation. This is also 
reflected by the previous finding that transcriptional regulators are the most abundant 
regulated functional group (Figure 3.5). Transcription can be regulated by various mechanisms 
at different cellular levels such as elevated expression levels of a transcription factor (TF), 
altered activity or cellular localization of a TF mediated by post-translational modification, the 
recruitment of cofactors, histone modifications or by interference of non-coding RNA (Lee and 
Young, 2013). To identify the influence of phosphorylation processes on transcriptome 
dynamics, large-scale transcriptome sequencing in resting and BCR-stimulated DG75 cells (10 
min, 20 min, 1 h and 2 h) was performed in collaboration with Ekkehard Schütz as described 
in Table 12, section 2.2.6.1, and shown in Figure 3.7 A. A total of 105 transcripts were 
identified as being significantly regulated within two hours after BCR stimulation (Figure 3.7 
B; supplementary table S4). Several transcripts already showed elevated expression levels 
(FC > 1) after 10 min of BCR stimulation (e.g. FOSB, heat shock proteins, chemokines and EGR 
family proteins), while others such as the negative regulator of EGR, NAB2 reach their 
expression maximum after 2 hours (Kumbrink et al., 2005). Downregulated transcripts 
(FC < -0.1) can also be found already after 10 min of BCR stimulation (e.g. SEMA7A and 
LRRC32). PIM1, a serine/threonine kinase which regulates the stability of the oncogene MYC 
by phosphorylation, thereby regulating its transcriptional activity, is downregulated one hour 
after BCR stimulation (Zhang et al., 2008; Zippo et al., 2007). 
To identify TFs responsible for BCR-induced transcriptional regulation, a transcription factor 
enrichment analysis using the TRANSFAC database was performed in collaboration with Tim 
Beißbarth as described in Table 12 and section 2.2.6.1. The TRANSFAC database contains 
information about the relation of transcription factors to their respective target genes (Matys 
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and Kel, 2006). An over-representation analysis identified ten transcription factors that had a 
significant number of target genes identified as being differentially expressed in the 
transcriptome analysis (supplementary table S4). The counts of differential expressed targets 
of the mapped TFs showed a dynamic change as displayed in Figure 3.7 C. Early and transient 
transcriptional activity (10 and 20 min after BCR stimulation) for the transcription factors AP-1, 
HSF, ELK-1 and AhR, can be distinguished from a more sustained activation profile of NFAT-1, 
SRF and c-ETS. In contrast to that, IPF1 showed a late and slight increase of transcriptional 
activation. The bipartite graph expands the overrepresentation analysis by mapping the 
overrepresented transcription factors to their target genes in a time-resolved manner (Figure 
3.7 D). In order to link the PTM-based signal transduction to transcriptional regulation after 
BCR engagement, the phosphoproteomic as well as the TF enrichment datasets were screened 
for known transcription regulators in BCR signaling as stored in the IPA database (Figure 3.7 E). 
Five of the ten enriched transcription factors were previously described to play a role in B-cell 
development and function: CREB, Jun/AP1, ELK-1, ETS-1 and NFAT (blue coloured nodes, 
Figure 3.7 E) (Bories et al., 1995). Regulated p-sites after all four BCR stimulation durations 
were found in JUNB/AP-1 (T255 and S259) and NFAT (S233, S359 in NFATC1; S236, T325, S326 
in NFATC2; Figure 3.7 E). Both p-sites of JUNB/AP-1 were of particular interest as they are 
located within a phosphodegron, a motif involved in phosphorylation-dependent 
ubiquitination and subsequent proteasomal degradation of the target proteins (Pérez-
Benavente et al., 2012). The potential induced degradation by phosphorylation represented 
by the strong increase in phosphorylation of the respective pS-sites is in line with the 
observation of the decreased transcription activity of JunB/AP-1 after 10 min (Figure 3.7 E and 
C). The phosphorylation sites NFATC1 S233 and NFATC2 S236 lie within SPXX repeat regions 
which lead in case of dephosphorylation to the nuclear import of the proteins and could 
possibly influence the DNA binding affinity (Macian, 2005). The influence of phosphorylation 
of S359 (NFATC1) and T325/S326 (NFATC2) on transcriptional activity has not yet been 
functionally described. BCL-6 was not found to be enriched at the mRNA level, however BCL-
6 plays an important role in B cells. It is an inhibitory TF exclusively expressed in B cells, 
responsible for germinal center formation and antibody affinity maturation downstream of 
the RAF-MEK-ERK signaling axis (Schwartz et al., 2010). Ten phosphorylation sites of BCL-6 
upon BCR stimulation were identified. S427 was identified as regulated whereas the other 
quantified sites did not show any changes in phosphorylation after BCR stimulation (Figure 3.7 
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E). No phosphorylation changes could be monitored for BCL-6 S333 and S343 during the BCR 
stimulation time course (Figure 3.7 E). Phosphorylation of these two sites is described to lead 
to BCL-6 degradation (Niu et al., 1998). For the transcription factor TFII-I (GTF2) three out of 
six p-sites (S412, T413, S784 in isoform 1, corresponding to S371, T372 and S743 in isoform 2; 
supplementary table S4) were identified as being regulated after BCR stimulation (Figure 3.7 
E). The serines at positions S412 and S784 were previously connected to enhanced 
transcriptional activity when phosphorylated (Casteel et al., 2002). The heat shock factor 
protein (HSF1) regulates genes in response to stress (Holmberg et al., 2002). HSF1 S303 is 
described in the literature as an inhibitory site when phosphorylated. It was identified to be 
dephosphorylated after BCR stimulation in this study while transcription factor activity peaked 
at 10 min after BCR stimulation (Figure 3.7 E) (Holmberg et al., 2002). All enriched transcripts 
with their respective mapped transcription factors and p-site dynamics of overrepresented 




Figure 3.7: Time-dependent transcriptome analyses of BCR signaling 
(A) Experimental workflow for the transcriptome sequencing of BCR stimulated DG75 cells. (B) Heat map illustrating the 
dynamics of 105 differentially expressed transcripts after 10 min, 20 min, 1 h and 2 h after BCR stimulation. (C) Heat map 
representing significantly enriched transcription factors for individual durations of BCR stimulation. Shown are the 
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transcription factors assignable to target genes, which match the differentially expressed transcripts. (D) Bipartite graphs 
relating the transcription factors to their target genes for each BCR stimulation duration. Matching of the identified, 
differentially expressed transcripts to a transcription factor was done with the TRANSFAC database. (E) Enriched transcription 
factors (from C) set in context to database knowledge about BCR signaling using Ingenuity pathway analysis (left side). 
Enriched transcription factors that are not yet linked to BCR signaling, SRF, HSF and TFII-I (GTF2), are located in the right part 
of the scheme. Transcription factors responsible for the observed transcriptomic changes are marked with a blue border. 
Transcription factors with a green fill indicate p-sites that were identified in the DG75 global phosphoproteomic experiment. 
Quantifiable phosphorylation sites for these transcription factors are marked with ‘P’. A red fill indicates regulation and the 
corresponding quantified phosphorylation profiles are shown in the respective bar diagrams below. All regulated transcripts 
shown in (B), their respective transcription factors and the p-sites of overrepresented transcription factors shown in (C) and 
(D) are listed in supplementary table S4. RNA sequencing shown in (A) was performed by Chronix Biomedical, San 
Jose/Göttingen. The following data analysis shown in (B)-(D) was performed at the Institute of Medical Statistics, University 
Medical Center Göttingen as part of the collaboration mentioned in Table 12. 
 
3.1.8. Kinobead analysis  
Kinases are of major importance in BCR signal transduction as they are the mediators of 
phosphorylation on serine, threonine or tyrosine residues (reviewed in Kurosaki et al., 2009). 
Moreover, kinases were found to be one of the predominant protein families with regulated 
p-sites (Figure 3.5). Since small-molecule inhibitors can selectively target kinases, they became 
of particular interest for therapeutic strategies. In order to obtain more experimental 
evidence for active kinases, kinases were affinity purified from DG75 whole cell lysates with 
non-selective, commercially available kinase inhibitors immobilized on beads, namely 
kinobeads in collaboration with Bernhard Küster as described in Table 12 and section 2.2.5.11 
(Bantscheff et al., 2007). The kinobead assay was performed for the time points after BCR 
stimulation defined for the previously described phosphoproteomic analysis i.e. 2, 5, 10 and 
20 min (Bantscheff et al., 2007). The bound kinases after each time point were relatively 
quantified compared to the non-stimulated ground state with a label-free approach by mass 
spectrometry as described in 2.2.5.11 and Bantscheff et al., 2007. In total, 211 kinases could 
be quantified over the BCR stimulation time course of which three showed label-free 
quantitation values ≤ -1 and twelve showed values ≥ +1 on a log2 scale for at least one time 
point (supplementary table S5). It can be excluded from the protein expression analysis shown 
in 3.1.2. that increased binding to the kinobeads at very early time points after BCR stimulation 
is due to changes in kinase protein expression levels. Since kinase-to-bead binding is not 
necessarily associated with kinase activity, phosphorylation sites were used as an additional 
indicator to monitor kinase activity (Ruprecht et al., 2015). The p-site dynamics of potentially 
activated kinases as determined by the quantitative phosphorylation analysis shown in 3.1.3 
were compared to their kinobead binding profiles, and additionally, set in a functional context 





Figure 3.8: Kinase activation pattern in DG75 cells  
(A- D) Bar diagrams showing kinases with a ratio ≥ 1 or ≤ -1 (on a log2 scale) in DG75 cells as revealed by a label-free kinobead-
based proteomic analysis and with quantifiable p-sites from the phosphoproteomic approach upon indicated durations of 
BCR stimulation. Line graphs represent indicated phosphorylation sites on the respective kinase (A) SYK (B) RSK family kinases 
(C) SRC and (D) BRAF, identified from the global phosphoproteome or the pYome dataset. All kinases with an altered affinity 
to kinobeads after BCR stimulation are listed in supplementary table S5. The kinobead assay and following data analysis was 
performed at the Chair of Proteomics and Bioanalytics at the Technical University München, Freising, as part of the 
collaboration mentioned in Table 12. 
 
For seven kinases with an altered binding behaviour, p-sites could be identified from both, the 
GP or the pYome experimental data: SYK, four members of the ribosomal S6 kinase (RSK) 
family, SRC and BRAF. The time-resolved kinase binding profiles after BCR stimulation are 
shown in Figure 3.8 A-D. For SYK, 11 p-sites with a full phosphorylation profile could be 
quantified. The observed dynamics in the phosphorylation of sites (Figure 3.8 A) are located 
in kinase activity-regulating regions within the interdomain B (aa positions 260-370) or the 
kinase domain (aa positions 371-631). The correlation of the phosphorylation status of specific 
sites and the activation status of the kinase has been extensively described (Tsang et al., 2008). 
All SYK p-sites detected closely resemble the time profile for SYK binding to the kinobeads. For 
the four RSK family members RPS6KA1, RPS6KA3, RPS6KA4 and RPS6KB1, six p-sites could be 
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quantified (Figure 3.8 B). A few were already associated with enhanced enzymatic activity e.g. 
T359 and S363 in RPS6KA1, S227 and S369 in RPS6KA3 and S447 in RPS6KB1 (Lekmine et al., 
2003; Merienne et al., 2000; Wu et al., 2013). The phosphorylation of both sites in RPS6KA1 
followed the kinobead-kinase binding profile and therefore could reflect kinase activity. The 
adjacent phosphorylation sites Y419 and T420 on the non-receptor tyrosine kinase SRC 
showed a similar fluctuating profile with phosphorylation maxima at 2 and 10 min, 
respectively (Figure 3.8 C). In contrast to that, kinase-to-bead binding increased until 10 min 
of BCR stimulation and declined afterwards. The BRAF phosphorylation sites S446, S447 and 
S729 were not found to be regulated during the time course of stimulation although S446 and 
S729 are described as influencing kinase activity (Figure 3.8 D) (MacNicol et al., 2000; Tran et 
al., 2005). BRAF S363 was found to be dephosphorylated immediately after BCR stimulation 
and became slightly phosphorylated during the time course of stimulation, therefore inversely 
correlating with kinase-to-bead affinity (Figure 3.8 D). In the context of lymphoma, especially 
Burkitt’s lymphoma, wild type BRAF is described rather than mutated, constitutively activated 
BRAF (V600E) (Cozzi et al., 2012; Schmitz et al., 2012; Spender and Inman, 2014). Several BRAF 
V600E inhibitors are available and BRAF inhibition is an approved treatment for melanoma 
patients (Flaherty et al., 2010). This made BRAF an interesting candidate for further analyses 
as described in the following.  
BRAF S363 is the first of three consecutive serines within the peptide: 
pSSSAPNVHINTIEPVNIDDLIR (aa positions 363–386 in isoform 1). They comprise the C-
terminal part of a generalized AKT consensus motif RXRXXS, where the two random amino 
acids represented by X prior to the terminal serine (S365) are replaced by serines (S363 und 
S364) (Schwartz and Gygi, 2005). S365 (in the following references referred to as S364) is 
described as an inhibitory phosphorylation site with AKT as upstream kinase (Cheung et al., 
2008; Guan et al., 2000; Zhang and Guan, 2001; Zimmermann and Moelling, 1999). It is not 
entirely clear if the upstream kinase AKT can exclusively target S365 or if rather the 
phosphorylation is distributed stochastically between the three serine residues. Furthermore, 
in previous studies the phosphorylation-mediated inhibition of BRAF was investigated with 
site-specific antibodies by western blot (Cheung et al., 2008; Guan et al., 2000; Zhang and 
Guan, 2001). It is also not entirely clear if these antibodies can selectively distinguish between 
the three potential site isomers pSSS, SpSS or SSpS. However, increased binding to the 
immobilized kinase inhibitors in combination with dephosphorylation of BRAF S363, adjacent 
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to the previously described inhibitory p-site S365 within the AKT consensus motif hinted 
towards BRAF activation. For the matter of interest and further potential functional studies, 
the exact position of phosphorylation was determined by manual spectra annotation of the 
peptide (Figure 3.9). As mentioned previously, unambiguous site localization is not trivial, 
especially if the potential modifiable amino acids are in close proximity and the fragment ion 
series is not complete (section 1.3.8). The spectrum shown in Figure 3.9 A provides evidence 
for assigning the p-site unambiguously to the first serine S363, corresponding to a localization 
probability of 75.9% (supplementary table S2). Other spectra derived from the singly 
phosphorylated peptide did not provide unambiguous information about the exact 





Figure 3.9: Phosphorylation site localization in BRAF  
Ion trap CID MS/MS spectrum of the tryptic peptide pSSSAPNVHINTIEPVNIDDLIR (aa positons 363 – 384) derived from BRAF. 
Neutral loss of H3PO4 (phosphoric acid) is indicated by an asterisk (*). B-ions are colored in blue, y-ions in red and fragments 
with a neutral loss of H2O (water) and NH3 (ammonia) are colored in yellow. The m/z values are indicated below, the charge 
state (z) is superscripted at the respective ions. The left y-axis shows the relative abundance of each fragment, the right y-axis 
the fragment ion intensity and the x-axis the m/z value. The score (Andromeda score) and the m/z value of the parent ion are 
displayed above the spectrum. The upper panel displays the fragmentation spectrum whereas the lower panel indicates the 
respective b- and y-ion series. Ions that help to determine the phosphorylation site position are highlighted with a box. For 
spectra annotation, MaxQuant Viewer expert annotation was used. The annotated spectra were further modified with 
Illustrator (v5.1) for better legibility and the indication of ions of special interest. (A) The neutral loss b-ion b3* and the b3-
ion indicate the phosphorylation of one of the three N-terminally located serines. The y-ions y212+ and y202+ localize the site 
of phosphorylation unambiguously to position S363. (B) The neutral loss b-ion b3* indicates the phosphorylation of one of 
the three N-terminally located serines while the y202+-ion rules S365 as site of phosphorylation out. (C) The neutral loss b-ion 
b3* indicates the phosphorylation of one of the three N-terminally located serines.  
 
3.1.9. BRAF interactome 
BRAF involvement in antigen-dependent BCR signaling in DG75 was further investigated by 
the analysis of its interactome. BRAF is a serine-threonine kinase, namely a MAPKKK (or 
MAP3K) and therefore an upstream kinase in the classical MAP-kinase signaling cascade 
(reviewed in Chang and Karin, 2001 and Dhillon et al., 2007). As BRAF is not described to be 
mutated in Burkitt’s lymphoma, for example the V600E point mutation leading to its 
constitutive activation, the kinase is amenable to activity regulation (Davies et al., 2002). As 
other MAP-kinases, BRAF activation depends amongst other processes on activating and 
inhibiting of phosphorylation sites and their dephosphorylation (reviewed in Chang and Karin, 
2001 and Dhillon et al., 2007). BRAF is therefore expected to interact with its upstream 
interactors as well as with its downstream targets. The interactome analysis to identify 
putative BRAF binding partners was performed with a triple SILAC experimental design: light- 
and medium-labeled DG75 cells were left non-stimulated whereas the BCRs of heavy-labeled 
cells were stimulated for 5 min via their BCR (Figure 3.10 A). BRAF was purified with a BRAF-
specific antibody from the medium and heavy cell lysates (Figure 3.10 A). As a control, the 
light-labeled lysates were incubated with the beads lacking the antibody. Immunopurified 
proteins were mixed in equimolar amounts, separated by SDS-PAGE, digested with trypsin and 
analyzed by LC-MS/MS (Figure 3.10 A). Of note, the DG75 cells used for the BRAF interactome 
analysis were affected to some extent by metabolic arginine-to-proline conversion as 
described in 3.1.12 and shown in Figure 3.13 E (Blagoev and Mann, 2006; Lössner et al., 2011; 
Ong et al., 2003; Van Hoof et al., 2007). However, the distribution of the normalized protein 
ratios was normally distributed and specific BRAF enrichment could be observed. Therefore 
results were used for analysis but might be considered carefully.  
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Highly specific enrichment of BRAF by immunopurification compared to the control state is 
demonstrated by high medium-to-light (M/L) and heavy-to-light (H/L) quantitation ratios 
(right upper quadrant; Figure 3.10 B). As a proof-of-principle, the downstream MAP-kinase of 
BRAF, MAP2K1 (MEK1) was found to be enriched together with BRAF in both the non-
simulated (medium) and the BCR stimulated cells (heavy) (reviewed in Chang and Karin, 2001; 
Dhillon et al., 2007). The diagonal distribution of protein H/L and M/L SILAC ratios showed a 
Pearson’s correlation efficient of 75.9%, indicating correlation in the binding behaviour of 
BRAF interactors after 5 min of BCR stimulation compared to the non-stimulated state. The 
majority of proteins (grey squares) cluster around the intersection of the y- and x-axis base 




Figure 3.10: BRAF interactome analysis in DG75 
(A) For the BRAF interactome analysis, light- and medium-labeled DG75 cells were left non-stimulated whereas the BCRs of 
heavy-labeled cells were stimulated for 5 min. BRAF was affinity purified from the medium and heavy lysates with a BRAF-
specific antibody. As a control, the light-labeled lysates were incubated with the beads lacking the antibody. Immunopurified 
proteins were mixed in equimolar amounts, separated by SDS-PAGE, digested with trypsin and analysed by LC-MS/MS. (B) 
The scatter plot shows the distribution of the normalized SILAC heavy-to-light (H/L) ratio of proteins (y-axis) reflecting 5 min 
of BCR stimulation and the medium-to-light (M/L) ratio (x-axis; both log2) reflecting the non-stimulated ground state. 
Interaction partners with ratios ≤ -1.5 and ≥ 1.5 are highlighted in red and gene names are indicated, proteins below the 
threshold (red dashed lines) are marked in grey. Proteins with a H/L ratio above or below the threshold are highlighted in 
blue. The vertical and horizontal base lines are shown as light grey dashed line. The Pearson’s correlation coefficient is 
displayed in the upper right corner of the scatter plot. BRAF is represented two times in the scatter plot due to two different 
sequence database entries (C) The scatter plot shows the distribution of the intensity (y-axis; log10) against the normalized 
SILAC ratio H/M (x-axis; log2). The H/M ratio reflects binding after 5 min of BCR stimulation compared to ground state. 
Proteins highlighted in green are the most abundant seen in (B). The threshold and color code settings are mentioned in (B). 




The proteins enriched together with BRAF in the ground and the BCR stimulated state in the 
upper right quadrant: CUX1, TRIM21, KIF3A, DHX8, ARHGEF2, AKAP13 and MAP2K1 could 
potentially be interaction partners of BRAF (highlighted in red, Figure 3.10 B; supplementary 
table S6). Potential contaminant proteins were depleted in the medium- and heavy-labeled 
state i.e. enriched in the light-labeled control experiment and appeared in the left lower 
quadrant: IGHG1, SPATC1, KRT2, SH3RF3, DCD, IGLC2, CRYAA and SOAT1. Proteins specifically 
depleted (CD79A and SCCPDH) or enriched (SRPR, RIF1 and histone proteins) only after 5 min 
of BCR stimulation (heavy label) and not in the non-stimulated (medium label) state are 
highlighted in blue (Figure 3.10 B; supplementary table S6). No protein was found to be 
specifically depleted in one state and enriched in the other state (right lower or the left upper 
quadrant). To further link the experimental BRAF interaction data with the BCR stimulation 
data in DG75, p-site and protein expression levels of potentially interesting interacting 
candidates were mapped. For three proteins with the highest SILAC ratios, CUX1, TRIM21 and 
KIF3A, no regulated p-site could be mapped from the phosphoproteomic dataset and no 
protein expression change could be detected over the time course of stimulation 
(supplementary table S6).  
To thoroughly visualize BCR stimulation induced partners, the normalized heavy-to-medium 
(H/M) SILAC ratios which directly compare 5 min of BCR stimulation to the ground state were 
plotted against the log10 intensity (Figure 3.10 C). The majority of proteins did not show an 
altered binding behaviour as can be seen by the evenly distribution around the vertical zero 
line (light grey dashed line) and SILAC ratios between -1 and 1 on a log2 scale (grey squares). 
BRAF and its co-purified putative interaction partners (CUX1, TRIM21 and KIF3A) shown in 
Figure 3.10 B are highlighted in green (Figure 3.10 C). Potential BRAF interaction partners 
enriched prior to BCR stimulation can be found on the left side of the scatter plot: CD79A/B 
(signaling module of the BCR), SCCPDH, and S1PR4 whereas putative BRAF interactors after 5 
min of BCR engagement can be found on the right side of the scatter plot: HIST1H2BL/AJ, 
HIST1H4A, HIST2H3A, SH3RF3, SRPR, NDUFS3, and RIF1. 
 
3.1.10. BRAF inhibition 
After the identification of the activation-induced BRAF interactome, BRAF downstream 
actions in antigen-dependent BCR signaling in DG75 were analysed. This was accomplished by 
BCR stimulation in combination with BRAF inhibition in DG75 cells followed by a global 
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phosphoproteome analysis (Figure 3.11 A). As experimental design a triple SILAC labeling 
approach was used: light-labeled cells were left non-stimulated, the BCRs of medium- and 
heavy-labeled cells were both stimulated for 5 min, respectively. In addition to BCR 
stimulation, the heavy-labeled cells were treated with the small-molecule BRAF inhibitor 
Raf265 (Figure 3.11 A) (Williams et al., 2015). Of note, the DG75 cells used for this experiment 
were also affected to some extent by arginine-to-proline conversion as described in 3.1.12 
and shown in Figure 3.13 F (Blagoev and Mann, 2006; Lössner et al., 2011; Ong et al., 2003; 
Van Hoof et al., 2007). As normalized protein and p-site ratios were approximately normally 
distributed and centered around zero, results were used for analysis but might be considered 
carefully (Figure 3.11 B). Moreover, M/L ratios appeared to be more severely affected by this 
effect as can be seen by a stronger indirect correlation of the shift towards light and proline 
content compared to the heavy-to-light ratios (Figure 3.13 F, left panel: M/L, right panel: H/L). 
 
Figure 3.11: BCR signaling during BRAF inhibition  
(A) Experimental design of the BRAF inhibition analysis in DG75 cells. Light-labeled DG75 cells were left non-stimulated 
whereas the BCRs of medium- and heavy-labeled cells were stimulated for 5 min. Additionally, heavy-labeled cells were 
treated with the BRAF inhibitor Raf265 for 45 min before BCR stimulation. Cells were lysed; the different labeling states were 
mixed in equimolar amounts. Lysates were digested in-solution and enriched for phosphopeptides with the SCX + TiO2-based 
enrichment and subjected to LC-MS/MS analysis. (B) The y-axis of the scatter plot shows the intensity values (log10) and the 
x-axis the normalized heavy-to-medium (H/M) SILAC ratios (log2) of individual class I phosphorylation sites. P-sites with a 
SILAC ratio between -2 and 2 on a log2 scale are colored in grey, sites with lower or higher ratios are colored in red and gene 
names are indicated. Phosphorylation sites specifically mentioned in the text are highlighted in bold and sites are indicated. 




From the global BRAF inhibition phosphorylation site analysis, 3845 class I p-sites could be 
quantified upon 5 min BCR stimulated cells with pharmacological inhibited BRAF (heavy label) 
and 5 min BCR stimulated cells (medium label; Figure 3.11 A; supplementary table S7). The 
identified BRAF p-sites S151, S446 and S729 did not show phosphorylation changes in the 
different experimental conditions (supplementary table S7). 57 p-sites on 52 effector proteins 
were found with normalized H/M ratios ≤ -2 or ≥ 2 on a log2 scale and were therefore 
considered to be regulated after BRAF inhibition. The effector proteins, MEF2C and DBNL were 
previously linked to BCR signaling (supplementary table S7) (Le Bras et al., 2004; Muzio et al., 
2007; Swanson et al., 1998). The transcription activator MEF2C was found dephosphorylated 
at S98. No particular p-site annotation for this p-site is available, however the protein is 
associated with BCR signaling and plays a role in BCR survival and proliferation (Swanson et 
al., 1998). The second BCR effector protein, DBNL (HIP-55) showed an upregulated p-site at 
position S232 during Raf265 treatment. As for MEF2C, no particular functional information for 
the p-site S232 is available. However, DBNL is known to be involved in endocytosis and actin 
cytoskeleton processes in T-cell receptor signaling (Le Bras et al., 2004). Furthermore, two 
regulated phosphorylated p-sites were annotated according to PSP as regulatory sites: PGAM1 
S118 and RB1 S249. PGAM1 S118 is an inhibitory site which is involved in metabolic processes 
to drive cancer (Hitosugi et al., 2012; Shalom-Barak and Knaus, 2002). The phosphorylation 
site S249 of the tumor suppressor RB1 is involved in cell cycle regulation function and was 
associated with breast cancer (Caldon et al., 2007). None of the two sites could be additionally 
detected in the BCR stimulation time course of DG75 cells (supplementary table S7). In 
summary, the serine-threonine kinase BRAF appeared to be an interesting candidate for 
further large-scale analyses. The BRAF interactome and the altered p-sites identified from the 
global phosphoproteomic analysis during inhibitor-induced BRAF ablation provided 
interesting insights in BRAF involvement in BCR signaling. However, the overall outcome is 
difficult to interpret and requires more replicates, methodical refinement and further 
functional validation. 
 
3.1.11. Acetylation and ubiquitination 
Besides phosphorylation, other PTMs are known to also play a major role in BCR signaling as 
described previously in section 1.3.8 (reviewed in Kurosaki et al., 2009). To complement the 
large-scale phosphorylation study, lysine ubiquitination and acetylation was additionally 
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analyzed in DG75 in a double-label SILAC approach, respectively. Light-labeled cells were not 
stimulated whereas the BCRs of heavy-labeled cells were stimulated for 2 min (Figure 3.12 A). 
Peptides were immunopurified analogous to the phosphotyrosine enrichment with 
commercially available antibodies as previously described 2.2.2.2.2 directed against the 
ubiquitin di-glycine remnant at lysine residues or acetylated lysine residues. The DG75 
samples used for this analysis were affected by metabolic arginine-to-proline conversion as 
described in 3.1.12 (data not shown) (Blagoev and Mann, 2006; Lössner et al., 2011; Ong et 
al., 2003; Van Hoof et al., 2007). Nonetheless, the results were used for analysis as the 
experiments were primarily conducted as a feasibility and screening study but have to be 
considered carefully.  
Figure 3.12 B shows the normalized SILAC ratios of 372 quantified class I ubiquitination sites 
derived from 224 proteins. 32 sites derived from 21 proteins were considered as regulated 
with SILAC ratios ˂ -2 or ˃ 2 (Figure 3.12 B, highlighted red; Figure 3.12 D, upper panel). Of 
particular interest was the increase in ubiquitination of CD79B K219 after 2 min of BCR 
stimulation (Figure 3.12 B, highlighted bold). The site lies on the intracellular domain of CD79B, 
C-terminal of the ITAM-motif and is not yet functionally described (supplementary table S8). 
From the acetylation study, 148 class I sites on 93 proteins could be quantified (Figure 3.12 C). 
Five acetylated lysine residues on distinct different proteins were quantified with a SILAC ratio 




Figure 3.12: Ubiquitination and acetylation in BCR signaling 
(A) Experimental design of the acetylation and ubiquitination analysis in DG75 cells. Light-labeled DG75 cells were left non-
stimulated whereas the BCRs of heavy-labeled cells were stimulated for 2 min. Cells were lysed, the two labeling states were 
mixed in equimolar amounts. Proteins were digested in-solution, peptides were immunopurified with modification specific 
antibodies (GG(L): ubiquitin remnant motif, Ac(L): acetyl-lysine; green=ubiquitination, pink=acetylation) and subjected to LC-
MS/MS analysis. (B) and (C) Intensities (log10) of quantified class I ubiquitination and acetylation sites are plotted against the 
normalized heavy-to-light (H/L) SILAC ratios (log2). Modified sites with a ratio between -2 and 2 are colored as grey dots, sites 
with ratios lower or higher are highlighted as red dots and gene names are indicated. The dashed grey line represents the 
vertical zero line, the red dashed lines the regulation threshold. (D) Table listing the numbers (#) of quantified class I sites, 
number of effector proteins, regulated sites and regulated effector proteins (upper panel). Ubiquitination is color-coded in 
green, acetylation in pink. The right Venn diagram shows the overlap of regulated effector proteins identified from the 
ubiquitination, acetylation and phosphorylation site analyses. The left Venn diagram displays the overlap of lysine sites being 
ubiquitinated and acetylated (both lower panel). (E) Comparison of the normalized SILAC H/L ratios (y-axis) of the 14 lysine 
residues (lower left Venn diagram in D) that are ubiquitinated (dark grey bars) as well as acetylated (light grey bars). All 
quantified sites are listed in supplementary table S8.  
 
When screening for positive PTM cross talk between ubiquitinated, acetylated and 
phosphorylated sites, no overlap in regulated effector proteins could be identified. However, 
a few ubiquitinated or acetylated proteins were found in common with phosphorylation, 
respectively (Figure 3.12 D, left lower panel). Fatty acid synthase (FASN) was the only protein 
identified with a regulated acetylation and phosphorylation site. FASN K1704 was acetylated 
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after 2 min of BCR stimulation while T2204 became phosphorylated after 10 min of BCR 
stimulation (supplementary table S8). HIST1H1E, TUBA1B and TUBB were identified with 
regulated ubiquitination and phosphorylation sites. HIST1H1E K17 became deubiquitinated 
after 2 min while T18 became dephosphorylated after 5 min of BCR stimulation 
(supplementary table S8). Multiple TUBA1B phosphotyrosine sites (Y103, Y224, Y272, Y312, 
Y357 and Y399) were identified as upregulated whereas ubiquitination from all lysine sites 
(K60, K96, K304, K326, K336 and K370) was removed after BCR engagement (supplementary 
table S8). TUBB became phosphorylated at Y32 while K40, K324, K336 became 
deubiquitinated (supplementary table S8). To identify potential negative cross talk, both 
acetylation and ubiquitination site datasets were compared. 14 modified sites on twelve 
unique proteins e.g. ACTB, ENO1, PTMA and different histone proteins, were found to be 
modified by ubiquitination as well as acetylation (Figure 3.12 D, right lower panel and Figure 
3.12 E). The bar diagram in Figure 3.12 E shows the normalized SILAC ratios of the 14 lysine 
class I sites that were found to be modified with acetylation and ubiquitination (Figure 3.12 D, 
left lower panel). Two common sites exceeded the regulation threshold with at least one type 
of modification (HIST1H1C K17 and HIST1H1E K17) whereas all other common modified lysine 
sites were considered as non-regulated. Eight of the common sites were responding 
accordingly to BCR stimulation. Five sites (ACTB K326, HIST1H1B K49, HIST1H1E K46, 
HIST1H2BK K109 and PPIA K28) were found to be deacetylated and –ubiquitinated. In contrast, 
HIST1H1E K85, HIST1H4A K78, and PTMA K15 became acetylated and ubiquitinated, 
respectively after BCR stimulation. ALDOA K42 and RPS8 K128 showed a change for only one 
modification where as ENO1 K5 and HIST1H2BC K121 were regulated in opposite directions, 
respectively (supplementary table S8). Overall, the general yield in acetylated and 
ubiquitinated sites was low, therefore less sites potentially involved in PTM cross talk were 
identified. Experiments have to be refined as will be discussed later in chapter 4. 
 
3.1.12. Arginine-to-proline conversion 
Metabolic labeling strategies such as SILAC are one of the most robust quantitation methods 
available for mass spectrometry (Ong et al., 2002). As mentioned earlier in 1.3.6.1, an 
advantage is the early sample mixing and therefore parallel sample handling which makes the 
method robust against sample loss (Ong et al., 2002). However, its robustness is compromised 
by the metabolic conversion of arginine to proline, Arg+10 to Pro+6 and Arg+6 to Pro+5, 
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respectively (Blagoev and Mann, 2006; Ong et al., 2003; Van Hoof et al., 2007). The conversion 
affects correct quantitation, as it lowers the intensity of the heavy arginine- and lysine-labeled 
SILAC peptides and introduces heavy satellite peaks derived from peptides containing 
additional heavy proline which are not taken into account for quantitation (Lössner et al., 
2011). Strategies to avoid conversion are the reduction of the arginine concentration, the 
addition of unlabeled proline or the use of quantitation strategies to correct for the conversion 
(Bendall et al., 2008; Blagoev and Mann, 2006). A low arginine concentration is not well 
tolerated by every cell line and in silico correction is feasible if the sample complexity is low 
and samples are duplex labeled only i.e. light and heavy (Bendall et al., 2008; Park et al., 2009). 
For highly complex samples with triplex labeling and phosphorylation as further variable 
parameter, correction strategies are not feasible anymore. Unfortunately, arginine-to-proline 
conversion appeared in a few samples (BRAF interactome, BRAF inhibition, and the antigen-
dependent BCR acetylation and ubiquitination signaling analyses in DG75, respectively) used 
for the investigation of Burkitt’s lymphoma. The effect became obvious by global shifts of the 
SILAC ratios from the protein or modified peptide population towards light (data not shown). 
Retrospective, manual spectra investigation revealed complex SILAC patterns with satellite 
peaks with an additional mass of 5 or 6 Da in proline containing peptides (an example is given 
in Figure 3.13 A). Those satellite peaks were absent in peptides lacking proline (Figure 3.13 B). 
In order to get an overview about the magnitude of conversion, the non-normalized SILAC 
peptide ratios of all experiments analyzed were plotted against the number of prolines 
contained in the peptide sequence and color-coded according to the density. Indirect 
correlation of the peptide SILAC ratio shifts with the peptide proline content indicates 
conversion (Figure 3.13 C-F). The BCR stimulation time course of DG75 cells used for the global 
phosphoproteome and the pYome analysis showed no or at least only minor proline 
conversion (Figure 3.13 C and D; Results described in section 3.1.3). The BRAF interactome 
experiments in DG75 were slightly affected (Figure 3.13 E; Results described in section 3.1.9). 
In contrast to that, DG75 cells treated with a BRAF inhibitor used for the global 
phosphoproteome analysis were affected more severely by arginine-to-proline conversion 
(Figure 3.13 F; Results described in section 3.1.10). The medium-labeled cells appeared to be 
affected to a higher extent by conversion as can be deduced from the greater inverse 
correlation compared to the heavy-labeled cells (Figure 3.13 F, left and right panel, 
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respectively). However, the experiments were taken into account for data analysis but need 
to be considered more cautiously.  
 
 
Figure 3.13: Arginine-to-proline conversion 
(A) Parent ion spectrum of a doubly charged (z=2), tryptic peptide APQTSSSPPPVR derived from the protein SRRM1, harboring 
one phosphorylation site on the threonine or serine residues (general indicated as +p). The peptide is derived from BCR 
stimulated Daudi BL cells with triple SILAC labeling (R+0, R+6 and R+10; indicated in the MS spectrum) enriched for a global 
phosphoproteomic analysis. Medium (R+6) and heavy arginine (R+10) are converted in medium (P+5) and heavy proline (P+6), 
respectively. For simplicity reasons, only the peaks corresponding to up to three converted heavy prolines are highlighted in 
the MS spectrum (P+6, 2P+6 and 3P+6). The y-axis displays the relative intensity of the peaks, the x-axis the m/z values of the 
ions. (B) Parent ion spectrum of the doubly charged (z=2), tryptic peptide EKLYDFVK derived from the protein INPP5D. The 
peptide lacks proline and contains two labeled lysines (2x K+0, 2x K+4 and 2x K+8) due to a missed cleavage site and 
additionally, the tyrosine residue at position four is phosphorylated (indicated as p in the amino acid sequence). The sample 
is derived from the same experimental sample mentioned above. The peaks corresponding to the three SILAC states are 
highlighted in the MS spectrum. Axis legend can be found in (A). (C) – (I) Density plots of different experimental setups 
analyzed for arginine-to-proline conversion. The x-axis shows the number of prolines in the peptide sequence (P count), the 
y-axis the non-normalized peptide SILAC ratios while the dots are color-coded by density (see legend). (C) One of four 
biological replicates of a DG75 BCR stimulation time course with global phosphoproteome enrichment (D) One of two 
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biological replicates of a DG75 BCR stimulation time course with pYome enrichment (E) DG75 BRAF interactome analysis (F) 
Global phosphoproteome enriched DG75 cells after BRAF inhibition. 
 
3.1.13. Antigen-dependent BCR signaling in three distinct Burkitt’s lymphoma cell lines  
The antigen-dependent signaling dynamics in DG75 were additionally compared to two other 
Burkitt’s lymphoma cell lines on the pYome level: the EBV-positive, endemic Burkitt’s 
lymphoma cell line Daudi and a primary cell line (FFM_BL1 or BL1), derived from a patient 
suffering from BL. Further details about the mutational background for the cell lines are 
described in Table 9. Daudi cells were triplex SILAC labeled: light-labeled cells were left non-
stimulated, the BCRs of medium- and heavy-labeled cells were stimulated for 2 min and 10 
min, respectively. The patient derived Burkitt’s lymphoma cells could only be cultivated for a 
short time under cell culture conditions, therefore metabolic labeling was not amendable and 
cell numbers were sufficient for one biological replicate only. As alternative quantitation 
strategy, a label-free quantitation approach was chosen. BL1 cells were also stimulated for 2 
and 10 min via their BCRs, respectively. To make the different datasets more easily 
comparable, raw files from the DG75 and Daudi pYome SILAC experiments were jointly 
submitted to MaxQuant processing and the results matched to the independently processed 
label-free BL1 dataset as described in 2.2.5.3.  
577 p-sites could be quantified after antibody-based phosphotyrosine enrichment in DG75 
cells, in at least two time points of BCR stimulation (Figure 3.14 A). The Daudi pYome analysis 
lead to the quantitation of 304 p-sites and BL1 cells lead to the quantitation of 325 p-sites at 
both stimulation time points, respectively (Figure 3.14 A). 165 p-sites were found commonly 
in all three cell lines (Figure 3.14 A, supplementary table S9). As a first step, the 165 common 
p-sites were subjected to principal component analysis (PCA) to visualize differences between 
the different BL cell lines and time-dependent BCR stimulation (Figure 3.14 B). Component 2 
and 3 separated the EBV-positive Daudi cell from the other cell lines (Figure 3.14 B). The ‘early’ 
(including 2 and 5 min) and the ‘late’ time points (including 10 and 20 min) after BCR 
stimulation of both the sporadic BL cell lines DG75 and BL1 clustered together, rather than 
clustering according to the cell line (Figure 3.14 B). To extract accordingly upregulated p-sites 
in all three cell lines, p-sites with SILAC ratios greater than 1 on a log2 scale in at least one BCR 
stimulation time point were filtered (supplementary table S9). This lead unsurprisingly to the 
identification of 24 p-sites on 19 mostly upstream BCR signaling effectors such as CBL, CD19, 
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INPP5D, LAT2, MAPK1, MAPK3, NCK1, PIK3AP1, PLCG2, and SYK (supplementary table S9). 165 
common p-sites were further subjected to Z-scoring and hierarchical cluster analysis to 
highlight quantitative differences between p-sites in different cell lines (Figure 3.14 C). The 
population of p-sites fell into three distinguishable clusters of which the largest comprised of 
104 p-sites (light blue row tree, Figure 3.14 C). From this largest cluster a smaller sub-cluster 
was extracted that contained differential BL cell line-dependent p-sites (dark blue row tree, 
Figure 3.15 C). This cluster consisted of 65 p-sites derived from 51 effector proteins 




Figure 3.14: Antigen-dependent BCR signaling in three distinct BL cell lines 
(A) The Venn diagram shows the number of individual and commonly quantified p-sites (not proportionally) in three distinct 
Burkitt’s lymphoma cell lines, DG75, Daudi and FFM_BL1 (or BL1) after B-cell receptor stimulation derived from the respective 
pYome analyses (B) B-cell line and BCR engagement-dependent PCA analysis (C) Heat map of 165 common p-sites quantified 
in DG75 (in at least two of four time points), Daudi and FFM_BL1 primary cells. Normalized SILAC ratios (log2) were Z-scored 
and subjected to hierarchical cluster analysis. Z-scored p-site SILAC ratios (row) of all experimental conditions (column) are 
colored according to color scale at the bottom. The dataset was split in three distinct clusters and additionally, the most 
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differential sites were manually extracted. The extracted row tree, gene names, the position of the phosphorylated amino 
acid (in brackets) and the phosphorylation profile of the cluster are shown right to the heat map (D) PhosphoPath network 
analysis of the most differential sites (see C) (Raaijmakers et al., 2015). Proteins were subjected to protein-protein and 
additionally p-sites to kinase-substrate interaction analysis (according to BioGRID, STRING and PSP, respectively). Proteins 
are represented by a rounded rectangle, p-sites by ellipses. The quantitative SILAC ratio (log2) information across all time 
points and conditions is plotted below each p-site. Each rectangle represents a different cell line and time point. Quantitative 
values are color-coded (see legend), sites not quantified are coloured in white. Gene names and the position and amino acid 
of modification are indicated within the respective nodes. PPI interactions are represented by a line, kinase-substrate 
interactions by an arrow. PPI: Protein-protein interaction. P-site positions indicated in the figure dependent on the respective 
protein isoform and are listed together with all p-sites and quantitation values in supplementary table S9.  
Protein and quantitative p-site information was subjected to PPI and kinase-substrate 
interaction analysis via PhosphoPath (Figure 3.14 D) (Raaijmakers et al., 2015). Solely five 
effectors, could be integrated in a functional interaction network (INPP5D, G3BP1, LCK, CBL 
and SYK) whereas the majority of proteins were not annotated as interacting (Figure 3.14 C), 
INPP5D, LCK, CBL and SYK are well known effectors of BCR signaling (reviewed in Kurosaki et 
al., 2009, Rickert, 2013 and Young and Staudt, 2013). G3BP1 (Ras GTPase-activating protein-
binding protein 1) is a phosphorylation-dependent endoribonuclease not yet directly 
associated with BCR signaling (Tourrière et al., 2001). Two phosphorylation sites, G3BP1 Y56 
and Y125, localized within the nuclear transport factor 2 domain were commonly quantified 
in all cell lines. G3BP1 Y56 became phosphorylated after 2 and 5 min BCR stimulation in DG75 
cells (1- and 1.4-fold, respectively) whereas in Daudi no, and in BL1 only a slight regulation 
behavior (0.3-fold increase after 10 min of BCR stimulation) was detected (Figure 3.14 D; 
supplementary table S9). G3BP1 Y125 became phosphorylated in DG75 after 2 and 5 min of 
BCR engagement (1- and 1.3-fold, respectively) while in Daudi no regulation behavior could 
be observed. In BL1, the G3BP1 Y125 was detected as dephosphorylated after 2 and 10 min of 
BCR stimulation (0.6-fold and 3.1-fold decrease after 2 min and 10 min, respectively; Figure 
3.14 D). Interestingly, G3PB1 has been associated with MYC RNA cleavage thereby promoting 
its decay (Tourrière et al., 2001). In the following, a few p-sites of not interconnected proteins 
shown in Figure 3.14 D will be briefly discussed (Figure 3.14; supplementary table S9). ITSN2 
(Intersectin-2) is a multidomain (SH3, PH, C2, DH, EH, EF-hand) adapter protein, involved in 
clathrin-mediated endocytosis (Pucharcos et al., 2000). The phosphorylation site Y951 
(corresponding to Y968 in isoform 1) was upregulated in response to BCR stimulation in DG75 
(2.4- and 2.2-fold after 2 and 5 min, respectively) and in Daudi cells (1.1- and 1.2-fold after 2 
and 10 min, respectively) whereas no regulation of ITSN2 Y951 was detected in BL1 cells 
(Figure 3.14 D). The site lies in the linker region between two SH3 domains and was shown to 
be dependent on the activation of another receptor, namely the EGFR (Huang et al., 2007). 
Additionally, the site was identified in many large-scale analyses across different diseases 
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models and cell lines (according to UniProt and PSP database information) but was not further 
functionally characterized. Another p-site that showed substantial differences between the 
three model cell lines was CD37 Y206. CD37 (Leukocyte antigen CD37) is expressed on mature 
human B cells as well as on human B-cell leukemia and lymphoma (Norton and Isaacson, 1987; 
Smith et al., 1989). It belongs to the tetraspanin family of membrane proteins characterized 
by four transmembrane domains. The protein family is functionally associated with antigen 
presentation, T-cell and B-cell interaction and adhesion (Knobeloch et al., 2000; Schwartz-
Albiez et al., 1988; Tarrant et al., 2003). In DG75 cells, CD37 Y206 (in isoform 2, corresponding 
to Y274 in isoform 1) was constantly upregulated during the BCR stimulation time course 
(supplementary table S9). In contrast, CD37 Y206 was identified as downregulated in Daudi 
cells (0.7- and 0.8-fold, respectively) while in BL1 cells the p-site was not regulated 
(supplementary table S9). IKZF3 (Zinc finger protein Aiolos) is a transcription factor that 
regulates B-cell differentiation, proliferation and maturation (Wang et al., 1998). It regulates 
the expression of the anti-apoptotic factor Bcl2 and associates with anti-apoptotic Bcl-xL, 
thereby controlling apoptosis (Rebollo et al., 2001; Romero et al., 1999). Phosphorylation of 
IKZF3 Y286 is associated with nuclear localization whereas the functional association of the 
other phosphorylation sites is characterized (Antica et al., 2007). IKZF3 Y62 (corresponding to 
Y96 in isoform 1) became upregulated in DG75 after 2 and 5 min of BCR stimulation (2- and 
1.7-fold, respectively). In contrast, IKZF3 Y62 was dephosphorylated at both times points after 
BCR engagement in Daudi as well as in BL1 cells (1- and 0.6-fold in Daudi and 1.6- and 0.3-fold 
in BL1 at 2 and 10 min, respectively; supplementary table S9). 
 
3.1.14. Tonic BCR signaling 
Normal B cells as well as Burkitt’s lymphoma cells critically depend on expression of a 
functional B-cell receptor (Kraus et al., 2004). BCR engagement by anti-IgM antibodies mimics 
a stimulus similar to antigen binding. Antigen-dependent signaling was intensively analyzed in 
this work under various experimental conditions (section 3.1.1 to 3.1.11). However, Burkitt’s 
lymphoma survival and proliferation is thought to be mainly driven by tonic BCR signaling (Lam 
et al., 1997; Schmitz et al., 2012). In order to also investigate the much weaker signals derived 
from antigen-independent BCR signaling, two tonic signaling conditions were experimentally 
designed in DG75 as described in 2.2.1.3.2. First, cells were genetically modified with an 
inducible CD79A knockdown construct. CD79A is the signaling module of the BCR harbouring 
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an ITAM-motif with two phosphorylatable tyrosine residues (Reth, 1989). Former studies 
showed that the knockdown of the BCR signaling module decreases the expression of the 
whole BCR complex on the cell surface (Lam et al., 1997). Therefore, BCR signals are shut down 
and remaining signaling emanates from the multitude of all other cell surface receptors. 
Diminished surface BCR expression could be observed in DG75 after CD79A knockdown (data 
not shown). Second, SYK, a central tyrosine kinase in BCR signaling was pharmacologically 
halted with the small-molecule inhibitor PRT062607 (Spurgeon et al., 2012). Both 
experimental states were compared to the BCR stimulated (wild-type BCR expressing) cells on 
the pYome level. These approaches were sought to determine the signals derived from tonic 
BCR signaling. The analyses of tonic signaling were performed as a double SILAC experiment 
in DG75: in light-labeled cells, the BCR was knocked down via a CD79A-specific, tetracyclin-
inducible shRNA while heavy wild-type BCR expressing cells were left non-stimulated. In the 
second tonic signaling condition, SYK was inhibited in the heavy state while the light-labeled 
cells were left untreated. The decreased expression of surface BCR after the knockdown was 
verified by western blot analysis (data not shown). The diminished expression of CD79A after 
knockdown was validated by protein expression analysis while SYK expression did not change 
after inhibition (Figure 3.15 A). Antibody-based enrichment of phosphorylated tyrosine 
peptides identified 325 class I p-sites after BCR knockdown (BCR kd) and 489 class I p-sites 
after SYK inhibition (SYK-). 253 class I p-sites (239 pY p-sites) were commonly found in both 
conditions (Figure 3.15 B; supplementary table S10). Scatter plot analysis revealed hardly any 
correlation between the quantified p-sites upon BCR knockdown and SYK inhibition (Figure 
3.15 C). Overall, among the proteins with altered p-sites in at least one tonic signaling 
condition only a few belong to the class of standard BCR signaling proteins such as PLCG2, LYN, 
SYK, MAPK1/3 and CD79B (Figure 3.15 C). CD79B T195 (in isoform 1, corresponding to T91 in 
isoform 2; Figure 3.16 C; supplementary table S10) and CD79A Y210 (Figure 3.16 D; 
supplementary table S10) were found dephosphorylation after BCR knockdown. This finding 
can be attributed to a general low expression of the BCR complex after knockdown. During 
Syk inhibition CD79B T195 phosphorylation was not changed, whereas CD79A Y210 could not 
be identified (Figure 3.15 C). LYN Y194 which is located within the SH2 domain was found 
phosphorylation after CD79A ablation while no change could be detected after SYK inhibition. 
The activity determining MAP-kinase TXY motif was found to be dephosphorylated at Y178 (in 
MAPK1) and Y204 (in MAPK3) in both tonic signaling conditions, respectively. Furthermore, 
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the Src-target site PRKCD Y313 located in a hinge region and being associated with regulating 
serine-threonine kinase activity was found to be dephosphorylated in both tonic signaling 
models (Figure 3.15 C; supplementary table S10) (Hall et al., 2007).  
 
Figure 3.15: Antigen-independent and early antigen-dependent BCR signaling 
(A) Protein expression ratios for CD79A and SYK derived from the antibody-based pY enrichment during BCR engagement (2, 
5, 10 and 20 min) and antigen-independent (BCR kd and Syk-) conditions. (B) Venn diagram displaying the number of 
individual and commonly quantified tonic signaling p-sites with BCR knockdown and SYK inhibition, respectively. (C) Scatter 
plot comparing the commonly quantified p-sites in antigen-independent signaling. The x-axis shows the normalized L/H ratio 
(log2) of p-sites in the BCR knockdown experiment and the y-axis the normalized H/L ratio (log2) after pharmacological SYK 
inhibition. Outlier sites are marked in red and gene names are indicated. Sites specifically mentioned in the text are 
highlighted bold red and the phosphorylation position is indicated. (D) and (E) Scatter plot comparing commonly quantified 
p-sites immediately after antigen-mediated BCR stimulation (on the y-axis respectively) and in antigen-independent signaling 
(BCR kd in (D) and SYK inhibition in (E)). Outlier sites are marked in red and gene names are indicated. Sites specifically 
mentioned in the text are highlighted bold red and the position of phosphorylation is indicated. All sites identified and 
quantified in at least one experimental condition are listed in supplementary table S10. 
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To determine differences between tonic signaling conditions and early phosphorylation 
events in antigen-dependent signaling derived from the respective pYome analyses, the SILAC 
ratios after 2 min of BCR engagement were plotted against the ratios after BCR knockdown 
and SYK inhibition (Figure 3.15 D and E). Compared to BCR stimulation, the tonic signals are as 
expected much weaker as can be seen by maximum upregulation of 1.7 and 1.7 and minimum 
downregulation of -1.6 and -1.2 of class I p-sites during BCR knockdown and SYK inhibition, 
respectively (Figure 3.15 D and E; supplementary table S10). Common BCR signaling effectors 
identified such as SYK, MAP-kinases, CBL, HCK, SHC1, DAPP1 and INPP5D (SHIP1) were 
detected as differentially phosphorylated in antigen-dependent and -independent signaling, 
respectively (Figure 3.15 D and E). SYK Y323 and Y352, two auto-phosphorylation and activity 
regulating p-sites became phosphorylated after 2 min of BCR engagement as well as after 
CD79A knockdown (Y323: 4.5- and 0.6-fold, Y352: 4.4- and 0.4-fold; Figure 3.15 D; 
supplementary Table S10) (Deckert et al., 1998; Tsang et al., 2008). Another SYK p-site, Y296, 
was identified as phosphorylated after antigen stimulus but was not altered by the BCR 
knockdown (Figure 3.16 D; supplementary table S10). Y296 has been previously described in 
the context of BCR signaling, however, the functional role is not yet determined 
(Bohnenberger et al., 2011). MAPK13 Y182 (in isoform 2, corresponding to Y104 in isoform 1) 
within the activity determining TXY motif became dephosphorylated in both tonic signaling 
conditions (Figure 3.15 C and D, supplementary table S10) (Burack and Sturgill, 1997). DAPP1 
(BAM32) Y139 was identified to be dephosphorylated after BCR knockdown whereas the site 
became phosphorylated after 2 min of BCR engagement (Figure 3.15 D; supplementary table 
S10). DAPP1 is a B cell-specific protein that becomes recruited by its PH domain to the cell 
membrane after B cell engagement followed by phosphorylation of Y139 by PI3K, LYN, LCK or 
SRC (Allam et al., 2004; Anderson et al., 2000; Montalvo et al., 2000; Marshall et al., 2000). 
DAPP1 is of special interest as is has been functionally associated with cytoskeleton regulator 
remodelling after BCR stimulation (Allam et al., 2004; Anderson et al., 2000). Furthermore, it 
has been also linked to the activation of the MAP-kinase pathway (Allam et al., 2004). NOA1 
is a mitochondrial GTPase that became dephosphorylated at Y77 after 2 min of BCR 
stimulation whereas BCR knockdown lead to an increase in phosphorylation (Figure 3.15 D) 
(Kolanczyk et al., 2010). During SYK inhibition, the phosphorylation status of NOA1 Y77 did not 
change (Figure 3.15 D and E; supplementary table S10). SIT1 Y90 became phosphorylated after 
BCR knockdown (1-fold; Figure 3.15 D; supplementary table 10) but was not found to be 
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regulated after BCR stimulation. SIT1 is involved in negative regulation of TCR signaling and 
phosphorylation of Y90 is described to provide an interaction site for GRB2 (Marie-Cardine et 
al., 1999). CD84 Y279 was upregulated after BCR knockdown (0.7-fold) while the p-site was 
not regulated during the BCR stimulation time course and the p-site but could not be identified 
after SYK inhibition (Figure 3.15 D; supplementary table S10). CD84 is a receptor of the Ig-
superfamily, expressed on immune cells (Tangye et al., 2003; la Fuente et al., 1997). 
Phosphorylation of Y279 (in isoform 3, corresponding to Y296 in isoform 1) is associated with 
protein interaction by providing a SH2 domain binding site (Schweigel et al., 2013; Tangye et 
al., 2003). CD19 Y500 was identified as phosphorylated after early BCR stimulation as well 
slightly increased after SYK-mediated BCR signaling ablation (2.6- and 0.4-fold, respectively) 
while the site was not identified after BCR knockdown (Figure 3.15 E; supplementary table 
S10). CD19 is a BCR co-receptor that lowers the BCR activation threshold and is involved in 
BCR-dependent PI3K-signaling (Carter and Fearon, 1992; Otero et al., 2000). Phosphorylated 
CD19 Y500 is involved in the activity amplification of the Src kinase LYN (Fujimoto et al., 2000). 
During the process, phosphorylated Y500 provides an interaction platform for other LYN 
proteins that phosphorylates further tyrosine residues leading to LYN activation (Y500 
corresponds to Y482 in Fujimoto et al., 2000).  
The Glucose-6-phosphate 1-dehydrogenase (G6PD) is a metabolic enzyme that was found to 
be phosphorylated at position Y503 after 2 min of BCR stimulation and SYK inhibition whereas 
the site became dephosphorylated after BCR knockdown (1.4- and 1.7-fold increase and 0.6-
fold decrease, respectively; Figure 3.15 C and E, supplementary table S10). The p-site Y503 is 
in close proximity to the C-terminus of the enzyme and has been identified in many cell lines 
and disease models (listed in the PSP database) but is functionally not further described in the 
literature. GEMIN8 Y179 phosphorylation was found to be increased after BCR activation, 
whereas SYK inhibition leads to a decrease in phosphorylation (1.3-fold increase and 1.4-fold 
decrease, respectively; Figure 3.15 E; supplementary table S10). GEMIN8 is a catalytic protein 
in the SMN complex required for the assembly of snRNPs. No functional p-site information is 
available (Carissimi et al., 2006; Pellizzoni, 2007). The Abl interactor 1 (ABI1) phosphorylation 
on Y193 (corresponding to Y198 in isoform 1) was identified with a 1.9-fold increased after 
2 min of BCR stimulation and 0.8-fold decreased after SYK inhibition (Figure 3.15 E; 
supplementary table S10). ABI1 Y193 could only be identified after 2 and 5 min of BCR 
engagement, after SYK inhibition but not during CD79A knockdown. ABl1 is known to be 
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involved in cytoskeleton regulation, however, functional information about the p-site is not 
deposited in databases (supplementary table S10) (Leng et al., 2005; Stradal et al., 2001).  
To determine globally substantial differences between the time-resolved BCR stimulation and 
antigen-independent signaling in DG75 cells, the p-site SILAC ratios of the BCR stimulation 
time course were compared to both tonic signaling conditions on the pYome level. In total, 
203 class I p-sites (192 pY sites) were commonly quantified in the antigen-dependent time 
course (in at least two time points) and the antigen-independent conditions (Figure 3.15 A; 
supplementary table S10). Unsupervised hierarchical clustering was performed and the 
common p-sites could be separated in three main cluster profiles (Figure 3.15 A). From the 
largest cluster (red row tree), a subcluster (bracket) consisting of 41 p-sites (38 pY sites) 
derived from 31 effector proteins was extracted representing a set of highly differential p-
sites between the two experimental settings (heat map and cluster representation in Figure 
3.16; supplementary table S10). The cluster represents p-sites that became phosphorylated 
after BCR engagement and showed no changes or became dephosphorylated during tonic 
signaling (Figure 3.16 A). The effector proteins together with their p-sites were subjected to 
visualization with PhosphoPath to complement the dataset with protein-protein interaction, 
kinase-substrate and signaling pathway information (Figure 3.16 B) (Raaijmakers et al., 2015). 
Pathway enrichment analysis of the involved effector proteins included ‘B-cell receptor 
signaling pathway’ and ‘IL-3 signaling pathway’ as the most enriched signaling pathways 





Figure 3.16: Differential regulation in antigen-dependent and tonic BCR signaling 
(A) Heat map of 203 common p-sites quantified in the antigen-dependent time course (in at least two of four time points) 
and the antigen-independent experiments. Normalized SILAC ratios (log2) were Z-scored and subjected to hierarchical cluster 
analysis. Z-scored p-site SILAC ratios (row) of all experimental conditions (column) are colored according to the color scale at 
the bottom. The dataset was split in three distinct clusters and additionally, the most differential sites were manually 
extracted. The extracted row tree, gene names, the position of the phosphorylated amino acid (in brackets) and the profile 
of the cluster are shown right to the heat map. (B) The extracted, most differential sites (see A) were visualized by the 
Cytoscape App PhosphoPath (Raaijmakers et al., 2015). Proteins were subjected to protein-protein and additionally p-sites 
to kinase-substrate interaction analysis (according to BioGRID, STRING and PSP, respectively). Proteins are represented by a 
rounded rectangle, p-sites by ellipses. The quantitative SILAC ratio information across all time points and conditions is plotted 
below each p-site. Each rectangle represents a different condition and the color filling represents quantitative values 
according to the color code (see legend), sites not quantified are coloured in white. A dashed diamond node indicates mapped 
interactors from (BioGRID or STRING) that were not directly extracted from the set of common sites or identified from the 
analysis. Gene names, the position and amino acid of the modification are indicated within the respective nodes. PPI 
interactions are represented by a line, kinase-substrate interactions by an arrow. PPI: Protein-protein interaction. P-sites 
positions indicated in the figure dependent on the respective protein isoform listed in the supplementary table. All common 
and differentially regulated p-sites are listed in supplementary table S10. 
 
19 of the 31 effector proteins were involved in protein-protein and kinase-substrate 
interactions as mapped by BioGRID, STRING and PSP implemented in PhosphoPath (Figure 
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3.16 B) (Raaijmakers et al., 2015). The connected proteins are most commonly known as BCR 
signaling effectors such as CBL, BLK, SYK, INPP5D (SHIP1), PLCG2, LCK, MAPK1 and MAPK3. The 
network was further expanded with known interactors (CD79A/B, GRB2, BLNK, VAV1 and 
MYC) by PSP and BioGRID database mapping (indicated as dashed red diamond-shaped nodes) 
which were not extracted as regulated or not quantified in either of the conditions (Figure 
3.16 B). The most differential phosphorylated sites between the two groups of antigen-
activated and tonic signaling were PRKCD Y313, MAPK1 Y187, MAPK3 Y204, PLCG2 Y759, NCK 
Y105, DAPP1 Y139, TBCB Y96 and CALM2 Y138 of which several were described above (Figure 
3.16; Figure 3.16 C, D and E; supplementary table S10). In the following, further p-sites that 
appeared to be differentially regulated in antigen-dependent and -independent signaling will 
be described and set in a functional context. The SYK p-sites, S295 and the auto-
phosphorylation and activity-determining p-sites Y296, Y323, Y352 could be commonly 
quantified during BCR stimulation and tonic BCR signaling (Mócsai et al., 2010 refers to a six 
amino acids shorter form of Syk). Phosphorylation of the before mentioned sites increased 
during BCR stimulation whereas in tonic signaling conditions, phosphorylation stayed at 
similar levels or was decreased compared to the ground state, respectively (Figure 3.16 B). 
Phosphorylated SYK S295 could be quantified for the early time points of BCR stimulation (2 
and 5 min) while being absent at the late time points (10 and 20 min). In the tonic signaling 
conditions, pS295 levels were only slightly altered compared to the ground state (0.3-fold 
increase and 0.3-fold decrease during BCR knockdown and SYK inhibition, respectively; Figure 
3.16 B). Phosphorylation of S295 is mediated by CHK1 and primes SYK for degradation via the 
ubiquitin/proteasome pathway (Hong et al., 2012). The TXY motif in MAPK1 and MAPK3 
became heavily phosphorylated at both positions simultaneously after BCR engagement 
reflecting kinase activation but could not be quantified in tonic signaling (supplementary Table 
S2 and S10). However, MAPK1 Y178 and MAPK1 Y204 (in isoform 1) were quantified as 
dephosphorylated during tonic signaling and SYK inhibition (0.4- and 0.3-fold and 0.6- and 0.8-
fold decrease, respectively; Figure 3.16 B). ABL2 (Abelson tyrosine-protein kinase 2) became 
phosphorylated at position Y418 (in isoform 10, corresponding to ABL2 Y439 in isoform 1) 
during the whole time course of BCR stimulation. No phosphorylation change could be 
observed under BCR knockdown and only a slight decrease was quantified after SYK inhibition 
(Figure 3.16 B; supplementary table S10). ABL2 is a non-receptor tyrosine kinase involved in a 
multitude of biological processes and signaling pathways. ABL2 Y439 is located in the 
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activation loop and its phosphorylation is mediated by autocatalysis or by Src-type kinases 
such as HCK (Tanis et al., 2003). Furthermore, Y418 phosphorylation leads to ABL2 degradation 
(Cao et al., 2005). The CALM2 (Calmodulin) p-site Y138 was identified as phosphorylated after 
BCR engagement and was found to be dephosphorylated during BCR knockdown and SYK 
inhibition (0.2- and 0.3-fold decreased, respectively; Figure 3.16 B; supplementary table S10). 
The p-site is not further described or characterized but lies within the EF hand domain 
required for calcium binding. PIK3AP (BCAP) Y516 (in isoform 2, corresponding to Y694 in 
isoform 1) became phosphorylated after BCR engagement (3-fold after 2 min) and is not 
regulated after BCR knockdown and after SYK inhibition (supplementary table S10). PIK3AP1 
is an adapter protein connecting BCR signaling to PI3K-kinase signaling. The site is one of five 
conserved tyrosine residues and is a substrate of ABL (Maruoka et al., 2005). 
Overall, analysis of tonic BCR signaling has not been performed in a global manner. The 
analysis revealed many interesting p-sites of which only a few were mentioned in this work. 
The provided dataset presents a basis for further functional characterization of 




 Acute myeloid leukemia 
The phosphoproteomic analysis of Burkitt’s lymphoma under various experimental conditions 
described in chapter 3.1 provides insights into intracellular signaling mechanisms mediated by 
phosphorylation. Especially antibody-based phosphotyrosine enrichment in different 
experimental conditions proofed to be a valuable methodology to study signaling. Therefore 
the comprehensive phosphoproteomic approach used for the analysis of Burkitt’s lymphoma 
was applied to another hematological disorder, namely acute myeloid leukemia (AML). AML 
is derived from malignant transformed hematopoietic cells. Cells are highly undifferentiated 
and show a variety of mutational backgrounds in patients that lead to different therapeutic 
outcomes (The Cancer Genome Atlas Research Network, 2013) . This makes the identification 
of common targets and the application of generalized therapeutic strategies difficult. In 
previous studies, the tyrosine kinases SYK and BTK were found to be constitutively activated 
in AML and therefore were considered as potential drug targets (Hahn et al., 2009; Rushworth 
et al., 2013; Zaitseva et al., 2014). Both kinases are throughout described in the context of BCR 
signaling and BTK inhibition is already a standard therapeutic treatment in chronic lymphatic 
leukemia (Ponader et al., 2011; de Rooij et al., 2012). It could be shown that the 
pharmacological inhibition of SYK in AML cells results in either apoptosis or differentiation into 
myeloid effector cells (Hahn et al., 2009). The SYK activation mechanism, how it drives 
oncogenic AML blast proliferation, the identification of SYK-dependent phosphorylation sites 
and the analysis of SYK interaction partners was already studied by Oellerich et al., 2013. 
Furthermore was BTK inhibition in AML cells reported to reduce AML blast proliferation and 
to increase the cytotoxic effects of standard chemotherapeutics (Rushworth et al., 2013). 
However, the underlying mechanisms i.e. the identity of the upstream regulators, the 
downstream signaling partners and pathways involved are not known to date. Point mutations 
in the tyrosine kinase and an internal tandem duplicaton (ITD) in the juxtamembrane domain 
in the FMS-like tyrosine kinase 3 (FLT3) are one of the most common mutational events in 
AML (Nakao et al., 1996; The Cancer Genome Atlas Research Network, 2013). Therefore, the 
role of BTK signaling in the context of different mutational backgrounds was investigated. The 
cell lines MV4-11 with a FLT3-ITD-positive and KG1 with a FLT3-ITD-negative background were 
representatively chosen for the comparative study. The generalized BTK expression and the 
BTK activation status, represented by the phosphorylation of the activating tyrosine residue 
at position Y223, were verified in MV4-11 and KG1 by Oellerich et al., 2015. BTK interactors in 
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MV4-11 and KG1 were identified by knockdown experiments in combination with SILAC-based 
quantitative mass spectrometry approaches as described in Oellerich et al., 2015. Based on 
the assumption that BTK activation in FLT3-ITD-positive AML cells is dependent on FLT3-ITD 
activity, BTK was found in the FLT3 signalosome of MV4-11 (Oellerich et al., 2015). The BTK 
signalosome in KG1 identified the CpG oligonucleotide recognizing Toll-like receptor 9 (TLR9) 
as interaction partner (Oellerich et al., 2015). According to previous studies, an interaction 
between TLRs and BTK is already described in B cells and macrophages (Kubo et al., 2009; 
Vijayan and Baumgart, 2011). The interaction of BTK and TLR9 and of FLT3-ITD and BTK in KG1 
and MV4-11 was further validated as described in Oellerich et al., 2015.  
 
3.2.1. BTK-dependent phosphoproteome networks in AML 
BTK was found expressed, active and moreover involved in the signalosomes as described 
above in KG1 and MV4-11 AML cell lines (Oellerich et al., 2015). The aim of the following 
experiments was to find out whether BTK inhibition with ibrutinib is also a suitable treatment 
strategy in AML and furthermore to describe the effects and mechanism of its signal inhibition 
properties. Ibrutinib is an irreversible BTK inhibitor already established in the treatment of 
other B lymphoid malignancies such as chronic lymphatic leukemia or mantle-cell lymphoma 
(Byrd et al., 2014; Wang et al., 2013). The application effects of ibrutinib in KG1 and MV4-11 
were investigated on the phosphoproteomic and protein expression level. To gain insights into 
signaling events downstream of BTK, heavy SILAC labeled cells treated with ibrutinib were 
compared to untreated light-labeled cells (Figure 3.17 A). A dual quantitative 
phosphoproteomic analyses was performed consisting first of antibody-based phosphorylated 
tyrosine enrichment (pYome) and second of SCX in combination with TiO2 affinity purification 
(global phosphoproteome) followed by LC-MS/MS measurement. After antibody-based 
phosphotyrosine enrichment in KG1, 875 class I p-sites (726 tyrosine sites) and in MV4-11, 571 
class I p-sites (476 tyrosine sites) could be quantified, respectively. 316 p-sites were commonly 
identified in both cell lines (Figure 3.17 B; supplementary table S11). 233 p-sites of those 
common sites showed a SILAC ratio difference ≤ |0.5| indicating concordant behaviour 
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(regulated as well as non-regulated) and 83 common sites had a SILAC ratio difference ≥ |0.5| 
(regulated and non-regulated; Figure 3.17 C).  
 
Figure 3.17: Phosphorylated tyrosine dynamics after BTK inhibition 
(A) Experimental design of the SILAC-based BTK inhibition pYome analysis. Heavy-labeled cells were treated for one hour with 
ibrutinib, light-labeled cells were treated with DMSO as a control. Cells were lysed, proteins were mixed at a 1:1 ratio, run on 
a SDS-PAGE gel and digested with trypsin. Peptides were immunopurified for phosphorylated tyrosine residues followed by 
mass spectrometric analysis (B) Venn diagram displaying the number of exclusively and commonly quantified class I p-sites 
for KG1 and MV4-11 cells, respectively. (C) The pie chart shows the relative abundance of p-sites with a SILAC ratio differences 
smaller or greater than |0.5| of commonly quantified p-sites. (D) The Venn diagram shows the number of exclusively and 
commonly regulated p-sites (primarily pY sites) after 1 h of ibrutinib treatment for KG1 and MV4-11, respectively. The 
regulation interval was set outside to ]-1;0.5[. (E) The bar diagram shows the normalized SILAC ratios H/L (log2) of the 
regulated p-sites found in both, KG1 and MV4-11 cells. (F) and (G) Signaling networks contain proteins that were identified 
as being phosphorylated (red P) or dephosphorylated (green P) on serine, threonine or tyrosine residues in response to BTK 
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inhibition. Proteins were grouped according to their known protein-protein interaction status listed in the STRING database. 
The assigned protein functions were derived by manual annotation using UniProt, PhosphoSitePlus and PubMed databases 
and are visualized by color coding (see legend). The nodes of STAT5A, STAT3, CBL, and MAPK1/3 are highlighted by color fill. 
(H) Normalized SILAC ratios of the regulated phosphotyrosines sites STAT5A Y694, STAT3 Y705, CBL Y674 in KG1 and STAT5A 
Y694, MAPK1 T185/Y187, MAPK3 T202/Y204 in MV4-11 cells. The color coding of the bars refers to the functional groups of 
the proteins highlighted (filled nodes) in (F) and (G). (I) Cleared cellular lysates, derived from KG1 and MV4-11 cells that had 
either been left untreated or been treated with 500 nM ibrutinib for one hour were subjected to immunoblotting using 
antibodies against phosphorylated STAT5, ERK, STAT3, FOXO1 and c-CBL, respectively. Cell culture of KG1 and MV4-11, 
ibrutinib treatment as shown in (A), and western blot analysis shown in (I) was performed at the Department of Internal 
Medicine, Hematology/Oncology at the University Hospital Frankfurt/Main as part of the collaboration mentioned in Table 
12. The figure is adapted from Oellerich et al., 2015. All identified and regulated p-sites for KG1 and MV4-11 cell lines are 
listed in supplementary table S11. 
 
In KG1, 58 p-sites and in MV4-11 78 p-sites were found regulated (Figure 3.17 D; 
supplementary table S11). Eleven tyrosine p-sites derived from distinct proteins were found 
regulated in both cell lines (Figure 3.17 D). Those common, regulated sites showed overall 
concordant regulation behaviour: nine p-sites were dephosphorylated while ACACA Y1370 
and PAG1 Y387 were phosphorylated after BTK inhibition (Figure 3.17 E). The BTK SH2 domain 
p-site Y344 was among those sites found to be dephosphorylated after ibrutinib treatment. 
According to database information, no functional process, upstream kinase or regulatory 
behavior could be associated yet with this site (according to PSP and UniProt). To examine in 
detail how the identified BTK effector proteins are integrated into signalosomes and signaling 
cascades, protein network analyses (Figure 3.17 F and G) were generated based on the 
differentially phosphorylated proteins (Figure 3.17 D). The identified BTK effectors proteins 
fall into a multitude of functional protein classes, including cell cycle and metabolism 
regulators. Among the regulated effectors, STAT5A/B, CBL and MAPK1/3 were previously 
described in the context of AML cell survival and proliferation (Hayakawa et al., 2000; Sargin 
et al., 2007). The p-sites on the mentioned proteins, STAT5A Y694, STAT3 Y705, CBL Y674 in 
KG1 and STAT5A Y694, MAPK1 T185/Y187, MAPK3 T202/Y204 in MV4-11 cells were 
dephosphorylated after ibrutinib treatment (Figure 3.17 F, G and H). STAT5A Y694 and CBL 
Y674 are putative targets of BTK (according to NetworKIN; data not shown). The MS-based 
phosphorylation status of the before mentioned proteins after ibrutinib treatment was 
additionally verified by immunoblotting (Figure 3.17 I).  
For the determination of changes in the global phosphoproteome after BTK inhibition i.e. 
mainly phosphorylation changes on serine and threonine residues, the same experimental 
setup as described above for the pYome was applied (Figure 3.17 A). In KG1 cells 2891 class I 
p-sites and in MV4-11 cells 2011 class I p-sites could be quantified of which 186 and 139 p-
sites where considered to be regulated, respectively (highlighted red, Figure 3.18 A and B; 
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supplementary table S12). To determine biological meaningful p-sites, the ones with SILAC 
ratios ˂ -0.5 or ˃ 0.5 in KG1 and MV4-11 were selected, respectively. This resulted in 42 p-sites 
for KG1 and 26 p-sites for MV4-11 (highlighted data points represent individual p-sites, gene 
names are indicated; Figure 3.18 A and B).  
 
Figure 3.18: Global phosphoproteomic analysis after BTK inhibition in AML 
(A) and (B) Scatter plots of the distribution of normalized p-site H/L SILAC ratios (x-axis) versus their intensity (y-axis) after 
one hour of BTK inhibition with ibrutinib in KG1 (A) or MV4-11 (B). P-sites with H/L SILAC ratios outside the range ]-0.5;0.5[ 
were considered to be regulated and are highlighted in red. For the most prominent outlier p-sites (for KG1 < -1.2 or > 1; for 
MV4-11 < -1 or > 1) the gene names are indicated additionally. Cell lines were cultured and treated at the Department of 
Internal Medicine, Hematology/Oncology at the University Hospital Frankfurt/Main as part of the collaboration mentioned 
in Table 12. Regulated p-sites derived from the global phosphoproteomic analysis of KG1 and MV4-11 cells are listed in 
supplementary table S12. 
 
To not only highlight individual differences between the two cell lines, the quantified p-sites 
were compared to each other. 1399 p-sites were quantified in both cell lines (data not shown) 
of which 19 common p-sites on 16 effector proteins were regulated in both cell lines (Figure 
3.19). Both, the SHC-transforming protein 1 (SHC1) Y317 (in isoform 2; corresponding to Y427 
in isoform 1) and the tumour protein TPD52 (D52) S136 (in isoform 2; corresponding to S176 
in isoform 1) were quantified as dephosphorylated after BTK inhibition. The former site 
provides a binding site for GRB2 and is described in the context of a multitude of cellular 
processes such as cell differentiation, cytoskeleton, apoptosis, and different diseased tissues 
(Patrussi et al., 2005). TPD52 S136 phosphorylation is associated with plasma membrane 





Figure 3.19: Common regulated sites in KG1 and MV4-11 
Bar diagram showing the normalized H/L SILAC ratios for the 19 common regulated p-sites derived from the global 
phosphoproteome. Quantitation ratios of common p-sites shown above are listed in supplementary table S12. 
 
3.2.2. BTK-dependent protein expression levels 
Changes on the protein expression levels are expected to require a longer time compared to 
changes on the PTM level like phosphorylation. Therefore the time scale for the protein 
expression analysis was performed at a wider range with 6 h and 24 h of ibrutinib treatment 
for heavy-labeled KG1 and MV4-11 cells, respectively. These were compared to their light-
labeled, untreated counterparts (Figure 3.20 A). FLT3 and TLR9 were associated with 
malignant BTK activation and CBL, STAT5A/B and MAPK1/3 were previously described as 
differentially phosphorylated in the pYome analysis in section 3.2.1 and therefore presumably 
play a role in AML signaling. Protein expression changes of BTK, FLT3 and further interesting 
candidates like CBL, STAT5A/B and MAPK1/3 were extracted from the proteomic dataset and 
are shown in Figure 3.20 B (supplementary table S12). TLR9 was identified as putative BTK 
activator in the FLT3-ITD-negative cell line KG1 but could not be quantified on the proteomic 
level after BTK inhibition in KG1 and MV4-11, respectively. BTK could be quantified in the two 
cell models for both ibrutinib treatment durations (Figure 3.20 B; supplementary table S12). 
BTK levels were slightly elevated (normalized SILAC ratio of 0.64) in KG1 after 24 h of BTK 
inhibition whereas only small changes could be monitored in MV4-11 (Figure 3.20 B; 
supplementary table S12). The mutated and therefore constitutive active receptor tyrosine 
kinase FLT3 was quantified in MV4-11 with slightly increased expression levels after 6 h of 
ibrutinib treatment (0.48-fold) and was 1-fold increased on a log2 scale after 24 h (Figure 3.20 
B). The protein expression of the phosphorylation regulated E3-ubiquitin-ligase CBL was not 
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changed in both cell lines (Figure 3.20 B; supplementary table S12). The transcription factor 
STAT5B was upregulated after 24 h of ibrutinib treatment in KG1 and MV4-11 cells whereas 
STAT5A was only upregulated after 24 h in KG1 but not in MV4-11 (Figure 3.20 B; 
supplementary table S12). MAPK1 and 3 could only be quantified in MV4-11 and did not show 
regulation behaviour (Figure 3.20 B).  
 
 
Figure 3.20: Protein expression changes after BTK inhibition in AML 
(A) Experimental design of the SILAC-based protein expression analysis in KG1 and MV4-11 cells after BTK inhibition. Heavy-
labeled cells were treated for 6 h or 24 h with ibrutinib, light-labeled cells were treated with DMSO as a control. Proteins 
were analyzed by mass spectrometry after in-gel digestion. (B) Bar diagrams displaying the normalized SILAC ratios H/L (log2) 
for selected proteins identified as relevant from the phosphotyrosine analysis (BTK, FLT3, MAPK1/3, STAT5A/B) for KG1 
and/or MV4-11 after 6 h and 24 h of ibrutinib treatment. Cell lines were cultured and treated as shown in (A) at the 
Department of Internal Medicine, Hematology/Oncology at the University Hospital Frankfurt/Main as part of the 





 Phosphorylation dynamics in TCR signaling adapters 
The antigen recognition process of the TCR leads to complex downstream signaling cascades 
which are as antigen-dependent signal initiation in B cells mainly mediated by reversible 
phosphorylation of kinases and adapter proteins such as SLP76 (LCP2), GADS (GRAP2), GRB2, 
LAT, ZAP70, LCK and many others. TCR signaling responses depend on a heterotrimeric 
complex consisting of three adapter proteins: SLP76, GADS and LAT (Chakraborty and Weiss, 
2014; Kambayashi et al., 2009; Koretzky et al., 2006; Lugassy et al., 2015). Large-scale MS-
based p-sites analyses in TCR signaling have been previously performed, however, 
phosphorylation of the adapter proteins SLP76 and GADS were not covered in these datasets 
(Cao et al., 2012; Nguyen et al., 2009). The phosphorylation changes of SLP76 and GADS 
signaling adapters were studied in the SLP76-deficient Jurkat derivative cell line J14  
reconstituted with a STREP-tagged SLP76 (Yablonski et al., 1998a). The Jurkat T-cell line is an 
established model to study TCR signaling with a long history of major scientific breakthroughs 
made in the field of signaling e.g. the detection of intracellular Ca2+ flux, tyrosine 
phosphorylation after TCR stimulation and the role of ITAM motifs in signal transmission 
(Abraham and Weiss, 2004). For the comparison of the ground to the TCR stimulated state, 
cells were duplex SILAC labeled: the TCRs of the heavy-labeled cells were stimulated for 1, 2, 
5 and 10 min respectively whereas the light-labeled cells remained in the non-stimulated 
state. Cell lysates from equal cell numbers of light- and heavy-labeled cells were mixed and 
the STREP-tagged SLP76 was affinity purified. Proteins were separated on a SDS-PAGE gel, 
SLP76 and GADS were excised from the gel and digested with three endoproteinases, 
respectively in order to increase protein sequence coverage as described previously in section 
2.2.2.2.3. Phosphopeptides were enriched with TiO2 affinity purification from the in-gel 
digests prior to LC-MS/MS analysis (Figure 3.21 A). 
3.3.1. SLP76/LCP2 phosphorylation site dynamics 
SLP76 is expressed in all cells derived from the hematopoietic lineage except for B cells where 
a similar protein, SLP65 (or BLNK) is expressed (Fu et al., 1998; Wienands et al., 1998). SLP76 
contains an N-terminal acidic region with a SAM domain, a central proline-rich domain which 
mediates interaction with GADS and a C-terminal SH2 domain (Myung et al., 2001). For SLP76, 
33 non-redundant class I p-sites could be identified (25 pS, 4 pT and 4 pY) within this study. 30 
p-sites (22 pS, 4 pT and 4 pY) could be quantified in the singly and multiply phosphorylated 
state in at least one biological replicate and one stimulation time point, respectively (data not 
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shown). In order to deduce differences in phosphorylation behaviour, p-sites were required 
to be quantified in at least three of four biological replicates quantified over the whole time 
course were considered for further analysis. This resulted in 11 p-sites (9 pS, 1 pT, 1 pY) which 
fall in separate categories: ‘steady-state’, ‘late’ and ‘early’ inducible (Figure 3.21 B). In general, 
SLP76 phosphorylation sites are functionally not well studied. The analysis presented here 
provides a reference point for further functional studies. However, sites that have been 
functionally studied and described will be discussed and set in context to the phosphorylation 
dynamics identified in this experimental work.  
 
 
Figure 3.21: Phosphorylation dynamics in the TCR signaling mediators SLP76 and GADS 
(A) Schematic representation of a double SILAC approach with the SLP76-deficient J14 Jurkat derivative cell line to determine 
phosphorylation regulation of SLP76 and Gads p-sites after TCR stimulation. Cells were doubly SILAC labeled with three amino 
acids: Lys+0, Arg+0, Tyr+0 for the light and Lys+8, Arg+10, Tyr+10 in the heavy state. Light- and heavy-labeled cells were 
reconstituted with a twin-STREP-tagged SLP76 (green attachment on SLP76). The TCRs of the heavy-labeled cells were 
stimulated for 1, 2, 5 and 10 min respectively with a TCR β-chain-specific monoclonal antibody C305 (indicated as red 
antibody) while the light-labeled cells remained in the non-stimulated state. Light and heavy cell lysates were mixed at a 1:1 
ratio, twin-STREP-tagged SLP76 was affinity purified with streptactin and separated on a SDS-PAGE gel. Gel bands 
corresponding to SLP76 and GADS were excised from the gel and were digested with the endoproteinases, trypsin, 
chymotrypsin and AspN, respectively. Resulting peptides were enriched for phosphorylation with TiO2 solid phase extraction 
and analysed by LC-MSMS. The experiments were performed in four independent biological replicates. (B) and (C) The line 
diagrams display the normalized SILAC ratios of individual class I p-sites on a log2 scale during the time course of TCR 
stimulation (1, 2, 5 and 10 min) for SLP76 (B) and GADS (C). P-sites were identified in at least three of the four biological 
replicates across the time course. P-site are separated according to their distinct phosphorylation behavior, ‘steady-state’ 
(upper panel), ‘late’ (middle panel) and ‘early’ (only for SLP76, lower panel). Jurkat cell culture, TCR stimulation and affinity 
purification as shown in (A) were performed at the Immune Cell Signaling Lab at the Rappaport Faculty of Medicine, Technion, 
Israel Institute of Technology in Haifa, Israel as part of the collaboration mentioned in Table 12. All sites shown in (B) are 




All SLP76 p-sites quantified according to the above mentioned conditions are located between 
the N-terminal SAM and the C-terminal SH2 domain. SLP76 S376 was identified as a ‘late’ 
phosphorylation site and is known to be associated with SLP76 ubiquitination followed by its 
degradation (Figure 3.21 B, middle panel, red line) (Wang et al., 2012). Therefore, SLP76 S376 
‘late’ phosphorylation could be a part of a negative feedback loop leading to signal 
determination by adapter protein degradation. As putative upstream kinase MAP4K HPK1 was 
identified (Di Bartolo et al., 2007; Wang et al., 2012). The two p-sites SLP76 S338 and T341 
showed the same phosphorylation behavior as S376 but have not been functionally 
associated. The phosphotyrosine site SLP76 Y173 was of particular interest as it was 
functionally studied in earlier collaboration experiments with the group of Debbie Yablonski 
(Sela et al., 2011). The p-site Y173 showed an ‘early’ increase in phosphorylation already after 
1 min of TCR stimulation which slightly decreased until 10 min but maintained at an overall 
high level (Figure 3.21 B, lower panel, red line). In the previous study, a Tec family kinase was 
identified as the SLP76 Y173 modifying kinase. Furthermore, phosphorylated Y173 was 
identified to be a prerequisite for the phosphorylation-induced activation of the 
phospholipase C-ɣ1 (PLC-ɣ1) (Sela et al., 2011). The recruitment of the Tec family kinase to 
SLP76 depends on three ZAP70-targeted tyrosines at the N-terminus of SLP76 which were not 
identified in the analysis presented here. Recently, SLP76 Y173 became of particular interest 
as the activation mechanism was revealed by Devkota et al., 2015. Phosphorylated Y173 
provides a binding site for the C-terminal SH2 domain of PLC-ɣ1C. After binding, PLC-ɣ1C gets 
phosphorylated by the SLP76-associated Tec family kinase at Y738 and therefore becomes 
enzymatically active (Devkota et al., 2015).  
 
3.3.2. GADS/GRAP2 phosphorylation site dynamics 
GADS (also known as GRAP2 or p38) belongs to the Grb2 family of adaptor proteins. It 
possesses an N- and C-terminal SH3 and a central SH2 domain and resides in the cytoplasm. 
The C-terminal SH3 domain binds constitutively to the cytoplasmic adaptor SLP76 and 
becomes therefore co-purified with SLP76. 14 p-sites (10 pS, 2 pT and 2 pY) on GADS were 
identified as class I p-sites presented in this work from which 13 sites were identified in at 
least one biological replicate in at least one time point of stimulation (data not shown). Five 
p-sites were quantified in at least three of four biological replicates with a complete 
phosphorylation profile (Figure 3.21 C). The five sites (4 pS, 1 pT) could be divided in two 
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distinct categories: ‘steady-state’ and ‘late’ inducible, missing the ‘early’ inducible which can 
be seen for SLP76 (Figure 3.21 C, upper and middle panel). GADS S41, S87 and S88 showed no 
major regulation behavior after TCR stimulation and were classified as ‘steady-state’ p-sites 
(Figure 3.21 C, upper panel). S41 lies in the N-terminal SH3 domain, whereas S87 and S88 are 
positioned in the central SH2 domain. GADS S159 and T262 showed a ‘late’ regulation 
behavior (Figure 3.21 C, middle panel). Both p-sites lie within the linker region between the 
SH2 and the C-terminal SH3 domain. T262 is proposed to be a phosphorylation site involved 
in tonic TCR signaling with a slight phosphorylation response after TCR stimulation (Figure 3.21 
C, middle panel, red line) (Lugassy et al., 2015). The orthologous murine p-site to human T262 
(mouse: T254) is proposed to be a negative regulatory p-site that may promote the 
detachment of GADS from the LAT-nucleated signaling complex (Lasserre et al., 2011). 





The presented work focused on the global investigation of phosphorylation sites in diverse 
experimental conditions by mass spectrometry-based phosphoproteomics. As the main focus 
was set on Burkitt’s lymphoma, the results of this main project will be discussed in the first 
part in terms of comparability to other large-scale PTM studies, sample preparation including 
PTM enrichment, LC-MS/MS instrumentation, and the integration of other large-scale 
datasets with phosphoproteomic data. In the second part, the biological impact of this work 
will be discussed such as the BCR signaling signature in different Burkitt’s lymphoma 
genotypes. Additionally, the tonic signaling models and single proteins that appeared to be 
interesting candidates for further investigations or might present drug targets will be 
highlighted.  
 Mass spectrometry-based large-scale studies 
Mass spectrometry is a suitable tool for the hypothesis-free, large-scale analysis of proteins 
and PTMs. The up to now most comprehensive human proteome draft was presented in 2014 
by the groups of Akhilesh Pandey and Bernhard Küster, providing evidence for more than 80% 
of the human protein-coding genes on the protein level by mass spectrometry (Kim et al., 
2014; Wilhelm et al., 2014). However, merely the identification, relative quantitation or even 
the copy number of proteins does not necessarily provide evidence about their activity, 
interaction capabilities or subcellular localization in a given cellular context (reviewed in 
Larsen et al., 2006). Therefore, one ultimate aim of understanding the diversification of 
cellular behavior is the identification, quantitation, and functional characterization of all PTMs 
in a certain state of a cell at a given time point.  
4.1.1. Phosphorylation in cell signaling 
The rise of large-scale, mass spectrometry-based PTM studies began with the identification of 
a few hundred phosphorylation sites (Ficarro et al., 2002). Numbers have ever since increased: 
In 2004, a HeLa nuclear phosphoproteome consisting of 2,002 p-sites was published 
(Beausoleil et al., 2004). In 2006, 6,600 phosphorylation sites were identified in HeLa cells after 
EGF stimulation (Olsen et al., 2006). In 2009, a study was published that identified 10,844 p-
sites in human embryonic stem cells (Swaney et al., 2009). In 2010, 20,443 p-sites were 
Discussion 
116 
identified during cell cycle progression in HeLa cells (Olsen et al., 2010). The largest number 
of identified p-sites to date was published in 2014, when more than 38,000 class I p-sites were 
identified in EGF stimulated HeLa cells (Sharma et al., 2014). The workflow for phosphopeptide 
enrichment in this study consisted of FASP-based proteolysis, SCX peptide fractionation, and 
TiO2 affinity purification for global phosphoproteomic analysis. Specific enrichment of 
phosphotyrosine residues was done with antibodies directed against phosphotyrosine 
residues (Sharma et al., 2014). Samples were measured on a hybrid quadrupole-Orbitrap mass 
spectrometer and quantified by XIC-based label-free quantitation (Sharma et al., 2014).  
Within this study presented here, approximately 4,700 p-sites were identified after BCR 
stimulation in DG75 cells (supplementary tables S2 and S3). Triplex SILAC labeling hinders 
sequencing depth due to increased complexity on the MS1 level. This can be circumvented by 
using label-free quantitation as demonstrated by Sharma et al., 2014. Furthermore, the use of 
faster, more sensitive MS instruments contributes to higher identification rates. The large 
number of p-sites shown by Sharma et al., 2014 are impressive, however, cells were treated 
with pervanadate, a tyrosine phosphatase inhibitor, which leads to accumulation of p-sites 
and does not necessarily reflect the physiological cellular state (Sharma et al., 2014; Zhao et 
al., 1996).  
4.1.2. Acetylation and ubiquitination in cell signaling 
The development of modification-specific antibodies against acetylated and di-glycine 
modified lysine residues made large-scale MS-based acetylation and ubiquitination studies 
feasible (Choudhary et al., 2009; Kim et al., 2006; Xu et al., 2010). One of the first global lysine 
acetylation studies identified 3,600 acetyl-lysine sites (Choudhary et al., 2009). A large-scale 
ubiquitination study lead to the identification of 11,054 di-glycine modified lysine residues in 
HEK293T and MV4-11 cells (Wagner et al., 2011). The characterization of acetylation and 
ubiquitination in BCR signaling in Burkitt’s lymphoma shown in this work (section 3.1.11) did 
not reach the analysis depth of the studies mentioned above. The analyses in this work should 
rather be considered as preliminary feasibility study. Further analyses require sample 
preparation refinements such as the titration of sample to antibody ratio, the use of 
proteasome, DUB and KDAC inhibitors in the lysis buffers, respectively. Furthermore, the 
alkylating agent needs to be replaced by chloroacetamide in the ubiquitination study as IAA 
was reported to mimic the di-glycine adduct resulting from protein hydrolysis with trypsin 
(Nielsen et al., 2008). In general, results obtained from the ubiquitination study are difficult to 
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put into a biological context as after proteolytic digest with trypsin, mono- and the differently 
linked poly-ubiquitination chains cannot be distinguished anymore. Therefore it is not possible 
to differentiate between ubiquitination-mediated signaling and tagging for degradation.  
4.1.3. Large-scale B-cell receptor signaling studies  
T-cell signaling has been extensively studied in low- and high-throughput studies in the past 
whereas B cells remained underrepresented. Early mass spectrometric studies investigating 
phosphorylation-mediated B-cell signaling in DT40 (chicken) were low-throughput studies 
based on single proteins such as SLP65, SYK and GRB2 (Bohnenberger et al., 2011; Neumann 
et al., 2009; Oellerich et al., 2011; 2009). As the next step to understand B-cell signaling, a 
global analysis of phosphorylation-mediated signaling processes in human B cells was 
performed. The investigation of antigen-dependent and -independent signaling in Burkitt’s 
lymphoma derived B cells on the phosphoproteomic level presented within this work is 
conceptually novel. However, the investigation focus of other groups has recently moved to B 
cells and large-scale, MS-based phosphoproteomic signaling studies of activated antigen-
dependent BCR signaling in different B-cell types with similar methodology (Rolland et al., 
2014; Satpathy et al., 2015; Tsai et al., 2014). Some of the studies will be discussed in terms of 
number of identified p-sites, methodology and interesting proteins with regulated p-sites. 
None of the previously mentioned studies were performed on DG75 cells, however two 
phosphoproteomic studies based on DG75 emphasizing methodical aspects of 
phosphopeptide enrichment rather than giving biological insights will not be discussed in the 
following (Iliuk et al., 2010; Pan et al., 2015).  
Rolland et al., 2014 investigated differences in the global phosphoproteomes in Burkitt’s 
lymphoma, follicular lymphoma (both germinal center and antigen-experienced cells) and 
mantle cell lymphoma (naïve B cells) cell lines. The BCRs of the cells were not stimulated, 
reflecting the general tonic signaling state that might be affected by growth factors in the 
culture medium and is thus not considered as being representative for tonic BCR signaling 
(Rolland et al., 2014). Differentiation of the different lymphoma subtypes was achieved by 
spectral counting. TiO2 and antibody-based phosphotyrosine enrichment lead to the 
identification of 6,579 p-sites (Rolland et al., 2014). Rolland et al., 2014 found the involvement 
of proximal BCR signaling proteins as a hallmark of BL and follicular lymphoma compared to 
naïve B cells. This is also reflected in the study presented here as many regulated effector 
proteins in any condition are known B-cell effectors (Figure 3.6; section 3.1.13; and 
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supplementary table S10) (Rolland et al., 2014). Furthermore, Rolland et al., 2014 showed an 
increase of phosphorylation of several tyrosine residues of the lipid-raft membrane anchored 
PAG1 protein in germinal center-derived Burkitt’s lymphoma cell lines compared to naïve B 
cells (Rolland et al., 2014). Most of the described tyrosine p-sites of PAG1 were quantified as 
upregulated as well in the BCR stimulation time course of DG75, Daudi and FFM_BL1 Burkitt’s 
lymphoma cells, and in the tonic signaling conditions in DG75 presented in this study 
(supplementary tables S3, S9, and S10). Differences can be attributed to the use of different 
Burkitt’s lymphoma cell lines which confer genotype specificity especially in BCR distal 
phosphorylation sites as described in section 3.1.13. Quantitation was achieved by spectral 
counting which might be sufficient for rough estimates of protein expression levels, but is not 
reliable enough for the quantitation of low abundant species such as phosphopeptides 
(section 1.3.6) (Cox et al., 2014) (reviewed in Bantscheff et al., 2007; 2012). While writing this 
thesis, a study was published which resembles the work presented here closely and therefore 
will be discussed in more detail (Satpathy et al., 2015). The authors investigated BCR signaling 
in a murine B-cell lymphoma cell line, expressing a BCR of the IgG isotype. Signaling was 
monitored after 5 and 15 min of BCR stimulation on the phosphoproteomic and the 
ubiquitination level; tonic BCR signaling was not analyzed (Satpathy et al., 2015). Quantitation 
was achieved by triplex SILAC labeling, and PTMs were enriched in a dual approach by either 
combining TiO2/SCX for phosphopeptide enrichment or by antibody-based phosphotyrosine 
enrichment (Satpathy et al., 2015). The phosphopeptide enrichment approaches lead to the 
identification of 10,663 class I p-sites. Compared to the approximately 4,700 p-sites quantified 
within this study (supplementary tables S2 and S3) Satpathy et al., 2015 identified significantly 
more p-sites. This can be partially attributed to performing measurements on a Q Exactive 
instrument for the reasons mentioned previously in section 4.1.1. Furthermore, the BCR 
stimulation time course with double triplex SILAC labeling to cover four time points in DG75 
cells shown in this study is more complex. For full quantitation across the whole time course 
more stringent criteria need to be applied which leads to a decrease in overall sites. 29.3% 
(3,121) of the p-sites identified by Satpathy et al., 2015 were considered to be regulated after 
5 and/or 15 min with a SILAC ratio fold-change ≥ 2 or ≤ 0.5 (corresponding to ≤ -1 or ≥ 1 on a 
log2 scale). Although the regulation threshold for the global phosphoproteome presented in 
this work was lower (0.75-fold on a log2 scale), overall only 19.2% of the quantified p-sites 
over the BCR stimulation time course in DG75 were considered as regulated (supplementary 
Discussion 
119 
table S2 and S3). Apart from the methodological differences mentioned above, B cells used 
for both studies differed in the isotype of their BCR: in this work, cells with a BCR of the IgM 
isotype were used, whereas Satpathy et al., 2015 used cells with a BCR of the IgG isotype. 
Receptors of the IgM isotype have different signaling outcomes compared to that of the IgG 
isotype due to the different constant region in the cytoplasmic tails (Silver and Cornall, 2003; 
Wakabayashi et al., 2002). Notably, the cytoplasmic tail of IgG BCRs harbors a signaling motif 
that is considered as an intrinsic enhancer of BCR signaling (Engels et al., 2009). Both projects 
share the same basic approach, however they differ not only with regard to genotype and Ig 
isotype, but also to species. The datasets were therefore mapped with the online tool 
PhosphOrtholog that matches p-sites across different species (www.phosphortholog.com; 
Chaudhuri et al., 2015). Comparison of 10,663 quantified class I p-sites derived from mouse B 
cells to 4,176 unique, quantified class I p-sites derived from human DG75 B cells revealed 
1,109 common p-sites (Figure 4.1 A). For the determination of similarity of both datasets, the 
SILAC ratios after 5 min of BCR stimulation respectively were plotted against each other 
(Figure 4.1 B). Overall, correlation of both datasets is moderate, while commonly regulated p-
sites are derived from SYK, CD79A, PRKCD and other formerly known proximal B cell effectors 
(Figure 4.1 B).  
 
 
Figure 4.1: Comparison of p-sites after 5 min of BCR stimulation in mouse and human B cells 
All quantified p-sites from both datasets were submitted to the online tool PhosphOrtholog (www.phosphortholog.com; 
Chaudhuri et al., 2015). (A) 1,109 p-sites overlapped between the Satpathy et al., 2015 dataset with 10,663 quantified mouse 
p-sites and the dataset with 4,176 unique, quantified human p-sites shown in this work. (B) Common p-site ratios after 5 min 
of BCR stimulation from both datasets were plotted against each other. The x-axis shows normalized SILAC ratios of human 
B cells and the y-axis the normalized SILAC ratios of mouse B cells after 5 min of BCR stimulation, respectively.  
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Satpathy et al., 2015 as well as Tsai et al., 2014 performed their experiments in mouse and 
not in human B-cell models. It needs to be further elucidated whether and how the results 
derived from other species can be related to human B-cell physiology (Satpathy et al., 2015; 
Tsai et al., 2014). The phosphoproteomic BCR stimulation time course presented in this study 
and by Satpathy et al., 2015 were analyzed within the minute range. In another study 
performed on antigen-dependent TCR signaling, the time-resolved phosphoproteome was 
analyzed after 5 to 60 s of receptor stimulation. Changes could be already identified after 5 s 
of TCR stimulation suggesting that phosphorylation-mediated signaling occurs almost 
immediately after the stimulus (Chylek et al., 2014). Due to the similarities of TCR to BCR 
signaling (described in section 1.1) antigen-dependent signaling in B cells most likely also 
occurs within a shorter time window and should be considered in designing time-resolved 
receptor stimulation experiments in future. 
 
 Sample preparation and LC-MS/MS instrumentation 
As mentioned earlier in section 4.1.1 and 4.1.3, the number of identified and quantified p-
sites has steadily increased over time. The number of phosphorylation sites - or in general 
PTM sites - that can be quantified depends mainly on the enrichment method and LC-MS/MS 
instrumentation. Therefore the development, evaluation and improvement of state-of-the-
art enrichment methods has been a popular topic in the mass spectrometric community in 
recent years. At the beginning of the project, SCX fractionation prior to TiO2 spin column 
enrichment with DHB as selective competitor was considered as the standard enrichment 
protocol for phosphopeptides (Thingholm et al., 2007; Zarei et al., 2011). Scaling of the 
peptide-to-bead ratio influences the selectivity of phosphopeptide enrichment. Fractionation 
entails difficulties in determining the final peptide amount for each fraction and accordingly 
scaling of TiO2 bead material (Li et al., 2009). This has been addressed by swapping the 
fractionation and the enrichment step, which has the additional advantage that TiO2 
enrichment can be performed on a batch basis instead of enriching each SCX fractions 
separately. Furthermore, DHB was replaced as competitor by more LC-MS/MS compatible and 
selective alternatives such as TFA, glycerol or glutamic acid (Fukuda et al., 2013; Thingholm et 
al., 2007). Basic reversed-phase (BRP) fractionation proved to be a good alternative to SCX 
fractionation as separation of peptides occurs according to hydrophobic interactions instead 
of the peptide charge state (Batth et al., 2014). Therefore, a higher separation resolution can 
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be reached, leading to a higher depth of mass spectrometry measurement (Batth et al., 2014). 
BRP is also suitable for other global PTM studies besides phosphorylation (Batth et al., 2014; 
Fukuda et al., 2013; Li et al., 2009; Mertins et al., 2013). Apart from methodological 
refinements, developments in LC-MS/MS instrumentation also contribute to an increasing 
number of PTM identifications. Ultra-high performance liquid chromatography systems allow 
a more reproducible separation and therefore more sophisticated algorithms for following 
data analysis such as the ‘match between runs’ option. This option transfers MS/MS 
identifications from one LC-MS/MS run to others where the peptide is not substantiated by a 
product ion spectrum but only its exact mass and the retention time (Geiger et al., 2010). 
Furthermore, newer mass spectrometers such as hybrid quadrupole-Orbitrap instruments 
perform shorter duty cycles and fragment spectra analyzed in the Orbitrap have a higher 
resolution and accuracy compared to the previously used hybrid linear ion trap-Orbitrap 
instruments (Michalski et al., 2011; Olsen et al., 2009; Sun et al., 2012). This leads to higher 
identification rates and improved PTM localization.  
The global phosphoproteome of the DG75 BCR stimulation time course as presented in this 
work was enriched by the combination of SCX and TiO2 affinity purification and measured on 
the LTQ Velos with ion trap CID fragmentation as described previously (2.2.3.1). After applying 
the filtering criteria mentioned in section 2.2.5.1, approximately 4,400 p-sites were quantified 
(Figure 3.3; supplementary tables S2). For the scope of the project, the global 
phosphoproteome analysis of BCR stimulated Daudi cells was enriched with TiO2 affinity 
purification as a first step followed by BRP chromatography, and was measured on a Q 
Exactive HF instrument (data not included in this work). The global phosphoproteome analysis 
of Daudi cells quantified approximately 7,100 class I p-sites over the time course of BCR 
stimulation. However, it needs to be considered that the Daudi time course does not contain 
four, but only two time points. Furthermore, more stringent filtering criteria concerning the 
quantitation across biological replicates in the DG75 dataset were applied and therefore might 
underestimate the number of p-sites that could be quantified. Nevertheless, TiO2/BRP is 
compared to SCX/TiO2 more robust, requires less input material and can be also applied with 




 Determination of transcription factor activation 
The Burkitt’s lymphoma phosphoproteomic analysis was supplemented with complementary 
analyses for example RNA seq analysis to monitor BCR stimulation-induced transcriptional 
changes and activation of transcription factors (TF). In the study presented here, activation of 
transcription factors was derived from RNA seq analysis by mapping overexpressed transcripts 
to database-stored transcription factors and performing an enrichment analysis as described 
previously (2.2.6.1.2). Furthermore, quantified p-sites of the particular TFs were mapped and 
manually evaluated for their potential influence on the activation status by information stored 
in the UniProt and PSP database (3.1.7). In general, transcriptional regulation is a complex 
process that requires for example the presence of activating histone marks, the binding of TFs, 
their activation, and the recruitment of RNA polymerase II (Simon and Kingston, 2013). 
Histone marks can be investigated by mass spectrometry or western blot analysis (reviewed 
in Strahl and Allis, 2000; Villar-Garea and Imhof, 2006). TF-DNA interactions can be globally 
determined by chromatin immunoprecipitation (ChIP seq) (Johnson et al., 2007; Park, 2009; 
Valouev et al., 2009; Whitfield et al., 2012). Like kinases, TFs possess phosphorylation sites 
indicating activation which can be investigated by immunoprecipitation or western blot 
(Hunter and Karin, 1992; Whitmarsh and Davis, 2000). Furthermore, RNA polymerase II 
recruitment can be investigated using anti-RNA polymerase II antibodies in ChIP analysis 
(Johnson et al., 2001). However, all mentioned approaches alone do not necessarily reflect 
the activity of a particular TF, therefore a combination of complementary approaches and 
computational modelling is necessary to predict and deduce activation of TFs (Gao et al., 2004) 
(reviewed in Banerjee and Zhang, 2002). An advantage of the approach presented here is the 
combination of two global high-throughput approaches, namely RNA seq and 
phosphoproteomic analysis. Drawbacks of the MS analysis might be posed by stochastic 
identification of TFs, and transcript-TF mapping relies on the quality of the database. The 
approach for the determination of activated transcription factors presented in this work could 
present an additional strategy to the tools mentioned previously. However, a few 
methodological refinements should be implemented such as a higher congruence of the time 
scale of the phosphoproteomic and the RNAseq analysis time courses. The global 
phosphoproteomic time course covered the BCR-induced stimulation after 2, 5, 10 and 20 
min, whereas the RNA seq analysis was performed after 10 min, 20 min, 1 h, and 2 h after BCR 
stimulation. Although it can be assumed that transcriptional regulation lags phosphorylation 
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changes, very fast transcriptional changes were observed for example for FOS, HSPA6, HSPA7, 
EGR1, and EGR3 already after 10 or 20 min of BCR stimulation (section 3.1.7; supplementary 
table S4). Therefore, transcriptional regulation should be monitored in a shorter time window 
as done within this work.  
 
 Genotype-specific and tonic BCR signaling in BL 
The main project for this work focused on the systematic investigation of signaling 
mechanisms in the Burkitt’s lymphoma cell line DG75. Uniform, activated upstream signaling 
events in DG75, Daudi and FFM_BL1 Burkitt’s lymphoma cell lines could be found on early 
upregulated ‘classic’ BCR signaling proteins (supplementary tables S2, S3, and S9). Also 
differential phosphorylation patterns of tyrosine residues on BCR signaling proteins could be 
detected for example on BTK and CD37 (3.1.13). Heterogeneity between the different cell lines 
can be explained by the different clinical subtypes: DG75 and FFM_BL1 are derived from 
sporadic BL disease whereas Daudi is an endemic, EBV-positive BL. DG75 and Daudi have a 
MYC translocation in common whereas FFM_BL1 possesses only MYC point mutations. 
Besides the biological aspect, FFM_BL1 p-sites were quantified with a label-free approach 
introducing additional methodical variation, as quantitation might not be as accurate as SILAC 
labeling. However, the differences in signaling outcomes are surprising as distinct diseased 
cells are indistinguishable from the histological and clinical point of view. Comparative analysis 
of the global phosphoproteomes of DG75, Daudi and FFM_BL1 covering mainly phosphoserine 
and -threonine residues showed an even higher variation in signaling responses and posed a 
challenge for analysis of these datasets (data not included in this work). 
Antigen-induced BCR signaling was intensively studied in different experimental conditions 
(3.1.3, 3.1.7, 3.1.8, 3.1.9, 3.1.10, 3.1.11, and 3.1.13). Burkitt’s lymphoma is thought to be 
mainly driven by tonic signaling that is dependent on a functional BCR but independent of 
antigen binding (Schmitz et al., 2012; Srinivasan et al., 2009). Tonic BCR signaling was 
investigated in two models by phosphotyrosine enrichment: an inducible knockdown of the 
ITAM-containing BCR signaling chain CD79A and pharmacological SYK ablation (3.1.14). For 
the scope of this work, the tonic BCR signaling analysis was planned to be performed in Daudi 
cells as well. After CD79A knockdown, Daudi cells could not be cultured to achieve sufficient 
cell numbers required for phosphoproteome analyses (data not shown). CD79A knockdown 
performed in several BL and ABC-DLBCL cell lines showed that it leads to a reduced BCR 
Discussion 
124 
expression on the cell surface and eventually to reduced cell viability of Daudi cells after 
several days (Schmitz et al., 2012). Therefore, tonic BCR signaling could only be analyzed in 
DG75 cells. Hampered cell growth and viability in cell culture was also observed in DG75, 
however to a lesser extent. The different responses to the CD79A knockdown furthermore 
point towards genotype specificity of signaling cascades as it can be tolerated by one cell line 
but not the other. Both tonic signaling conditions were designed as complementary models 
as SYK activation is dependent on binding to the tandem phosphorylated ITAM motif in CD79A 
(Figure 1.1). Therefore, it was expected that signal inhibition from either of the two directly 
interacting signaling molecules leads to the same or at least a similar cellular signaling 
outcome. Surprisingly, the data presented in this work showed that the correlation of 
identified p-sites derived from the pYome of both tonic signaling models is minor (Figure 3.15 
C). Although commonly regulated p-sites on MAPK1 and MAPK3 were identified, the majority 
of p-sites were differently regulated (Figure 3.15 C; supplementary table S10). Partial results 
render data interpretation even more challenging such as the lack of detection of auto-
phosphorylation and activating SYK p-sites after BCR knockdown and Syk inhibition or in 
general a low number of SYK target p-sites (supplementary table S10). The results could hint 
towards SYK independency of tonic signaling although, SYK dependence was described in 
diffuse large B-cell lymphoma (DLBCL) a disease similar to BL (Chen et al., 2007). However, 
DLBCL has point mutations in the ITAM motif of CD79A and B which induce chronic activated 
BCR signaling and which are not present in Burkitt’s lymphoma (Davis et al., 2010; Schmitz et 
al., 2012). The SYK inhibitor PRT062607 has been reported to be selective. Off-target effects 
on other kinases could still lead to a different signaling outcome (Spurgeon et al., 2012). It is 
known that tonic signaling not only depends on the BCR but also on other receptors such as 
the B cell-activating factor receptor (BAFF-R) (Rowland et al., 2010; Srinivasan et al., 2009; 
Stadanlick et al., 2008). From the data presented here, tonic signaling could also depend on 
other receptors such as CD37 as described in section 4.5.4. 
Tonic signaling is thought to involve fewer pathways compared to antigen-dependent 
signaling and is mainly driven via the PI3K pathway (Srinivasan et al., 2009; Young and Staudt, 
2013a). Schmitz et al., 2012 followed PI3K pathway activity after CD79A knockdown by FACS-
based analysis of the phosphorylation status of AKT S473 in different BL cell lines including 
Daudi. After the knockdown, reduced phosphorylation of AKT S473 could be observed in all 
BL cell lines, thereby providing evidence for PI3K involvement in BL (Schmitz et al., 2012). The 
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site could not be quantified in any of the BL cell lines or experimental conditions shown in this 
work. In general, many p-sites involved in PI3K signaling that were found regulated upon 
antigen-dependent BCR signaling but could not be detected or were not regulated in tonic 
BCR signaling in DG75, render data interpretation challenging (supplementary table S10). 
 Drug targets in Burkitt’s lymphoma 
As targeted therapeutic strategies for Burkitt’s lymphoma are lacking it is commonly treated 
by multiagent chemotherapy which is a highly aggressive treatment regimen (Blum et al., 
2004). Therefore, one aim of this study was to identify potential effector proteins that are 
suitable for targeted pharmacological inhibition. In the following, proteins that appeared as 
interesting candidates within this study will be discussed with regard to their functional role 
in BL signaling and/or therapeutic suitability. 
4.5.1. BRAF 
The MAP-kinase BRAF was already introduced as a potential therapeutic target based on 
dephosphorylation of the putative inhibiting p-site S363 in combination with enhanced affinity 
to kinobeads indicating its activation (section 3.1.8, Figure 3.8 and Figure 3.9). BRAF is known 
to be involved in different cancers, for example melanoma. In melanoma, BRAF is commonly 
mutated with a single amino acid substitution in the kinase domain (V600E). The mutation 
renders the kinase constitutively active, thus making it independent of RAS activation, and as 
a consequence drives the RAF-MEK-ERK signaling axis (Brose et al., 2002; Cheung et al., 2008; 
Davies et al., 2002a; Hatzivassiliou et al., 2010). Specific inhibitors targeting mutated BRAF are 
available and have proven to be a valuable treatment in melanoma (Flaherty et al., 2010b). 
For the inhibition of BRAF in DG75 cells as shown in section 3.1.10, the V600E BRAF inhibitor 
Raf265 was used (Williams et al., 2015). However, mutated BRAF has not been associated with 
Burkitt’s lymphoma (Love et al., 2012; Schmitz et al., 2012). Application of BRAF inhibitor in 
non-mutated BRAF can lead to its paradoxical activation by drug-mediated transactivation 
(Hatzivassiliou et al., 2010; Poulikakos et al., 2010). From the global phosphoproteome dataset 
shown in 3.1.10, it cannot be concluded if BRAF was inhibited or activated as the activating p-
sites of MAPK1 and MAPK3 were found to be slightly upregulated after BCR stimulation in 
combination with BRAF inhibition compared to BCR stimulation only (supplementary table S7). 
To determine kinase activity based on a single p-site might not provide enough analysis depth 
as BRAF possesses further activating and inhibiting p-sites that were not detected (Chong et 
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al., 2001). Furthermore, it is not clear if BRAF activation can be generalized to all BL models as 
BRAF S363 was not quantified in the global phosphoproteomes of BCR stimulated Daudi and 
FFM_BL1 BCR (data not shown) and signaling dynamics seem to highly depend on genetic 
background as stated previously in section 4.4. Taken together, BRAF is an interesting antigen-
dependent BCR signaling effector identified in BL within this study. However, the paradoxical 
activation and the missing evidence of activation in BL cells with a distinct genotype make 
BRAF as target for pharmacological inhibition presumably unsuitable. 
4.5.2. HSP90 
Another interesting and possibly druggable target identified within this work was the heat-
shock protein 90 (HSP90). One phosphotyrosine site on HSP90AA1 was found upregulated in 
the BCR stimulation time course in DG75 cells (supplementary table S3). Another 
phosphotyrosine site was identified as upregulated on HSP90AB1 in the BCR stimulation time 
courses in DG75 cells as well as in Daudi and FFM_BL1 cells (supplementary table S9) but no 
regulation could be observed in both tonic signaling conditions (supplementary table S10). 
HSP90 inhibition by small-molecule inhibitors has already been reported as cancer treatment 
option (Nakashima et al., 2010) (reviewed in Taldone et al., 2008; Trepel et al., 2010). 
Inhibitors of HSP90 such as AT13387 were currently tested in clinical trials for solid tumours 
where HSP90 inhibition leads to destabilization of growth receptors and kinases including AKT, 
MAPK, ARAF, and CRAF (Haarberg et al., 2013; Shapiro et al., 2014; Whitesell and Lindquist, 
2005). As BRAF is closely related to CRAF and ARAF, HSP90 is most like also a chaperone for 
BRAF (Haarberg et al., 2013). Furthermore, HSP90 has been identified as a chaperone for the 
tyrosine kinase ZAP70 in a leukemic disease. As ZAP70 is closely related to SYK, HSP90 could 
also be a chaperone for SYK (Castro et al., 2005). HSP90 inhibition with PU-H71 also showed 
good results in DLBCL which is closely related to BL in terms of antitumor activity (Cerchietti 
et al., 2009). However, it is not entirely clear if and how BRAF and SYK are involved in tonic 
signaling, therefore, the finding is preliminary and needs to be further validated. 
4.5.3. MYC 
MYC is a general transcription factor with several gene targets, amongst others CD79B and 
SYK (Li et al., 2003). MYC translocation is the mutational hallmark of BL and leads to MYC 
overexpression (reviewed in Ferry, 2006; Schmitz et al., 2012). MYC could not be identified on 
the protein expression level analysis as described in 3.1.2. In the DG75 BCR stimulation time 
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course, three MYC phosphorylation sites could be quantified of which one was of particular 
interest (MYC T58) as this p-site lies within a phosphodegron leading to MYC degradation after 
the priming phosphorylation (Welcker et al., 2004; Yada et al., 2004). However, none of the 
MYC p-sites in any of the experiments identified in this study, including T58 in the BCR 
stimulation time course in DG75 cells, were found to be regulated (supplementary tables S2). 
MYC T58 is also not affected by a point mutation that would hinder MYC degradation in the 
primary patient cell line FFM_BL1. MYC is therefore most likely not directly affected by 
regulation on the phosphorylation level. MYC activity is context-dependent by 
heterodimerization with other proteins such as MAX or MIZ-1. After interaction with MAX, the 
MYC-MAX heterodimer acts as transcription activating complex (reviewed in Cai et al., 2015). 
MAX possesses two N-terminal p-sites (S2 and S11) which were identified in the antigen-
dependent BCR stimulation time course in DG75 (supplementary table S2). Phosphorylation 
of both p-sites inhibits MAX homodimerization but not MYC-MAX heterodimerization 
(Berberich and Cole, 1992; Koskinen et al., 1994). MAX homodimers counteract MYC-MAX 
heterodimers and reduces the amount of available MAX (reviewed in Berg, 2010). Either of 
the two p-sites was differentially phosphorylated, however, both positions were not 
differentially phosphorylated at the same time (supplementary table S2). MAX 
homodimerization might be inhibited thereby favoring MYC-MAX heterodimerization leading 
to transcriptional activation of MYC target genes. Although MYC itself cannot be targeted by 
small-molecule inhibitors, there are strategies to indirectly inhibit MYC, for example by 
repressing its transcription. MYC transcription depends on BRD4, a bromodomain containing 
protein that binds to lysine acetylated histones and recruits further factors for transcriptional 
activation of MYC (Albihn et al., 2010; Delmore et al., 2011; Lovén et al., 2013). Inhibition by 
bromodomain inhibitors of MYC has shown good results even in case MYC is translocated 
(Lovén et al., 2013). Another strategy is the inhibition of MYC dimerization with its activating 
interaction partners by Omomyc thereby inhibiting MYC target gene expression (Soucek et al., 
2002). Omomyc can dimerize with MYC and does hinder the activation on gene transcription 
while the transcriptional repression function is maintained (Savino et al., 2011; Soucek et al., 
2002) (reviewed in Cai et al., 2015).  
4.5.4. CD37 
The cell surface receptor Leukocyte antigen CD37 (CD37) was identified as a candidate for 
targeted therapy in Burkitt’s lymphoma in this study. CD37 is expressed in mature B cells 
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including malignantly transformed B-cells, but not in plasma cells, and is described to be 
involved in T-cell-B-cell interactions (Knobeloch et al., 2000; Schwartz-Albiez et al., 1988; 
Tarrant et al., 2003). The CD37 p-site identified in this study lies within an ITAM-like motif and 
therefore is thought to be phosphorylated by Src family kinases to recruit SYK (Lapalombella 
et al., 2012). Phosphorylation of this site has been described to drive survival by signaling 
through the PI3K pathway (Lapalombella et al., 2012). Indeed, the p-site was found to be 
dephosphorylated upon SYK inhibition, but was upregulated after BCR knockdown 
(supplementary table S10). Furthermore, SYK was found to be regulated after BCR stimulation 
in DG75 as described in 3.1.13. The involvement of this p-site was dependent on the genetic 
context as the phosphorylation behavior was different in the three distinct BL cell lines after 
BCR stimulation (3.1.13; Figure 3.14; supplementary table S9). Of note, CD37 has already been 
considered to be a promising target for immunotherapy in B-cell malignancies (Heider et al., 
2011). As CD37 could be an additional driver of malignant tonic signaling, knockdown as 
described in this study for CD79A (2.2.1.3.2) and the CD37 interactome have to be further 
investigated to validate CD37 as therapeutic option. 
 Conclusion and perspective 
In combination with other experimental approaches, the phosphoproteome analyses 
presented in this work under various experimental conditions and in different disease models 
allowed an in-depth characterization of signal transducing events. In particular, the analysis 
of distinct cell lines after BCR stimulation showed highly individual responses in cells that 
cannot be easily distinguished on the histological level. Therefore, MS-based signaling analysis 
could be a suitable tool for the characterization of patient-derived samples in clinical 
diagnostics to develop personalized therapeutic approaches. Furthermore, the targeted 
receptor ablation in combination with mass spectrometry-based phosphoproteomic analysis 
enabled the investigation of the contribution of the BCR alone on signaling processes. The 
influence of kinase ablation could be directly investigated on the phosphoproteomic level as 
well as the involvement of signaling adapters in receptor signaling. The generated datasets 
may provide a basis for further functional studies of single phosphorylation sites or proteins. 
The improvement of enrichment methods and the development of new mass spectrometers 
will in future lead to even higher identification rates and therefore will reach a yet unknown 
depth of analysis. Database knowledge will also grow and more sophisticated modeling tools 
will be developed that will altogether lead to the generation of a more detailed picture of 
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systems biology. Taken together, this work provides a valuable basis for further functional 
studies of druggable protein targets by receptor knockdown, interactome analyses, inhibition 
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B  Mass spectrometric settings 
 
In the following detailed LC-MS/MS instrumental settings are listed for the instruments used 
for this work: LTQ Orbitrap Velos, Q Exactive, Q Exactive HF, and Orbitrap Fusion. The following 
abbreviations are used: BR: biological replicate; GP: global phosphoproteome analysis i.e. SCX 
fractionation in combination with TiO2 phosphopeptide enrichment; pYome: antibody-based 
phosphotyrosine enrichment; PE: protein expression analysis; LC: liquid chromatography; 
TopN: Maximum number of MS2 scans that can be performed after one intact peptide 
precursor scan; AGC: automated gain control; IT: injection time; Th: Thomson, unit for the 
mass-to-charge ratio; MS1: intact peptide precursor scan, MS2: product ion scan of selected 
precursor; NCE: normalized collision energy; CID: collision induced dissociation ; HCD: higher 
energy collisional dissociation; DG75, Daudi and FFM_BL1: Burkitt’s lymphoma cell lines; KG1 
and MV4-11: acute myeloid leukemia cell lines. 
 
B.1 LTQ Orbitrap Velos 
Table 13: LTQ Orbitrap Velos settings 
Project DG75 BCR stimulation time course TCR signaling adapters 
Experiment GP/pY BR 1/2/3 
Spray voltage [kV] 1.8 1.8 
LC method length [min] 118 50 
LC gradient length [min] 101 33 
TopN 10 10 
MS1 Resolution 30000 30000 
MS1 AGC target 1.00E+06 1.00E+06 
MS1 Maximum IT [ms] 500 500 
Intensity threshold 1.00E+04 1.00E+03 
Fragmentation mode CID CID 
Isolation window [Th] 2 2 
NCE [%] 35 35 
MS2 AGC target 5.00E+04 1.00E+04 
MS2 Maximum IT [ms] 100 100 
Dynamic exlusion [s] 60 60 
Charge state inclusion [z] 2, 3, 4+ 2, 3, 4+ 
Linear gradient [%B] 4 - 34 % 4 - 34 % 
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B.2 Q Exactive 
Table 14: Q Exactive settings 
Project DG75 BCR stimulation time course DG75 BRAF inhibition 
DG75 BRAF 
interactome 
AML KG1/MV4-11 BTK inhibition 




Spray voltage [kV] 2.3 1.8 1.8 1.8 1.8 1.8 1.8 
LC method length [min] 90 90 60 90 60 90 120 
LC gradient length [min] 80 82 52 81 52 81 110 
TopN 15 15 15 12 15 12 12 
MS1 Resolution 70000 70000 70000 70000 70000 70000 70000 
MS1 AGC target 1.00E+06 1.00E+06 1.00E+06 1.00E+06 1.00E+06 1.00E+06 1.00E+06 
MS1 Maximum IT [ms] 60ms 60ms 60ms 60ms 60ms 60ms 60ms 
Intensity threshold 4.00E+04 5.00E+04 4.80E+04 2.40E+04 4.80E+04 2.00E+04 2.00E+04 
Fragmentation mode HCD HCD HCD HCD HCD HCD HCD 
Isolation window [Th] 2 2 2 2 2 2 2 
NCE [%] 28 28 28 28 28 28 28 
MS2 Resolution 17500 17500 17500 35000 17500 35000 17500 
MS2 AGC target 2.00E+05 2.00E+05 2.00E+05 1.00E+05 2.00E+05 1.00E+05 1.00E+05 
MS2 Maximum IT [ms] 60ms 60ms 50ms 120ms 50ms 120ms 120ms 
Underfill ratio [%] 1.2 1.5 1.2 2.4 1.2 2.4 2.4 
Dynamic exlusion [s] 15s 18s 20s 20s 20s 20 20 
Charge state inclusion [z] 2, 3, 4 2, 3, 4 2, 3, 4 2, 3, 4, 5, 6, 7 2, 3, 4 2, 3, 4, 5, 6, 7 2, 3, 4, 5, 6, 7 
Peptide match preferred preferred preferred preferred preferred preferred preferred 
Linear gradient [%B] 4 - 34 % 4 - 32 % 4 - 36 % 4 - 37 % 4 - 36 % 4 - 37 % 4 - 37 % 
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B.3 Q Exactive HF 













Experiment GP/pY pY pY 4. BR 
Spray voltage [kV] 2.2 2.2 2.5 2.3 
LC method length [min] 90 90 120 90 
LC gradient length [min] 74 74 103 74 
TopN 20 20 30 15 
MS1 Resolution 120000 120000 120K 120K 
MS1 AGC target 1.00E+06 1.00E+06 1.00E+06 1.00E+06 
MS1 Maximum IT [ms] 40 40 50 80 
Intensity threshold 6.30E+04 6.30E+04 3.00E+04 1.90E+04 
Fragmentation mode HCD HCD HCD HCD 
Isolation window [Th] 1.4 1.4 2 1.4 
NCE [%] 28 28 28 28 
MS2 Resolution 30000 30000 30000 30000 
MS2 AGC target 1.00E+05 1.00E+05 1.00E+05 1.00E+05 
MS2 Maximum IT [ms] 64 64 50 50 
Underfill ratio [%] 4 4 1.5  
Dynamic exlusion [s] 30 30 30 30 
Charge state inclusion [z] 2, 3, 4, 5, 6 2, 3, 4, 5, 6 2, 3, 4, 5, 6 2, 3, 4, 5, 4 
Peptide match preferred preferred preferred Preferred 
Linear gradient [%B] 1 - 40 - 60 % 1 - 40 - 60 % 2 - 40 - 60 % 2 - 40 - 60 % 
 
B.4 Orbitrap Fusion 
Table 16: Orbitrap Fusion settings 
Project DG75 BCR stimulation time course 
Experiment Antibody-based acetyl- and GG-lysine enrichment 
Spray voltage [kV] 2.3 
LC method length [min] 90 min 
LC gradient length [min] 74 min 
TopN Top speed 
MS1 Resolution 120K 
MS1 AGC target 50000 
MS1 Maximum IT [ms] 50 
Intensity threshold 50000 
Fragmentation mode HCD 
Isolation window [Th] 1.6 
NCE [%] 30 
MS2 Resolution 30K 
MS2 AGC target 1.00E+04 
MS2 Maximum IT [ms] 128 
Fragmentation mode HCD 
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Underfill ratio  
Dynamic exlusion 20s 
Charge state inclusion 2, 3, 4, 5 
Peptide match  




C List of abbreviations 
ABC Ammonium bicarbonate 
Ac Acetylation 
ACN Acetonitrile 
AGC Automated gain control 
AML Acute myeloid leukemia 
BCR B-cell receptor 
BL Burkitt's lymphoma 
bp Base pair 
BSA Bovine serum albumine 
cDNA Complementary DNA 
CID Collision induced dissociation 
Ctrl Control 
Da Dalton 
DDA Data-dependent acquisition 
DHB Dihydrobenzoic acid 
DIA Data-indendent acquisition 
DMEM 
Dulbecco`s modified Eagle 
medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
DUB Deubiquitinase 
ETD Electron transfer dissociation 
EtOH Ethanol 
FCS Fetal calf serum 
FDR False discovery rate 
FTMS 
Fourier transform mass 
spectrometry 
GP Global phosphoproteome 
HCD 














KDAC Lysine deacetylase 
LC Liquid chromatography  
M Molar 
max. IT Maximum injection time 
mRNA Messenger RNA 
 
 
MS/MS Tandem mass spectrometry 
MS1 Peptide precursor spectrum 
MS2 or 
MS/MS 
Product ion spectrum of a 
selected precursor 
NP-40 Nonidet P-40 
P Phosphorylation 
PBS Phosphate buffered saline 
PE Protein expression 
ppm Parts per million 




pT Phosphorylated threonine 
PTM Post-translational modification 
PTP Protein tyrosine phosphatase 
pY Phosphorylated tyrosine 
R Arginine 
RNA Ribonucleic acid 
RNAseq Ribonucleic acid sequencing 
rpm Rounds per minute 
RT Room temperature 
SCX Strong cation exchange 
SDS-PAGE 
Sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis 
shRNA Small hairpin ribonucleic acid 
siRNA Small interfering ribonucleic acid 
SILAC 
Stable isotope labeling by amino 
acids in cell culture 
StageTips STop And Go Extraction Tips 
TCR T-cell receptor 
TFA Trifluoroacetic acid 




WB Western Blot 
WT Wild type 
xg Times g-force 
Y  Tyrosine 
 
 
 
